RELATED APPLICATIONS
[0001]This application claims the benefit of U.S. Provisional Application No. 60/663,621, filed Mar. 18, 2005, the contents of which are hereby incorporated by reference in their entirety.
BACKGROUND OF THE INVENTION
[0002]Carotenoids are organic pigments ranging in color from yellow to red that are naturally produced by certain organisms, including photosynthetic organisms (e.g., plants, algae, cyanobacteria), and some fungi. Carotenoids are responsible for the orange color of carrots, as well as the pink in flamingos and salmon, and the red in lobsters and shrimp. Animals, however, cannot produce carotenoids and must receive them through their diet.
[0003]Carotenoid pigments (e.g., β-carotene and astaxanthin) are used industrially as ingredients for food and feed stocks, both serving a nutritional function and enhancing consumer acceptability. For example, astaxanthin is widely used in salmon aquaculture to provide the orange coloration characteristic of their wild counterparts. Some carotenoids are also precursors of vitamin A. Also, carotenoids have antioxidant properties, and may have various health benefits (see, for example, Jyonouchi et al., Nutr. Cancer 16:93, 1991; Giovannucci et al., J. Natl. Cancer Inst. 87:1767, 1995; Miki, Pure Appl. Chem 63:141, 1991; Chew et al., Anticancer Res. 19:1849, 1999; Wang et al., Antimicrob. Agents Chemother. 44:2452, 2000). Some carotenoids such as β-carotene, lycopene, and lutein are currently sold as nutritional supplements.
[0004]In general, the biological systems that produce carotenoids are industrially intractable and/or produce the compounds at such low levels that commercial scale isolation is not practicable. Thus, most carotenoids used in industry are produced by chemical synthesis. There is a need for improved biological systems that produce carotenoids. Some efforts have previously been made to genetically engineer certain bacteria or fungi to produce higher levels of carotenoids (see, for example, Misawa et al., J. Biotechnol. 59:169, 1998; Visser et al., FEMS Yeast Research 4:221, 2003). However, improved systems, allowing higher levels of production and greater ease of isolation, are needed.
SUMMARY OF THE INVENTION
[0005]The present invention provides improved systems for the biological production of carotenoids. In one aspect, the invention encompasses the discovery that it is desirable to produce carotenoids in oleaginous organisms. Without wishing to be bound by any particular theory, the present inventors propose that biological systems may be able to accumulate higher levels of carotenoids if the compounds are sequestered in lipid bodies. Regardless of whether absolute levels are higher, however, carotenoids that are accumulated within lipid bodies in oleaginous organisms are readily isolatable through isolation of the lipid bodies.
[0006]The present invention therefore provides oleaginous fungi (including, for example, yeast or other unicellular fungi) that produce one or more carotenoids. The present invention also provides methods of constructing such yeast and fungi, methods of using such yeast and fungi to produce carotenoids, and methods of preparing carotenoid-containing compositions, such as food or feed additives, or nutritional supplements, using carotenoids produced in such oleaginous yeast or fungi. In particular, the present invention provides systems and methods for generating yeast and fungi containing one or more oleaginic and/or carotenogenic modifications that increase the oleaginicity and/or alter their carotenoid-producing capabilities as compared with otherwise identical organisms that lack the modification(s).
[0007]The present invention further encompasses the general recognition that lipid-accumulating systems are useful for the production and/or isolation of lipophilic agents (such as, but not limited to isoprenoids, or isoprenoid-derived compounds). Thus, according to the present invention, it is desirable to engineer organisms to produce such lipophilic agents and/or to accumulate lipid.
[0008]Various other aspects of the present invention will be apparent to those of ordinary skill in the art from the present description, including the appended claims.
BRIEF DESCRIPTION OF THE DRAWING
[0009]FIG. 1A-1D depicts certain common carotenoids.
[0010]FIG. 2 depicts how sufficient levels of acetyl-CoA and NADPH may be accumulated in the cytosol of oleaginous organisms to allow for production of significant levels of cytosolic lipids. Enzymes: 1, pyruvate decarboxylase; 2, malate dehydrogenase; 3, malic enzyme; 4, pyruvate dehydrogenase; 5, citrate synthase; 6, ATP-citrate lyase; 7, citrate/malate translocase.
[0011]FIGS. 3A and 3B depict the mevalonate isoprenoid biosynthesis pathway, which typically operates in eukaryotes, including fungi.
[0012]FIG. 4 depicts the mevalonate-independent isoprenoid biosynthesis pathway, also known as the DXP pathway, which typically operates in bacteria and in the plastids of plants.
[0013]FIG. 5 depicts intermediates in the isoprenoid biosynthesis pathway and how they feed into biosynthetic pathways of other biomolecules, including carotenoids as well as non-carotenoid compounds such as sterols, steroids, and vitamins, such as vitamin E or vitamin K.
[0014]FIGS. 6A-6D illustrate various carotenoid biosynthetic pathways. FIG. 6A highlights branches leading to various cyclic and acyclic xanthophylls; FIG. 6B shows certain X. dendrorhous pathways that generate dicyclic and monocyclic carotenoids, including astaxanthin; FIG. 6C shows interconnecting pathways for converting β-carotene into any of a variety of other carotenoids, including astaxanthin; FIG. 6D depicts possible routes of synthesis of cyclic carotenoids and common plant and algal xanthophylls from neurosporene.
[0015]FIGS. 7A-7I show an alignment of certain representative fungal HMG-CoA reductase polypeptides. As can be seen, these polypeptides show very high identity across the catalytic region, and also have complex membrane spanning domains. In some embodiments of the invention, these membrane-spanning domains are disrupted or are removed, so that, for example, a hyperactive version of the polypeptide may be produced.
[0016]FIGS. 8A-8D depict schematic representations of plasmids generated and described in detail in the exemplification.
DEFINITIONS
[0017]Carotenogenic modification: The term “carotenogenic modification”, as used herein, refers to a modification of a host organism that adjusts production of one or more carotenoids, as described herein. For example, a carotenogenic modification may increase the production level of one or more carotenoids, and/or may alter relative production levels of different carotenoids. In principle, an inventive carotenogenic modification may be any chemical, physiological, genetic, or other modification that appropriately alters production of one or more carotenoids in a host organism produced by that organism as compared with the level produced in an otherwise identical organism not subject to the same modification. In most embodiments, however, the carotenogenic modification will comprise a genetic modification, typically resulting in increased production of one or more selected carotenoids. In some embodiments, the selected carotenoid is one or more of astaxanth in, β-carotene, canthaxanth in, lutein, lycopene, phytoene, zeaxanth in, and/or modifications of zeaxanthin or astaxanthin (e.g., glucoside, esterified zeaxanthin or astaxanthin). In some embodiments, the selected carotenoid is one or more xanthophylls, and/or a modification thereof (e.g., glucoside, esterified xanthophylls). In certain embodiments, the selected xanthophyl is selected from the group consisting of astaxanthin, lutein, zeaxanthin, lycopene, and modifications thereof. In some embodiments, the selected carotenoid is one or more of astaxanthin, β-carotene, canthaxanthin, lutein, lycopene, and zeaxanthin and/or modifications of zeaxanthin or astaxanthin. In some embodiments, the carotenoid is β-carotene. In some embodiments, the selected carotenoid is astaxanthin. In some embodiments, the selected carotenoid is other than β-carotene.
[0018]Carotenogenicpolypeptide: The term “carotenogenic polypeptide”, as used herein, refers to any polypeptide that is involved in the process of producing carotenoids in a cell, and may include polypeptides that are involved in processes other than carotenoid production but whose activities affect the extent or level of production of one or more carotenoids, for example by scavenging a substrate or reactant utilized by a carotenoid polypeptide that is directly involved in carotenoid production. Carotenogenic polypeptides include isoprenoid biosynthesis polypeptides, carotenoid biosynthesis polypeptides, and isoprenoid biosynthesis competitor polypeptides, as those terms are defined herein. The term also encompasses polypeptides that may affect the extent to which carotenoids are accumulated in lipid bodies.
[0019]Carotenoid: The term “carotenoid” is understood in the art to refer to a structurally diverse class of pigments derived from isoprenoid pathway intermediates. The commitment step in carotenoid biosynthesis is the formation of phytoene from geranylgeranyl pyrophosphate. Carotenoids can be acyclic or cyclic, and may or may not contain oxygen, so that the term carotenoids include both carotenes and xanthophylls. In general, carotenoids are hydrocarbon compounds having a conjugated polyene carbon skeleton formally derived from the five-carbon compound 1PP, including triterpenes (C30diapocarotenoids) and tetraterpenes (C40carotenoids) as well as their oxygenated derivatives and other compounds that are, for example, C35, C50, C60, C70, C80in length or other lengths. Many carotenoids have strong light absorbing properties and may range in length in excess of C200. C30diapocarotenoids typically consist of six isoprenoid units joined in such a manner that the arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1,6-positional relationship and the remaining non-terminal methyl groups are in a 1,5-positional relationship. Such C30carotenoids may be formally derived from the acyclic C30H42structure, having a long central chain of conjugated double bonds, by: (i) hydrogenation (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v) esterification/glycosylation, or any combination of these processes. C40carotenoids typically consist of eight isoprenoid units joined in such a manner that the arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1,6-positional relationship and the remaining non-terminal methyl groups are in a 1,5-positional relationship. Such C40carotenoids may be formally derived from the acyclic C40H56structure, having a long central chain of conjugated double bonds, by (i) hydrogenation, (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v) esterification/glycosylation, or any combination of these processes. The class of C40carotenoids also includes certain compounds that arise from rearrangements of the carbon skeleton, or by the (formal) removal of part of this structure. More than 600 different carotenoids have been identified in nature; certain common carotenoids are depicted in FIG. 1. Carotenoids include but are not limited to: antheraxanthin, adonirubin, adonixanthin, astaxanthin, canthaxanthin, capsorubrin, β-cryptoxanthin, α-carotene, β-carotene, β,ψ-carotene, δ-carotene, ε-carotene, echinenone, 3-hydroxyechinenone, 3′-hydroxyechinenone, γ-carotene, ψ-carotene, 4-keto-γ-carotene, ζ-carotene, α-cryptoxanthin, deoxyflexixanthin, diatoxanthin, 7,8-didehydroastaxanthin, didehydrolycopene, fucoxanthin, fucoxanthinol, isorenieratene, β-isorenieratene, lactucaxanthin, lutein, lycopene, myxobactone, neoxanthin, neurosporene, hydroxyneurosporene, peridinin, phytoene, rhodopin, rhodopin glucoside, 4-keto-rubixanthin, siphonaxanthin, spheroidene, spheroidenone, spirilloxanthin, torulene, 4-keto-torulene, 3-hydroxy-4-keto-torulene, uriolide, uriolide acetate, violaxanthin, zeaxanthin-β-diglucoside, zeaxanthin, and C30 carotenoids. Additionally, carotenoid compounds include derivatives of these molecules, which may include hydroxy-, methoxy-, oxo-, epoxy-, carboxy-, or aldehydic functional groups. Further, included carotenoid compounds include ester (e.g., glycoside ester, fatty acid ester) and sulfate derivatives (e.g., esterified xanthophylls).
[0020]Carotenoid biosynthesis polypeptide: The term “carotenoid biosynthesis polypeptide” refers to any polypeptide that is involved in the synthesis of one or more carotenoids. To mention but a few, these carotenoid biosynthesis polypeptides include, for example, polypeptides of phytoene synthase, phytoene dehydrogenase (or desaturase), lycopene cyclase, carotenoid ketolase, carotenoid hydroxylase, astaxanthin synthase, carotenoid epsilon hydroxylase, lycopene cyclase (beta and epsilon subunits), carotenoid glucosyltransferase, and acyl CoA:diacyglycerol acyltransferase. Representative examples of carotenoid biosynthesis polypeptide sequences are presented in Tables 17-25.
[0021]Gene: The term “gene”, as used herein, generally refers to a nucleic acid encoding a polypeptide, optionally including certain regulatory elements that may affect expression of one or more gene products (i.e., RNA or protein).
[0022]Heterologous: The term “heterologous”, as used herein to refer to genes or polypeptides, refers to a gene or polypeptide that does not naturally occur in the organism in which it is being expressed. It will be understood that, in general, when a heterologous gene or polypeptide is selected for introduction into and/or expression by a host cell, the particular source organism from which the heterologous gene or polypeptide may be selected is not essential to the practice of the present invention. Relevant considerations may include, for example, how closely related the potential source and host organisms are in evolution, or how related the source organism is with other source organisms from which sequences of other relevant polypeptides have been selected.
[0023]Host cell: As used herein, the “host cell” is a yeast or fungal cell that is manipulated according to the present invention to accumulate lipid and/or to express one or more carotenoids as described herein. A “modified host cell”, as that term is used herein, is a host cell that contains at least one oleaginic modification and/or at least one carotenogenic modification according to the present invention.
[0024]Isolated: The term “isolated”, as used herein, means that the isolated entity has been separated from at least one component with which it was previously associated. When most other components have been removed, the isolated entity is “purified”. Isolation and/or purification may be performed using any techniques known in the art including, for example, fractionation, extraction, precipitation, or other separation.
[0025]Isoprenoid biosynthesis competitor polypeptide: The term “isoprenoid biosynthesis competitor polypeptide”, as used herein, refers to a polypeptide whose expression in a cell reduces the level of geranylgeranyl diphosphate (GGPP) available to enter the carotenoid biosynthesis pathway. For example, isoprenoid biosynthesis competitor polypeptides include enzymes that act on isoprenoid intermediates prior to GGPP, such that less GGPP is generated (see, for example, FIG. 5). Squalene synthase is but one isoprenoid biosynthesis competitor polypeptide according to the present invention; representative squalene synthase sequences are presented in Table 16. Prenyidiphosphate synthase enzymes and para-hydroxybenzoate (PHB) polyprenyltransferase are yet additional isoprenoid biosynthesis competitor polypeptides according to the present invention; representative prenyldiphosphate synthase enzymes and PHB polyprenyltransferase polypeptides are presented in Table 29 and 30 respectively.
[0026]Isoprenoid biosynthesis polypeptide: The term “isoprenoid biosynthesis polypeptide” refers to any polypeptide that is involved in the synthesis of isoprenoids. For example, as discussed herein, acetoacetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, IPP isomerase, FPP synthase, and GGPP synthase, are all involved in the mevalonate pathway for isoprenoid biosynthesis. Each of these proteins is also an isoprenoid biosynthesis polypeptide for purposes of the present invention, and sequences of representative examples of these enzymes are provided in Tables 7-15.
[0027]Isoprenoid pathway: The “isoprenoid pathway” is understood in the art to refer to a metabolic pathway that either produces or utilizes the five-carbon metabolite isopentyl pyrophosphate (IPP). As discussed herein, two different pathways can produce the common isoprenoid precursor IPP—the “mevalonate pathway” and the “non-mevalonate pathway”. The term “soprenoid pathway” is sufficiently general to encompass both of these types of pathway. Biosynthesis of isoprenoids from IPP occurs by polymerization of several five-carbon isoprene subunits. Isoprenoid metabolites derived from IPP are of varying size and chemical structure, including both cyclic and acyclic molecules. Isoprenoid metabolites include, but are not limited to, monoterpenes, sesquiterpenes, diterpenes, sterols, and polyprenols such as carotenoids.
[0028]Oleaginic modification: The term “oleaginic modification”, as used herein, refers to a modification of a host organism that adjusts the desirable oleaginy of that host organism, as described herein. In some cases, the host organism will already be oleaginous in that it will have the ability to accumulate lipid to at least about 20% of its dry cell weight. It may nonetheless be desirable to apply an oleaginic modification to such an organism, in accordance with the present invention, for example to increase (or, in some cases, possibly to decrease) its total lipid accumulation, or to adjust the types or amounts of one or more particular lipids it accumulates (e.g., to increase relative accumulation of triacylglycerol). In other cases, the host organism may be non-oleaginous (though may contain some enzymatic and regulatory components used in other organisms to accumulate lipid), and may require oleaginic modification in order to become oleaginous in accordance with the present invention. The present invention also contemplates application of oleaginic modification to non-oleaginous host strains such that their oleaginicity is increased even though, even after being modified, they may not be oleaginous as defined herein. In principle, the oleaginic modification may be any chemical, physiological, genetic, or other modification that appropriately alters oleaginy of a host organism as compared with an otherwise identical organism not subjected to the oleaginic modification. In most embodiments, however, the oleaginic modification will comprise a genetic modification, typically resulting in increased production and/or activity of one or more oleaginic polypeptides. In some embodiments, the oleaginic modification comprises at least one chemical, physiological, genetic, or other modification; in other embodiments, the oleaginic modification comprises more than one chemical, physiological, genetic, or other modification. In certain aspects where more than one modification is utilized, such modifications can comprise any combination of chemical, physiological, genetic, or other modification (e.g., one or more genetic modification and chemical or physiological modification).
[0029]Oleaginicpolypeptide: The term “oleaginic polypeptide”, as used herein, refers to any polypeptide that is involved in the process of lipid accumulation in a cell and may include polypeptides that are involved in processes other than lipid biosynthesis but whose activities affect the extent or level of accumulation of one or more lipids, for example by scavenging a substrate or reactant utilized by an oleaginic polypeptide that is directly involved in lipid accumulation. For example, as discussed herein, acetyl-CoA carboxylase, pyruvate decarboxylase, isocitrate dehydrogenase, ATP-citrate lyase, malic enzyme, and AMP deaminase, among other proteins, are all involved in lipid accumulation in cells. In general, reducing the activity of pyruvate decarboxylase or isocitrate dehydrogenase, and/or increasing the activity of acetyl CoA carboxylase, ATP-citrate lyase, malic enzyme and/or AMP deaminase is expected to promote oleaginy. Each of these proteins is an oleaginic polypeptide for purposes of the present invention, and sequences of representative examples of these enzymes are provided in Tables 1-6.
[0030]Oleaginous: The term “oleaginous”, refers to the ability of an organism to accumulate lipid to at least about 20% of its dry cell weight. In certain embodiments of the invention, oleaginous yeast or fungi accumulate lipid to at least about 25% of their dry cell weight. In other embodiments, inventive oleaginous yeast or fungi accumulate lipid within the range of about 20-45% of their dry cell weight. In some embodiments, oleaginous organisms may accumulate lipid to as much as about 70% of their dry cell weight. In some embodiments of the invention, oleaginous organisms may accumulate a large fraction of total lipid accumulation in the form of triacylglycerol. In certain embodiments, the majority of the accumulated lipid is in the form of triacylglycerol. Alternatively or additionally, the lipid may accumulate in the form of intracellular lipid bodies, or oil bodies. In certain embodiments, the present invention utilizes yeast or fungi that are naturally oleaginous. In some aspects, naturally oleaginous organisms are manipulated (e.g., genetically, chemically, or otherwise) so as to futher increase the level of accumulated lipid in the organism. In other embodiments, yeast or fungi that are not naturally oleaginous are manipulated (e.g., genetically, chemically, or otherwise) to accumulate lipid as described herein. For the purposes of the present invention, Xanthophyllomyces dendrorhous (Phaffia rhodozyma) and Candida utilis are not naturally oleaginous fungi.
[0031]Polypeptide: The term “polypeptide”, as used herein, generally has its art-recognized meaning of a polymer of at least three amino acids. However, the term is also used to refer to specific functional classes of polypeptides, such as, for example, oleaginic polypeptides, carotenogenic polypeptides, isoprenoid biosynthesis polypeptides, carotenoid biosynthesis polypeptides, and isoprenoid biosynthesis competitor polypeptides. For each such class, the present specification provides several examples of known sequences of such polypeptides. Those of ordinary skill in the art will appreciate, however, that the term “polypeptide” is intended to be sufficiently general as to encompass not only polypeptides having the complete sequence recited herein (or in a reference or database specifically mentioned herein), but also to encompass polypeptides that represent functional fragments (i.e., fragments retaining at least one activity) of such complete polypeptides. Moreover, those of ordinary skill in the art understand that protein sequences generally tolerate some substitution without destroying activity. Thus, any polypeptide that retains activity and shares at least about 30-40% overall sequence identity, often greater than about 50%, 60%, 70%, or 80%, and further usually including at least one region of much higher identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99% in one or more highly conserved regions (e.g., isocitrate dehydrogenase polypeptides often share a conserved AMP-binding motif; HMG-CoA reductase polypeptides typically include a highly conserved catalytic domain (see, for example, FIG. 7); acetyl coA carboxylase typically has a carboxyl transferase domain; see, for example, Downing et al., Chem. Abs. 93:484, 1980; Gil et al., Cell 41:249, 1985; Jitrapakdee et al. Curr Protein Pept Sci. 4:217, 2003; U.S. Pat. No. 5,349,126, each of which is incorporated herein by reference in its entirety), usually encompassing at least 3-4 and often up to 20 or more amino acids, with another polypeptide of the same class, is encompassed within the relevant term “olypeptide” as used herein.
[0032]Source organism: The term “source organism”, as used herein, refers to the organism in which a particular polypeptide sequence can be found in nature. Thus, for example, if one or more heterologous polypeptides is/are being expressed in a host organism, the organism in which the polypeptides are expressed in nature (and/or from which their genes were originally cloned) is referred to as the “source organism”. Where more than one heterologous polypeptides are being expressed in a host organism, one or more source organism(s) may be utilized for independent selection of each of the heterologous polypeptide(s). It will be appreciated that any and all organisms that naturally contain relevant polypeptide sequences may be used as source organisms in accordance with the present invention. Representative source organisms include, for example, animal, mammalian, insect, plant, fungal, yeast, algal, bacterial, cyanobacterial, archaebacterial and protozoal source organisms.
DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS OF THE INVENTION
[0033]As noted above, the present invention encompasses the discovery that carotenoids can desirably be produced in oleaginous yeast and fungi. According to the present invention, strains that both (i) accumulate lipid, often in the form of cytoplasmic oil bodies and typically to at least about 20% of their dry cell weight; and (ii) produce carotenoid(s) at a level at least about 1%, and in some embodiments at least about 3-20%, of their dry cell weight, are generated through manipulation of host cells (i.e., strains, including, e.g., naturally-occurring strains, strains which have been previously modified, etc.). These manipulated host cells are then used to produce carotenoids, so that carotenoids that partition into the lipid bodies can readily be isolated.
[0034]In general, it will be desirable to balance oleaginy and carotenoid production in inventive cells such that, as soon as a minimum desirable level of oleaginy is achieved, substantially all further carbon which is capable of being utilized and diverted into biosynthesis of products is diverted into a carotenoid production pathway. In some embodiments of the invention, this strategy involves engineering cells to be oleaginous; in other embodiments, it involves engineering cells to accumulate a higher level of lipid, particularly cytoplasmic lipid, than they would accumulate in the absence of such engineering even though the engineered cells may not become “oleaginous” as defined herein. In other embodiments, the extent to which an oleaginous host cell accumulates lipid is actually reduced so that remaining carbon can be utilized in carotenoid production.
[0035]Those of ordinary skill in the art will readily appreciate that a variety of yeast and fungal strains exist that are naturally oleaginous or that naturally produce carotenoids. Any of such strains may be utilized as host strains according to the present invention, and may be engineered or otherwise manipulated to generate inventive oleaginous, carotenoid-producing strains. Alternatively, strains that naturally are neither oleaginous nor carotenoid-producing may be employed. Furthermore, even when a particular strain has a natural capacity for oleaginy or for carotenoid production, its natural capabilities may be adjusted as described herein, so as to change the production level of lipid and/or carotenoid. In certain embodiments engineering or manipulation of a strain results in modification of a type of lipid and/or carotenoid which is produced. For example, a strain may be naturally oleaginous and/or carotenogenic, however engineering or modification of the strain may be employed so as to change the type of lipid which is accumulated and or to change the type of carotenoid which is produced.
[0036]When selecting a particular yeast or fungal strain for use in accordance with the present invention, it will generally be desirable to select one whose cultivation characteristics are amenable to commercial scale production. For example, it will generally (though not necessarily always) be desirable to avoid filamentous organisms, or organisms with particularly unusual or stringent requirements for growth conditions. However, where conditions for commercial scale production can be applied which allow for utilization of filamentous organisms, these may be selected as host cells. In some embodiments of the invention, it will be desirable to utilize edible organisms as host cells, as they may optionally be formulated directly into food or feed additives, or into nutritional supplements, as desired. For ease of production, some embodiments of the invention utilize host cells that are genetically tractable, amenable to molecular genetics (e.g., can be efficiently transformed, especially with established or available vectors; optionally can incorporate and/or integrate multiple genes, for example sequentially; and/or have known genetic sequence; etc), devoid of complex growth requirements (e.g., a necessity for light), mesophilic (e.g., prefer growth temperatures with in the range of about 25-32° C.), able to assimilate a variety of carbon and nitrogen sources and/or capable of growing to high cell density. Alternatively or additionally, various embodiments of the invention utilize host cells that grow as single cells rather than multicellular organisms (e.g., as mycelia).
[0037]In general, when it is desirable to utilize a naturally oleaginous organism in accordance with the present invention, any modifiable and cultivatable oleaginous organism may be employed. In certain embodiments of the invention, yeast or fungi of genera including, but not limited to, Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Mucor, Phycomyces, Pythium, Rhodosporidium, Rhodotorula, Trichosporon, and Yarrowia are employed. In certain particular embodiments, organisms of species that include, but are not limited to, Blakeslea trispora, Candida pulcherrima, C. revkaufi, C. tropicalis, Cryptococcus curvatus, Cunninghamella echinulata, C. elegans, C. japonica, Lipomyces starkeyi, L. lipoferus, Mortierella alpina, M. isabellina, M. ramanniana, M. vinacea, Mucor circinelloides, Phycomyces blakesleanus, Pythium irregulare, Rhodosporidium toruloides, Rhodotorula glutin is, R. gracilis, R. graminis, R. mucilaginosa, R. pinicola, Trichosporon pullans, T. cutaneum, and Yarrowia lipolytica are used.
[0038]Of these naturally oleaginous strains, some also naturally produce carotenoids and some do not. In most cases, only low levels (less than about 0.05% dry cell weight) of carotenoids are produced by naturally-occurring carotenogenic, oleaginous yeast or fungi. Higher levels of βcarotene are sometimes produced, but high levels of other carotenoids are generally not observed.
[0039]In general, any organism that is naturally oleaginous and non-carotenoid-producing (e.g., produce less than about 0.05% dry cell weight, do not produce the carotenoid of interest) may be utilized as a host cell in accordance with the present invention. In some embodiments, the organism is a yeast or fungus from a genus such as, but not limited to, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Pythium, Trichosporon, and Yarrowia; in some embodiments, the organism is of a species including, but not limited to, Mortierella alpina and Yarrowia lipolytica.
[0040]Comparably, the present invention may utilize any naturally oleaginous, carotenoid-producing organism as a host cell. In general, the present invention may be utilized to increase carbon flow into the isoprenoid pathway in naturally carotenoid-producing organisms (particularly for organisms other than Blakeslea and Phycomyces), and/or to shift production from one carotenoid (e.g., β-carotene) to another (e.g., astaxanthin). Introduction of one or more carotenogenic modifications (e.g., increased expression of one or more endogenous or heterologous carotenogenic polypeptides), in accordance with the present invention, can achieve these goals.
[0041]In certain embodiments of the invention, the utilized oleaginous, carotenoid-producing organism is a yeast or fungus, for example of a genus such as, but not limited to, Blakeslea, Mucor, Phycomyces, Rhodosporidium, and Rhodotorula; in some embodiments, the organism is of a species such as, Mucor circinelloides and Rhodotorula glutinis.
[0042]When it is desirable to utilize strains that are naturally non-oleaginous as host cells in accordance with the present invention, genera of non-oleaginous yeast or fungi include, but are not limited to, Aspergillus, Botrytis, Cercospora, Fusarium (Gibberella), Kluyveromyces, Neurospora, Penicillium, Pichia (Hansenula), Puccinia, Saccharomyces, Sclerotium, Trichoderma, and Xanthophyllomyces (Phaffia); in some embodiments, the organism is of a species including, but not limited to, Aspergillus nidulans, A. niger, A. terreus, Botrytis cinerea, Cercospora nicotianae, Fusarium fujikuroi (Gibberella zeae), Kluyveromyces lactis, K. lactis, Neurospora crassa, Pichia pastoris, Puccinia distincta, Saccharomyces cerevisiae, Sclerotium rolfsii, Trichoderma reesei, and Xanthophyllomyces dendrorhous (Phaffia rhodozyma).
[0043]It will be appreciated that the term “non-oleaginous”, as used herein, encompasses both strains that naturally have some ability to accumulate lipid, especially cytoplasmically, but do not do so to a level sufficient to qualify as “oleaginous” as defined herein, as well as strains that do not naturally have any ability to accumulate extra lipid, e.g., extra-membranous lipid. It will further be appreciated that, in some embodiments of the invention, it will be sufficient to increase the natural level of oleaginy of a particular host cell, even if the modified cell does not qualify as oleaginous as defined herein.
[0044]As with the naturally oleaginous organisms, some of the naturally non-oleaginous fungi naturally produce carotenoids, whereas others do not. Genera of naturally non-oleaginous fungi that do not naturally produce carotenoids (e.g., produce less than about 0.05% dry cell weight, do not produce carotenoid of interest) may desirably be used as host cells in accordance with the present invention include, but are not limited to, Aspergillus, Kluyveromyces, Penicillium, Saccharomyces, and Pichia; species include, but are not limited to, Aspergillus niger and Saccharomyces cerevisiae. Genera of naturally non-oleaginous fungi that do naturally produce carotenoids and that may desirably be used as host cells in accordance with the present invention include, but are not limited to, Botrytis, Cercospora, Fusarium (Gibberella), Neurospora, Puccinia, Sclerotium, Trichoderma, and Xanthophyllomyces (Phaffia); species include, but are not limited to, Xanthophyllomyces dendrorhous (Phaffia rhodozyma).
[0045]As discussed above, any of a variety of organisms may be employed as host cells in accordance with the present invention. In certain embodiments of the invention, host cells will be Yarrowia lipolytica cells. Advantages of Y. lipolytica include, for example, tractable genetics and molecular biology, availability of genomic sequence (see, for example. Sherman et al. Nucleic Acids Res. 32(Database issue):D315-8, 2004), suitability to various cost-effective growth conditions, and ability to grow to high cell density. In addition, Y. lipolytica is naturally oleaginous, such that fewer manipulations may be required to generate an oleaginous, carotenoid-producing Y. lipolytica strain than might be required for other organisms. Furthermore, there is already extensive commercial experience with Y. lipolytica.
[0046]Saccharomyces cerevisiae is also a useful host cell in accordance with the present invention, particularly due to its experimental tractability and the extensive experience that researchers have accumulated with the organism. Although cultivation of Saccharomyces under high carbon conditions may result in increased ethanol production, this can generally be managed by process and/or genetic alterations.
[0047]Additional useful hosts include Xanthophyllomyces dendrorhous (Phaffia rhodozyma), which is experimentally tractable and naturally carotenogenic. Xanthophyllomyces dendrorhous (Phaffia rhodozyma) strains can produce several carotenoids, including astaxanthin.
[0048]Aspergillus niger and Mortierella alpina accumulate large amounts of citric acid and fatty acid, respectively; Mortierella alpina is also oleaginous.
[0049]Neurospora or Gibberella are also useful. They are not naturally oleaginous and tend to produce very low levels of carotenoids, thus extensive modification may be required in accordance with the present invention. Neurospora and Gibberella are considered relatively tractable from an experimental standpoint. Both are filamentous fungi, such that production at commercial scales can be a challenge necessary to overcome in utilization of such strains.
[0050]Mucor circinelloides is another available useful species. While its molecular genetics are generally less accessible than are those of some other organisms, it naturally produces β-carotene, thus may require less modification than other species available.
[0051]Molecular genetics can be performed in Blakeslea, though significant effort may be required. Furthermore, cost-effective fermentation conditions can be challenging, as, for example, it may be required that the two mating types are mixed. Fungi of the genus Phycomyces are also possible sources which have the potential to pose fermentation process challenges, and these fungi are also may be less amenable to manipulate than several other potential host organisms.
[0052]Those of ordinary skill in the art will appreciate that the selection of a particular host cell for use in accordance with the present invention will also affect, for example, the selection of expression sequences utilized with any heterologous polypeptide to be introduced into the cell, and will also influence various aspects of culture conditions, etc. Much is known about the different gene regulatory requirements, protein targeting sequence requirements, and cultivation requirements, of different host cells to be utilized in accordance with the present invention (see, for example, with respect to Yarrowia, Barth et al. FEMS Microbiol Rev. 19:219, 1997; Madzak et al. J Biotechnol. 109:63, 2004; see, for example, with respect to Xanthophyllomyces, Verdoes et al. Appl Environ Microbiol 69: 3728-38, 2003; Visser et al. FEMS Yeast Res 4: 221-31, 2003; Martinez et al. Antonie Van Leeuwenhoek. 73(2):147-53, 1998; Kim et al. Appl Environ Microbiol. 64(5):1947-9, 1998; Wery et al. Gene. 184(1):89-97, 1997; see, for example, with respect to Saccharomyces, Guthrie and Fink Methods in Enzymology 194:1-933, 1991). In certain aspects, for example, targeting sequences of the host cell (or closely related analogs) may be useful to include for directing heterologous proteins to subcellular localization. Thus, such useful targeting sequences can be added to heterologous sequence for proper intracellular localization of activity. In other aspects (e.g., addition of mitochondrial targeting sequences), heterologous targeting sequences may be eliminated or altered in the selected heterologous sequence (e.g., alteration or removal of source organism plant chloroplast targeting sequences).
[0000]Engineering Oleaginy
[0053]All living organisms synthesize lipids for use in their membranes and various other structures. However, most organisms do not accumulate in excess of about 10% of their dry cell weight as total lipid, and most of this lipid generally resides within cellular membranes.
[0054]Significant biochemical work has been done to define the metabolic enzymes necessary to confer oleaginy on microorganisms (primarily for the purpose of engineering single cell oils as commercial sources of arachidonic acid and docosahexaenoic acid; see for example Ratledge Biochimie 86:807, 2004, the entire contents of which are incorporated herein by reference). Although this biochemical work is compelling, prior to the present invention, there have been no reports of de novo oleaginy being established through genetic engineering with the genes encoding the key metabolic enzymes.
[0055]It should be noted that oleaginous organisms typically only accumulate lipid when grown under conditions of carbon excess and nitrogen or other nutrient limitation. Under these conditions, the organism readily depletes the limiting nutrient but continues to assimilate the carbon source. The “excess” carbon is channeled into lipid biosynthesis so that lipids (usually triacylglycerols) accumulate in the cytosol, typically in the form of bodies.
[0056]In general, it is thought that, in order to be oleaginous, an organism must produce both acetyl-CoA and NADPH in the cytosol, which can then be utilized by the fatty acid synthase machinery to generate lipids. In at least some oleaginous organisms, acetyl-CoA is generated in the cytosol through the action of ATP-citrate lyase, which catalyzes the reaction:
citrate+CoA+ATP→acetyl-CoA+oxaloacetate+ADP+Pi. (1)
[0057]Of course, in order for ATP-citrate lyase to generate appropriate levels of acetyl-CoA in the cytosol, it must first have an available pool of its substrate citric acid. Citric acid is generated in the mitochondria of all eukaryotic cells through the tricarboxylic acid (TCA) cycle, and can be moved into the cytosol (in exchange for malate) by citrate/malate translocase.
[0058]In most oleaginous organisms, and in some non-oleaginous organisms, the enzyme isocitrate dehydrogenase, which operates as part of the TCA cycle in the mitochondria, is strongly AMP-dependent. Thus, when AMP is depleted from the mitochondria, this enzyme is inactivated. When isocitrate dehydrogenase is inactive, isocitrate accumulates in the mitochondria. This accumulated isocitrate is then equilibrated with citric acid, presumably through the action of aconitase. Therefore, under conditions of low AMP, citrate accumulates in the mitochondria. As noted above, mitochondrial citrate is readily transported into the cytosol.
[0059]AMP depletion, which in oleaginous organisms is believed to initiate the cascade leading to accumulation of citrate (and therefore acetyl-CoA) in the cytoplasm, occurs as a result of the nutrient depletion mentioned above. When oleaginous cells are grown in the presence of excess carbon source but under conditions limiting for nitrogen or some other nutrient(s), the activity of AMP deaminase, which catalyzes the reaction:
AMP→inosine 5′-monophosphate+NH3 (2)
is strongly induced. The increased activity of this enzyme depletes cellular AMP in both the cytosol and the mitochondria. Depletion of AMP from the mitochondria is thought to inactivate the AMP-dependent isocitrate dehydrogenase, resulting in accumulation of citrate in the mitochondria and, therefore, the cytosol. This series of events is depicted diagrammatically in FIG. 2.
[0060]As noted above, oleaginy requires both cytosolic acetyl-CoA and cytosolic NADPH. It is believed that, in many oleaginous organisms, appropriate levels of cytosolic NADPH are provided through the action of malic enzyme (Enzyme 3 in FIG. 2). Some oleaginous organisms (e.g., Lipomyces and some Candida) do not appear to have malic enzymes, however, so apparently other enzymes can provide comparable activity, although it is expected that a dedicated source of NADPH is probably required for fatty acid synthesis (see, for example, Wynn et al., Microbiol 145:1911, 1999; Ratledge Adv. Appl. Microbiol. 51:1, 2002, each of which is incorporated herein by reference in its entirety).
[0061]Thus, according to the present invention, the oleaginy of a host organism may be enhanced by modifying the expression or activity of one or more polypeptides involved in generating cytosolic acetyl-CoA and/or NADPH. For example, modification of the expression or activity of one or more of acetyl-CoA carboxylase, pyruvate decarboxylase, isocitrate dehydrogenase, ATP-citrate lyase, malic enzyme, and AMP-deaminase can enhance oleaginy in accordance with the present invention. Exemplary polypeptides which can be utilized or derived so as to enhance oleaginy in accordance with the present invention include, but are not limited to those acetyl-CoA carboxylase, pyruvate decarboxylase, isocitrate dehydrogenase, ATP-citrate lyase, malic enzyme, and AMP-deaminase polypeptides provided in Table 1, Table 2, Table 3, Table 4, Table 5, and Table 6, respectively.
[0062]In some embodiments of the invention, where an oleaginous host cell is employed, enzymes and regulatory components relevant to oleaginy are already in place but could be modified, if desired, by for example altering expression or activity of one or more oleaginic polypeptides and/or by introducing one or more heterologous oleaginic polypeptides. In those embodiments of the invention where a non-oleaginous host cell is employed, it is generally expected that at least one or more heterologous oleaginic polypeptides will be introduced.
[0063]The present invention contemplates not only introduction of heterologous oleaginous polypeptides, but also adjustment of expression or activity levels of heterologous or endogenous oleaginic polypeptides, including, for example, alteration of constitutive or inducible expression patterns. In some embodiments of the invention, expression patterns are adjusted such that growth in nutrient-limiting conditions is not required to induce oleaginy. For example, genetic modifications comprising alteration and/or addition of regulatory sequences (e.g., promoter elements, terminator elements) may be utilized to confer particular regulation of expression patterns. Such genetic modifications may be utilized in conjunction with endogenous genes (e.g., for regulation of endogenous oleagenic polypeptide(s)); alternatively, such genetic modifications may be included so as to confer regulation of expression of at least one heterologous polypeptide (e.g., oleagenic polypeptide(s)). For example, promoters including, but not limited to Tef1, Gpd1 promoters can be used in conjunction with endogenous genes and/or heterolous genes for modification of expression patterns of endogenous oleaginic polypeptides and/or heterolous oleagenic polypeptides. Similarly, exemplary terminator sequences include, but are not limited to, use of Y. lipolytica XPR2 terminator sequences.
[0064]In some embodiments, at least one oleaginic polypeptide is introduced into a host cell. In some embodiments of the invention, a plurality (e.g., two or more) of different oleaginic polypeptides is introduced into the same host cell. In some embodiments, the plurality of oleaginic polypeptides contains polypeptides from the same source organism; in other embodiments, the plurality includes polypeptides independently selected from different source organisms.
[0065]Representative examples of a variety of oleaginic polypeptides that may be introduced into or modified within host cells according to the present invention, include, but are not limited to, those provided in Tables 1-6. As noted above, it is expected that at least some of these polypeptides (e.g., malic enzyme and ATP-citrate lyase) should desirably act in concert, and possibly together with one or more components of fatty acid synthase, such that, in some embodiments of the invention, it will be desirable to utilize two or more oleaginic polypeptides from the same source organism.
[0066]In general, source organisms for oleaginic polypeptides to be used in accordance with the present invention include, but are not limited to, Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Mucor, Phycomyces, Pythium, Rhodosporidium, Rhodotorula, Trichosporon, Yarrowia, Aspergillus, Botrytis, Cercospora, Fusarium (Gibberella), Kluyveromyces, Neurospora, Penicillium, Pichia (Hansenula), Puccinia, Saccharomyces, Sclerotium, Trichoderma, and Xanthophyllomyces (Phaffia). In some embodiments, the source species for acetyl CoA carboxylase, ATP-citrate lyase, malice enzyme and/or AMP deaminase polypeptides include, but are not limited to, Aspergillus nidulans, Cryptococcus neoformans, Fusarium fujikuroi, Kluyveromyces lactis, Neurospora crassa, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Ustilago maydis, and Yarrowia lipolytica; in some embodiments, source species for pyruvate decarboxylase or isocitrate dehydrogenase polypeptides include, but are not limited to Neurospora crassa, Xanthophyllomyces dendrorhous (Phaffia rhodozyma), Aspergillus niger, Saccharomyces cerevisiae, Mucor circinelloides, Rhodotorula glutinis, Candida utilis, Mortierella alpina and Yarrowia lipolytica.
[0000]Engineering Carotenoid Production
[0067]Carotenoids are synthesized from isoprenoid precursors, some of which are also involved in the production of steroids and sterols. The most common isoprenoid biosynthesis pathway, sometimes referred to as the “mevalonate pathway”, is generally depicted in FIG. 3. As shown, acetyl-CoA is converted, via hydroxymethylglutaryl-CoA (HMG-CoA), into mevalonate. Mevalonate is then phosphorylated and converted into the five-carbon compound isopentenyl pyrophosphate (IPP). Following isomerization of IPP into dimethylallyl pyrophosphate (DMAPP), three sequential condensation reactions with additional molecules of IPP generate the ten-carbon molecule geranyl pyrophosphate (GPP), followed by the fifteen-carbon molecule famesyl pyrophosphate (FPP), and finally the twenty-carbon compound geranylgeranyl pyrophosphate (GGPP).
[0068]An alternative isoprenoid biosynthesis pathway, that is utilized by some organisms (particularly bacteria) and is sometimes called the “mevalonate-independent pathway”, is depicted in FIG. 4. This pathway is initiated by the synthesis of 1-deoxy-D-xyloglucose-5-phosphate (DOXP) from pyruvate and glyceraldehyde-3-phosphate. DOXP is then converted, via a series of reactions shown in FIG. 4, into IPP, which isomerizes into DMAPP and is then converted, via GPP and FPP, into GGPP as shown in FIG. 3 and discussed above.
[0069]Various proteins involved in isoprenoid biosynthesis have been identified and characterized in a number of organisms. Moreover, various aspects of the isoprenoid biosynthesis pathway are conserved throughout the fungal, bacterial, plant and animal kingdoms. For example, polypeptides corresponding to the acetoacetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, IPP isomerase, FPP synthase, and GGPP synthase shown in FIG. 3 have been identified in and isolated from a wide variety of organisms and cells. Representative examples of a wide variety of such polypeptides are provided in Tables 7-15. One or more of the polypeptides selected from those provided in any one of Tables 7-15 may be utilized or derived for use in the methods and compositions in accordance with the present invention.
[0070]According to the present invention, carotenoid production in a host organism may be adjusted by modifying the expression or activity of one or more proteins involved in isoprenoid biosynthesis. In some embodiments, such modification involves introduction of one or more heterologous isoprenoid biosynthesis polypeptides into the host cell; alternatively or additionally, modifications may be made to the expression or activity of one or more endogenous or heterologous isoprenoid biosynthesis polypeptides. Given the considerable conservation of components of the isoprenoid biosynthesis polypeptides, it is expected that heterologous isoprenoid biosynthesis polypeptides will often function even in significantly divergent organisms. Furthermore, should it be desirable to introduce more than one heterologous isoprenoid biosynthesis polypeptide, in many cases polypeptides from different source organisms will function together. In some embodiments of the invention, a plurality of different heterologous isoprenoid biosynthesis polypeptides is introduced into the same host cell. In some embodiments, this plurality contains only polypeptides from the same source organism (e.g., two or more sequences of, or sequences derived from, the same source organism); in other embodiments the plurality includes polypeptides independently selected from from different source organisms (e.g., two or more sequences of, or sequences derived from, at least two independent source organisms).
[0071]In some embodiments of the present invention that utilize heterologous isoprenoid biosynthesis polypeptides, the source organisms include, but are not limited to, fungi of the genera Blakeslea, Candida, Cryptococcus, Cunninghamella, Lipomyces, Mortierella, Mucor, Phycomyces, Pythium, Rhodosporidium, Rhodotorula, Trichosporon, Yarrowia, Aspergillus, Botrytis, Cercospora, Fusarium (Gibberella), Kluyveromyces, Neurospora, Penicillium, Pichia (Hansenula), Puccinia, Saccharomyces, Schizosaccharomyces, Sclerotium, Trichoderms, Ustilago, and Xanthophyllomyces (Phaffia). In certain embodiments, the source organisms are of a species including, but not limited to, Cryptococcus neoformans, Fusarium fujikuroi, Kluyverimyces lactis, Neurospora crassa, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Ustilago maydis, and Yarrowia lipolytica.
[0072]As noted above, the isoprenoid biosynthesis pathway is also involved in the production of non-carotenoid compounds, such as sterols, steroids, and vitamins, such as vitamin E or vitamin K. Proteins that act on isoprenoid biosynthesis pathway intermediates, and divert them into biosynthesis of non-carotenoid compounds are therefore indirect inhibitors of carotenoid biosynthesis (see, for example, FIG. 5, which illustrates points at which isoprenoid intermediates are channeled into other biosynthesis pathways). Such proteins are therefore considered isoprenoid biosynthesis competitor polypeptides. Reductions of the level or activity of such isoprenoid biosynthesis competitor polypeptides are expected to increase carotenoid production in host cells according to the present invention.
[0073]In some embodiments of the present invention, production or activity of endogenous isoprenoid biosynthesis competitor polypeptides may be reduced or eliminated in host cells. In some embodiments, this reduction or elimination of the activity of an isoprenoid biosynthesis competitor polypeptide can be achieved by treatment of the host organism with small molecule inhibitors of enzymes of the ergosterol biosynthetic pathway. Enzymes of the ergosterol biosynthetic pathway include, for example, squalene synthase, squalene epoxidase, 2,3-oxidosqualene-lanosterol cyclase, cytochrome P450 lanosterol 14α-demethylase, C-14 sterol reductase, C-4 sterol methyl oxidase, SAM:C-24 sterol methyltransferase, C-8 sterol isomerase, C-5 sterol desaturase, C-22 sterol desaturase, and C-24 sterol reductase. Each of these enzymes is considered an isoprenoid biosynthesis competitor polypeptide. Regulators of these enzymes may also be considered isoprenoid biosynthesis competitor polypeptides (e.g., the yeast proteins Sut1 (Genbank Accession JC4374 GI:2133159) and Mot3 (Genbank Accession NP—013786 GI:6323715), which may or may not have homologs in other organisms.
[0074]In other embodiments, reduction or elimination of the activity of an isoprenoid biosynthesis competitor polypeptide can be achieved by decreasing activity of the ubiquinone biosynthetic pathway. The commitment step in ubiquinone biosynthesis is the formation of para-hydroxybenzoate (PHB) from tyrosine or phenylalanine in mammals or chorismate in bacteria, followed by condensation of PHB and isoprene precursor, resulting in addition of the prenyl group. This reaction is catalyzed by PHB-polyprenyltransferase. The isoprenoid side chain of ubiquinone is determined by the prenyidiphosphate synthase enzyme. The 3-decaprenyl-4-hydroxybenzoic acid resulting from the condensation of PHB and decaprenyldiphosphate reaction undergoes further modifications, which include hydroxylation, methylation and decarboxylation, in order to form ubiquinone (CoQ10). Thus, inhibition of prenyidiphosphate synthase leading from famesyldiphosphate to extended isoprenoids, or inhibition of PHB polyprenyltransferase may be useful in increasing the amount of isoprenoid available for carotenoid biosynthesis. (Examples of prenyldiphosphate synthase and PHB-polyprenyltransferase enzymes are depicted in Tables 29 and 30, respectively).
[0075]Known small molecule inhibitors of isoprenoid biosynthesis competitor enzymes include, but are not limited to, zaragosic acid (including analogs thereof such as TAN1607A (Biochem Biophys Res Commun 1996 Feb. 15;219(2):515-520)), RPR 107393 (3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-1-azabicyclo[2-2-2]octane dihydrochloride; J Pharmacol Exp Ther. 1997 May;281(2):746-52), ER-28448 (5-{N-[2-butenyl-3-(2-methoxyphenyl)]-N-methylamino}-1,1-penthylidenebis(phosphonic acid) trisodium salt; Journal of Lipid Research, Vol. 41, 1136-1144, July 2000), BMS-188494 (The Journal of Clinical Pharmacology, 1998; 38:1116-1121), TAK-475 (1-[2-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-(2,3-dimethoxyphenyl)-4,1-benzoxazepine-3-yl]acetyl]piperidin-4-acetic acid; Eur J Pharmacol. 2003 April 11;466(1-2):155-61), YM-5360 ((E)-2-[2-fluoro-2-(quinuclidin-3-ylidene)ethoxy]-9H -carbazole monohydrochloride; Br J Pharmacol. 2000 September;131(1):63-70), or squalestatin I that inhibit squalene synthase; terbinafine that inhibits squalene epoxidase; various azoles that inhibit cytochrome P450 lanosterol 14α-demethylase; and fenpropimorph that inhibits the C-14 sterol reductase and the C-8 sterol isomerase. In other embodiments, heterologous isoprenoid biosynthesis competitor polypeptides may be utilized (whether functional or non-functional; in some embodiments, dominant negative mutants are employed).
[0076]One particular isoprenoid biosynthesis competitor polypeptide useful according to the present invention is squalene synthase which has been identified and characterized from a variety of organisms; representative examples of squalene synthase polypeptide sequences are included in Table 16. In some embodiments of the invention that utilize squalene synthase (or modifications of squalene synthase) source organisms include, but are not limited to, Neurospora crassa, Xanthophyllomyces dendrorhous (Phaffia rhodozyma), Aspergillus niger, Saccharomyces cerevisiae, Mucor circinelloides, Rhotorula glutinis, Candida utilis, Mortierella alpina, and Yarrowia lipolytica.
[0077]The carotenoid biosynthesis pathway branches off from the isoprenoid biosynthesis pathway at the point where GGPP is formed. The commitment step in carotenoid biosynthesis is the formation of phytoene by the head-to-head condensation of two molecules of GGPP, catalyzed by phytoene synthase (often called crtB; see FIG. 6). A series of dehydrogenation reactions, each of which increases the number of conjugated double bonds by two, converts phytoene into lycopene via neurosporene. The pathway branches at various points, both before and after lycopene production, so that a wide range of carotenoids can be generated. For example, action of a cyclase enzyme on lycopene generates γ-carotene; action of a desaturase instead produces 3,4-didehydrolycopene. γ-carotene is converted to β-carotene through the action of a cyclase. β-carotene can be processed into any of a number of products (see, for example, FIG. 6C), including astaxanthin (via echinone, hydroxyechinone, and phoenicoxanthin).
[0078]According to the present invention, carotenoid production in a host organism may be adjusted by modifying the expression or activity of one or more proteins involved in carotenoid biosynthesis. As indicated, in some embodiments, it will be desirable to utilize as host cells organisms that naturally produce one or more carotenoids. In some such cases, the focus will be on increasing production of a naturally-produced carotenoid, for example by increasing the level and/or activity of one or more proteins involved in the synthesis of that carotenoid and/or by decreasing the level or activity of one or more proteins involved in a competing biosynthetic pathway. Alternatively or additionally, in some embodiments it will be desirable to generate production of one or more carotenoids not naturally produced by the host cell.
[0079]According to some embodiments of the invention, it will be desirable to introduce one or more heterologous carotenogenic polypeptides into a host cell. As will be apparent to those of ordinary skill in the art, any of a variety of heterologous polypeptides may be employed; selection will consider, for instance, the particular carotenoid whose production is to be enhanced. The present invention contemplates not only introduction of heterologous carotenogenic polypeptides, but also adjustment of expression or activity levels of heterologous or endogenous carotenogenic polypeptides, including, for example, alteration of constitutive or inducible expression patterns. In some embodiments of the invention, expression patterns are adjusted such that growth in nutrient-limiting conditions is not required to induce oleaginy. For example, genetic modifications comprising alteration and/or addition of regulatory sequences (e.g., promoter elements, terminator elements) may be utilized to confer particular regulation of expression patterns. Such genetic modifications may be utilized in conjunction with endogenous genes (e.g., for regulation of endogenous carotenogenic); alternatively, such genetic modifications may be included so as to confer regulation of expression of at least one heterologous polypeptide (e.g., carotenogenic polypeptide(s)). For example, promoters including, but not limited to Tef1, Gpd1 promoters can be used in conjunction with endogenous genes and/or heterolous genes for modification of expression patterns of endogenous carotenogenic polypeptide(s) and/or heterolous carotenogenic polypeptide(s). Similarly, exemplary terminator sequences include, but are not limited to, use of Y. lipolytica XPR2 terminator sequences.
[0080]As indicated in FIG. 6 and in the literature, proteins involved in carotenoid biosynthesis include, but are not limited to, phytoene synthase, phytoene dehydrogenase, lycopene cyclase, carotenoid ketolase, carotenoid hydroxylase, astaxanthin synthase (a single multifunctional enzyme found in some source organisms that typically has both ketolase and hydroxylase activities), carotenoid epsilon hydroxylase, lycopene cyclase (beta and epsilon subunits), carotenoid glucosyltransferase, and acyl CoA:diacyglycerol acyltransferase. Representative example sequences for these carotenoid biosynthesis polypeptides are provided in Tables 17-25.
[0081]Xanthophylls can be distinguished from other carotenoids by the presence of oxygen containing functional groups on their cyclic end groups. For instance, lutein and zeaxanthin contain a single hydroxyl group on each of their terminal ring structures, while astaxanthin contains both a keto group and a hydroxyl on each terminal ring. This property makes xanthophylls more polar than carotenes such as beta-carotene and lycopene, and thus dramatically reduces their solubility in fats and lipids. Naturally occurring xanthophylls are often found as esters of the terminal hydroxyl groups, both mono- and diesters of fatty acids. They also occur as glucosides in certain species of bacteria. The solubility and dispersibility of xanthophylls can be greatly modified by the addition of ester moieties, and it is known that esterification can also affect the absorbability and/or bioavailability of a given carotenoid. It is an objective of this invention to maximize the amount of a particular xanthophyll accumulating within the intracellular triacylglyceride fraction of oleaginous yeasts, and one mechanism for achieving this goal is to increase the hydrophobic nature of the xanthophyll product that accumulates. One way of achieving this is to engineer the production of fatty-acyl mono- and/or diesters of the target xanthophyll compound.
[0082]A variety of enzymes can function to esterify carotenoids. For example, carotenoid glucosyltransferases have been identified in several bacterial species (see, e.g., Table 24). In addition, acyl CoA:diacyglycerol acyltransferase (DGAT) and acyl CoA:monoacylglycerol acyltransferases (MGAT), which function in the final steps of triacylglycerol biosynthesis, are likely to serve an additional role in the esterification of xanthophylls. Representative DGAT polypetides are shown in Table 25. Furthermore, other enzymes may specifically modify carotenoids and molecules of similar structure (e.g. sterols) and be available for modification and ester production.
[0083]In some embodiments of the invention, potential source organisms for carotenoid biosynthesis polypeptides include, but are not limited to, genera of naturally oleaginous or non-oleaginous fungi that naturally produce carotenoids. These include, but are not limited to, Botrytis, Cercospora, Fusarium (Gibberella), Mucor, Neurospora, Phycomyces, Puccina, Rhodotorula, Sclerotium, Trichoderma, and Xanthophyllomyces. Exemplary species include, but are not limited to, Neurospora crassa, Xanthophyllomyces dendrorhous (Phaffia rhodozyma), Mucor circinelloildes, and Rhodotorula glutinis. Of course, carotenoids are produced by a wide range of diverse organisms such as plants, algae, yeast, fungi, bacteria, cyanobacteria, etc. Any such organisms may be source organisms for carotenoid biosynthesis polypeptides according to the present invention.
[0084]It will be appreciated that the particular carotenogenic modification to be applied to a host cell in accordance with the present invention will be influenced by which carotenoid(s) is desired to be produced. For example, isoprenoid biosynthesis polypeptides are relevant to the production of most carotenoids. Carotenoid biosynthesis polypeptides are also broadly relevant. Ketolase is particularly relevant for production of canthaxanthin, as hydroxylase is for production of lutein and zeaxanthin, among others. Both hydroxylase and ketolase (or astaxanthin synthase) are particularly useful for production of astaxanthin.
[0000]Production and Isolation of Carotenoids
[0085]As discussed above, accumulation of lipid bodies in oleaginous organisms is generally induced by growing the relevant organism in the presence of excess carbon source and limiting nitrogen. Specific conditions for inducing such accumulation have previously been established for a number of different oleaginous organisms (see, for example, Wolf (ed.) Nonconventionalyeasts in biotechnology Vol. 1, Springer-Verlag, Berlin, Germany, pp. 313-338; Lipids 18(9):623, 1983; Indian J. Exp. Biol. 35(3):313, 1997; J. Ind. Microbiol. Biotechnol. 30(1):75, 2003; Bioresour Technol. 95(3):287, 2004, each of which is incorporated herein by reference in its entirety).
[0086]In general, it will be desirable to cultivate inventive modified host cells under conditions that allow accumulation of at least about 20% of their dry cell weight as lipid. In other embodiments, the inventive modified host cells are grown under conditions that permit accumulation of at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or even 80% or more of their dry cell weight as lipid. In certain embodiments, the host cells utilized are cells which are naturally oleaginous, and induced to produce lipid to the desired levels. In other embodiments, the host cells are cells which naturally produce lipid, but have been engineered to increase production of lipid such that desired levels of lipid production and accumulation are achieved.
[0087]In certain embodiments, the host cells of the invention are not naturally oleaginous, but have been engineered to produce lipid such that desired levels of lipid production are obtained. Those of ordinary skill in the art will appreciate that, in general, growth conditions that are effective for inducing lipid accumulation in a source organism, may well also be useful for inducing lipid accumulation in a host cell into which the source organism's oleaginic polypeptides have been introduced. Of course, modifications may be required in light of characteristics of the host cell, which modifications are within the skill of those of ordinary skill in the art.
[0088]It will also be appreciated by those of ordinary skill in the art that it will generally be desirable to ensure that production of the desired carotenoid by the inventive modified host cell occurs at an appropriate time in relation to the induction of oleaginy such that the carotenoid(s) accumulate(s) in the lipid bodies. In some embodiments, it will be desirable to induce production of the carotenoid(s) in a host cell which does not naturally produce the carotenoid(s), such that detectable levels of the carotenoid(s) is/are produced. In certain aspects the host cells which do not naturally produce a certain carotenoid(s) are capable of production of other carotenoid(s) (e.g. certain host cells may, for example, naturally produce β-carotene but may not naturally produce astaxanthin); in other aspects the host cells do not naturally produce any carotenoid(s). In other embodiments, it will be desirable to increase production levels of carotenoid(s) in a host cell which does naturally produce low levels of the carotenoid(s), such that increased detectable levels of the carotenoid(s) are produced. In certain aspects, the host cells which do naturally produce the carotenoid(s) (e.g., β-carotene) also produce additional carotenoid(s) (e.g., astaxanthin, etc.); in still other aspects, the cells which naturally produce the carotenoid(s) (e.g., β-carotene) do not produce additional carotenoid(s).
[0089]In certain embodiments of the invention, it will be desirable to accumulate carotenoids to levels (i.e., considering the total amount of all produced carotenoids together) that are greater than at least about 1% of the dry weight of the cells. In some embodiments, the total carotenoid accumulation in the lipid bodies will be to a level at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20% or more of the total dry weight of the cells. In certain embodiments of the invention, it will be desirable to achieve total levels of carotenoid accumulation in the lipid bodies (i.e., considering the total amount of all produced carotenoids together) that are greater than at least about 1% of the dry weight of the cells. In some embodiments, the total carotenoid accumulation in the lipid bodies will be to a level at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20% or more of the total dry weight of the cells.
[0090]Bacterial carotenogenic genes have already been demonstrated to be transferrable to other organisms, and are therefore particularly useful in accordance with the present invention (see, for example, Miura et al., Appl. Environ. Microbiol. 64:1226, 1998). In other embodiments, it may be desirable to utilize genes from other source organisms such as plant, alga, or microalgae; these organisms provide a variety of potential sources for ketolase and hydroxylase polypeptides. Still additional useful source organisms include fungal, yeast, insect, protozoal, and mammalian sources of polypeptides.
[0091]In certain embodiments, the Mucor circinelloides multi-functional phytoene synthase/lycopene cyclase and the Neurospora crassa phytoene dehydrogenase genes can be expressed in Yarrowia lipolytica. Subsequent overexpression of the catalytic domain from N. crassa hydroxymethylglutaryl-CoA reductase and/or treatment of the modified Y. lipolytica strains with the squalene synthase inhibitor zaragozic acid further increases carotenoid production. Finally, Paracoccus marcusii genes encoding carotenoid hydroxylase and carotenoid ketolase enzymes are expressed in Y. lipolytica β-carotene-producing strains, and this modification results in the accumulation of astaxanthin. Similar approaches to enhance carotenoid production could be employed in other oleaginous or non-oleaginous host organisms can be undertaken, using the same, homologous, or functionally similar carotogenic polypeptides.
[0092]It should be noted that, for inventive organisms that produce more than one carotenoid, it will sometimes be possible to adjust the relative amounts of individual carotenoids produced by adjusting growth conditions. For example, it has been reported that controlling the concentration of dissolved oxygen in a culture during cultivation can regulate relative production levels of certain carotenoids such as β-carotene, echinenone, β-cryptoxanthin, 3-hydroxyechinenone, asteroidenone, canthaxanthin, zeaxanthin, adonirubin, adonixanthin and astaxanthin (see, for example, U.S. Pat. No. 6,825,002 to Tsubokura et al., the entire contents of which are incorporated herein by reference).
[0093]Particularly for embodiments of the present invention directed toward production of astaxanthin, it will often be desirable to utilize one or more genes from a natural astaxanthin-producing organism. Where multiple heterologous polypeptides are to be expressed, it may be desirable to utilize the same source organism for all, or to utilize closely related source organisms.
[0094]One advantage provided by the present invention is that, in addition to allowing the production of high levels of carotenoids, the present invention allows those produced compounds to be readily isolated because they accumulate in the lipid bodies within oleaginous organisms. Methods and systems for isolating lipid bodies have been established for a wide variety of oleaginous organisms (see, for example, U.S. Pat. Nos. 5,164,308; 5,374,657; 5,422,247; 5,550,156; 5,583,019; 6,166,231; 6,541,049; 6,727,373; 6,750,048; and 6,812,001, each of which is incorporated herein by reference in its entirety). In brief, cells are typically recovered from culture, often by spray drying, filtering or centrifugation. In some instances, cells are homogenized and then subjected to supercritical liquid extraction or solvent extraction (e.g., with solvents such as chloroform, hexane, methylene chloride, methanol, isopropanol, ethyl acetate, etc.), yielding a crude oil suspension. This oil suspension may optionally be refined as known in the art. Refined oils may be used directly as feed or food additives. Alternatively or additionally, carotenoids can be isolated from the oil using conventional techniques.
[0095]Given the sensitivity of carotenoids generally to oxidation, many embodiments of the invention employ oxidative stabilizers (e.g., tocopherols, vitamin C; ethoxyquin; vitamin E, BHT, BHA, TBHQ, etc, or combinations thereof) during and/or after carotenoid isolation. Alternatively or additionally, microencapsulation, for example with proteins, may be employed to add a physical barrier to oxidation and/or to improve handling (see, for example, U.S. Patent Application 2004/0191365).
[0096]Carotenoids produced according to the present invention can be utilized in any of a variety of applications, for example exploiting their biological or nutritional properties (e.g., anti-oxidant, anti-proliferative, etc.) and/or their pigment properties. For example, according to the present invention, carotenoids may be used in pharmaceuticals (see, for example, Bertram, Nutr. Rev. 57.182, 1999; Singh et al., Oncology 12:1643, 1998; Rock, Pharmacol. Ther. 75:185, 1997; Edge et al, J. Photochem Photobiol 41:189, 1997; U.S. Patent Application 2004/0116514; U.S. Patent Application 2004/0259959), food supplements (see, for example, Koyama et al, J. Photochem Photobiol 9:265, 1991; Bauemfeind, Carotenoids as colorants and vitamin A precursors, Academic Press, NY, 1981; U.S. Patent Application 2004/0115309; U.S. Patent Application 2004/0234579), electro-optic applications, animal feed additives (see, for example, Krinski, Pure Appl. Chem. 66:1003,1994; Polazza et al., Meth. Enzymol. 213:403, 1992), cosmetics (as anti-oxidants and/or as cosmetics, including fragrances; see for example U.S. Patent Application 2004/0127554), etc. Carotenoids produced in accordance with the present invention may also be used as intermediates in the production of other compounds (e.g., steroids, etc.).
[0097]For example, astaxanthin and/or esters thereof may be useful in a variety of pharmaceutical applications and health foods including treatment of inflammatory diseases, asthma, atopic dermatitis, allergies, multiple myeloma, arteriosclerosis, cardiovascular disease, liver disease, cerebrovascular disease, thrombosis, neoangiogenesis-related diseases, including cancer, rheumatism, diabetic retinopathy; macular degeneration and brain disorder, hyperlipidemia, kidney ischemia, diabetes, hypertension, tumor proliferation and metastasis; and metabolic disorders. Additionally, carotenoids and astaxanthin may be useful in the prevention and treatment of fatigue, for improving kidney function in nephropathy from inflammatory diseases, as well as prevention and treatment of other life habit-related diseases. Still further, astaxanthin has been found to play a role as inhibitors of various biological processes, including interleukin inhibitors, phosphodiesterase inhibitors inhibitors, phospholipase A2 inhibitors, cyclooxygenase-2 inhibitors, matrix metalloproteinase inhibitors, capillary endothelium cell proliferation inhibitors, lipoxygenase inhibitors. See, e.g., Japanese Publication No. 2006022121, published Jan. 26, 2000(JP Appl No. 2005-301156 filed Oct. 17, 2005); Japanese Publication No. 2006016408, published Jan. 19, 2006(JP Appl No. 2005-301155 filed Oct. 17, 2005); Japanese Publication No. 2006016409, published Jan. 19, 2006(JP Appl No. 2005-301157 filed Oct. 17, 2005); Japanese Publication No. 2006016407, published Jan. 19, 2006(JP Appl No. 2005-301153 filed Oct. 17, 2005); Japanese Publication No. 2006008717, published Jan. 12, 2006(JP Appl No. 2005-301151 filed Oct. 17, 2005); Japanese Publication No. 2006008716, published Jan. 12, 2006(JP Appl No. 2005-301150 filed Oct. 17, 2005); Japanese Publication No. 2006008720, published Jan. 12, 2006(JP Appl No. 2005-301158 filed Oct. 17, 2005); Japanese Publication No. 2006008719, published Jan. 12, 2006(JP Appl No. 2005-301154 filed Oct. 17, 2005); Japanese Publication No. 2006008718, published Jan. 12, 2006(JP Appl No. 2005-301152 filed Oct. 17, 2005); Japanese Publication No. 2006008713, published Jan. 12, 2006(JP Appl No. 2005-301147 filed Oct. 17, 2005); Japanese Publication No. 2006008715, published Jan. 12, 2006(JP Appl No. 2005-301149 filed Oct. 17, 2005); Japanese Publication No. 2006008714, published Jan. 12, 2006(JP Appl No. 2005-301148 filed Oct. 17, 2005); and Japanese Publication No. 2006008712, published Jan. 12, 2006(JP Appl No. 2005-301146 filed Oct. 17, 2005).
[0098]It will be appreciated that, in some embodiments of the invention, carotenoids produced by manipulated host cells as described herein are incorporated into a final product (e.g., food or feed supplement, pharmaceutical, cosmetic, dye-containing item, etc.) in the context of the host cell. For example, host cells may be lyophilized, freeze dried, frozen or otherwise inactivated, and then whole cells may be incorporated into or used as the final product. The host cell may also be processed prior to incorporation in the product to increase bioavailability (e.g., via lysis). Alternatively or additionally, a final product may incorporate only a portion of the host cell (e.g., fractionated by size, solubility), separated from the whole. For example, in some embodiments of the invention, lipid droplets are isolated from the host cells and are incorporated into or used as the final product. In other embodiments, the carotenoids themselves, or individual carotenoid compounds are isolated and reformulated into the final product.
[0099]As stated above, fatty acid and glucoside esters are the predominant carotenoid esters found in nature, whereas additional esters (e.g. with organic acids or inorganic phosphate) can be synthesized to generate useful product forms. For delivery, carotenoid esters can also be formulated as salts of the ester form. See, e.g., US Publication No. 20050096477.
[0100]The amount of carotenoid incorporated into a given product may vary dramatically depending on the product, and the particular carotenoid(s) involved. Amounts may range, for example, from less than 0.01% by weight of the product, to more than 1%, 10%, 20%, 30% or more; in some cases the carotenoid may comprise 100% of the product.
[0101]In some embodiments of the invention, one or more produced carotenoids is incorporated into a component of food or feed (e.g., a food supplement). Types of food products into which carotenoids can be incorporated according to the present invention are not particularly limited, and include beverages such as teas, juices, and liquors; confections such as jellies and biscuits; fat-containing foods and beverages such as dairy products; processed food products such as rice and soft rice (or porridge); infant formulas; or the like. In some embodiments of this aspect of the invention, it may be useful to incorporate the carotenoids within bodies of edible lipids as it may facilitate incorporation into certain fat-containing food products.
[0102]Examples of feedstuffs into which carotenoids produced in accordance with the present invention may be incorporated include, for instance, pet foods such as cat foods, dog foods and the like, feeds for aquarium fish, cultured fish or crustaceans, etc., feed for farm-raised animals (including livestock and further including fish or crustaceans raised in aquaculture). Food or feed material into which the carotenoid(s) produced in accordance with the present invention is incorporated is preferably palatable to the organism which is the intended recipient. This food or feed material may have any physical properties currently known for a food material (e.g., solid, liquid, soft).
[0103]In some embodiments of the invention, one or more produced carotenoids is incorporated into a cosmetic product. Examples of such cosmetics include, for instance, skin cosmetics (e.g., lotions, emulsions, creams and the like), lipsticks, anti-sunburn cosmetics, makeup cosmetics, fragrances, products for daily use (e.g., toothpastes, mouthwashes, bad breath preventive agents, solid soaps, liquid soaps, shampoos, conditioners), etc.
[0104]In some embodiments, one or more produced carotenoids is incorporated into a pharmaceutical. Examples of such pharmaceuticals include, for instance, various types of tablets, capsules, drinkable agents, troches, gargles, etc. In some embodiments, the pharmaceutical is suitable for topical application. Dosage forms are not particularly limited, and include capsules, oils, granula, granula subtilae, pulveres, tabellae, pilulae, trochisci, or the like. Oils and oil-filled capsules may provide additional advantages both because of their lack of ingredient decomposition during manufacturing, and because inventive carotenoid-containing lipid droplets may be readily incorporated into oil-based formulations.
[0105]Pharmaceuticals according to the present invention may be prepared according to techniques established in the art including, for example, the common procedure as described in the United States Pharmacopoeia, for example.
[0106]Carotenoids produced according to the present invention may be incorporated into any pigment-containing product including, for example, fabric, paint, etc. They may also be incorporated into a product which is an environmental indicator, or an instrument such as a biosensor for use as a detection agent.
EXEMPLIFICATION
[0107]Table 26 below describes certain Yarrowia lipolytica strains used in the following exemplification:
[0108] |
| Yarrowia lipolytica strains. |
| NRRL Y-1095 | Wild type diploid |
|
| ATCC76861 | MATB ura2-21 lyc1-5 LYS1-5B | |
| ATCC76982 | MATB ade1 leu2-35 lyc1-5 xpr2 |
| ATCC201249 | MATA ura3-302 leu2-270 |
| lys8-11 PEX17-HA |
| MF346 | MATA ura2-21 | ATCC76861 × |
| | ATCC201249 |
| MF350 | MATB ura2-21 leu2-35 ade1 | ATCC76982 × MF346 |
|
[0109](The genotypes at LYC1, LYS1, XPR2, and PEX17 were not determined in crosses nor verified for ATCC strains.)
[0110]All basic molecular biology and DNA manipulation procedures described herein are generally performed according to Sambrook et al. or Ausubel et al. (Sambrook J, Fritsch E F, Maniatis T (eds). 1989. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press: New York; Ausubel F M, Brent R, Kingston R E, Moore D D, Seidman J G, Smith J A, Struhl K (eds). 1998. Current Protocols in Molecular Biology. Wiley: New York).
Example 1
Production of Plasmids for Carotenoid Strain Construction
[0111]Plasmids were generated for construction of carotenoid producing strains. The following subparts describe production of plasmids encoding carotenogenic polypeptides. Plasmids used in these studies and details of their construction are described in Table 27. Additional plasmid construction details and descriptions of their use are found in the text of the relevant subsection. All PCR amplifications used NRRL Y-1095 genomic DNA as template unless otherwise specified. The URA5 gene described below is allelic with the ura2-21 auxotrophy above. The GPD1 and TEF1 promoters are from Y. lipolytica as is the XPR2 terminator.
[0112]GGS1 is the gene encoding the Y. lipolytica gene encoding geranylgeranylpyrophosphate synthase. The nucleic acid coding sequence, and encoded Ggs1 protein of pMB4591 and pMB4683 are as follows:
[0113]| atggattataacagcgcggatttcaaggagatatggggcaaggccgccgacaccgcgctgctgggaccgtacaactac | |
|
| ctcgccaacaaccggggccacaacatcagagaacacttgatcgcagcgttcggagcggttatcaaggtggacaagagcgatctcgagaccattt |
|
| cgcacatcaccaagattttgcataactcgtcgctgcttgttgatgacgtggaagacaactcgatgctccgacgaggcctgccggcagcccattgtc |
|
| tgtttggagtcccccaaaccatcaactccgccaactacatgtactttgtggctctgcaggaggtgctcaagctcaagtcttatgatgccgtctccatttt |
|
| caccgaggaaatgatcaacttgcatagaggtcagggtatggatctctactggagagaaacactcacttgcccctcggaagacgagtatctggaga |
|
| tggtggtgcacaagaccggtggactgtttcggctggctctgagacttatgctgtcggtggcatcgaaacaggaggaccatgaaaagatcaactttg |
|
| atctcacacaccttaccgacacactgggagtcatttaccagattctggatgattacctcaacctgcagtccacggaattgaccgagaacaagggatt |
|
| ctgcgaagatatcagcgaaggaaagttttcgtttccgctgattcacagcatacgcaccaacccggataaccacgagattctcaacattctcaaacag |
|
| cgaacaagcgacgcttcactcaaaaagtacgccgtggactacatgagaacagaaaccaagagtttcgactactgcctcaagaggatacaggcca |
|
| tgtcactcaaggcaagttcgtacattgatgatctagcagcagctggccacgatgtctccaagctacgagccattttgcattattttgtgtccacctctg |
|
| actgtgaggagagaaagtactttgaggatgcgcagtga |
| (SEQ ID NO: 1) |
|
| mdynsadfkeiwgkaadtallgpynylannrghnirehliaafgavikvdksdletishitkilhnssllvddvedns |
|
| mlrrglpaahclfgvpqtinsanymyfvalqevlklksydavsifteeminlhrgqgmdlywretltcpsedeylemvvhktgglfrlalrlm |
|
| Isvaskqedhekinfdlthltdtlgviyqilddylnlqsteltenkgfcedisegkfsfplihsirtnpdnheilnilkqrtsdaslkkyavdymrte |
|
| tksfdyclkriqamslkassyiddlaaaghdvsklrailhyfvstsdceerkyfedaq |
| (SEQ ID NO: 2) |
[0114] |
| Plasmids |
| Plasmid | Backbone | Insert | Oligos or source |
|
| pMB4529 | PCR2.1 | 3.4 kb ADE1 PCR product | MO4475 & MO4476 |
| pMB4534 | PCR2.1 | 2.1 kb LEU2 PCR product | MO4477 & MO4478 |
| pMB4535 | PCR2.1 | 1.2 kb URA5 PCR product | MO4471 & MO4472 |
| pMB4589 | pMB4535 (KpnI + SpeI) | 1.2 kb GPD1 promoter (KpnI + NotI); | MO4568 & |
| | 0.14 kb XPR2 | MO4591; MO4566 |
| | terminator (NotI + SpeI) | & MO4593 |
| pMB4590 | pMB4535 (KpnI + SpeI) | 0.4 kb TEF1 promoter (KpnI + NotI); | MO4571 & |
| | 0.14 kb XPR2 | MO4592; MO4566 |
| | terminator (NotI + SpeI) | & MO4593 |
| pMB4591 | pMB4590 (NheI + MluI) | 1.0 kb GGS1 ORF (XbaI + MluI) | MO4534 & MO4544 |
| pMB4597 | pMB4534 (Acc65I + SpeI) | GPD1 promoter & XPR2 | From pMB4589 |
| | terminator (Acc65I + SpeI) |
| pMB4603 | pMB4597 (RsrII + MluI) | Residual backbone | From pMB4590 |
| | & TEF1 promoter (RsrII + MluI) |
| pMB4616 | pMB4529 (RsrII + SpeI) | Residual backbone | From pMB4589 |
| | & GPD1 promoter & XPR2 |
| | terminator (RsrII + SpeI) |
| pMB4629 | pMB4616 (RsrII + MluI) | Residual backbone | From pMB4590 |
| | & TEF1 promoter (RsrII + MluI) |
| pMB4631 | pMB4603 (KpnI + NheI) | 1.2 kb GPD1 promoter (KpnI + NheI); | MO4568 & MO4659 |
| pMB4628 | pMB4603 | Carp | See 1A |
| pMB4637 | pMB4629 (NheI + MluI) | 1.5 kb hmg1truncORF (XbaI + MluI) | See 1D |
| pMB4638 | pMB4629 | carB(i−) | See 1B |
| pMB4660 | pMB4638 (+URA3) | carB(i−) | See 1C |
| pMB4662 | pMB4631 (SpeI + XhoI) | 1.8 kb URA3 fragment (SpeI + BsaI) | MO4684 & MO4685 |
| | | See 1C |
| pMB4683 | pMB4662 (Acc65I + MluI) | 1.4 kb tef1p-GGS1 fragment | From pMB4591 |
| | (Acc65I + MluI) |
| pMB4692 | pMB4662 (Acc65I + MluI) | 0.4 kb TEF1 promoter | See 1E |
| | (Acc65I + NheI); 0.55 kb crtZ |
| | ORF (XbaI + MluI) |
| pMB4698 | pMB4629 (NheI + MluI) | 0.9 kb crtW ORF (XbaI + MluI) | See 1F |
| pMB4599 | pBluescriptSKII- | 1.9 kb carRP gene | MO4525 & MO4541 |
| (EcoRV) |
| pMB4606 | pBluescriptSKII- | 1.9 kb carB gene | MO4530 & |
| (EcoRV) | | MO4542 |
| pMB4613 | pMB4599 (Acc65I + PpuMI) | carRP(i−) | See text |
| pMB4619 | pBluescriptSKII- | carB(i−) | See text |
| (BamHI + Acc65I)) |
|
[0115]Certain oligonucleotides referred to in Table 27 above are as follows:
[0116]| MO4471 | 5′-CTGGGTGACCTGGAAGCCTT | |
| (SEQ ID NO: 3) |
|
| MO4472 | 5′-AAGATCAATCCGTAGAAGTTCAG |
| (SEQ ID NO: 4) |
|
| MO4475 | 5′-AAGCGATTACAATCTTCCTTTGG |
| (SEQ ID NO: 5) |
|
| MO4476 | 5′-CCAGTCCATCAACTCAGTCTCA |
| (SEQ ID NO: 6) |
|
| MO4477 | 5′-GCATTGCTTATTACGAAGACTAC |
| (SEQ ID NO: 7) |
|
| MO4478 | 5′-CCACTGTCCTCCACTACAAACAC |
| (SEQ ID NO: 8) |
|
| MO4534 | 5-CACAAACGCGTTCACTGCGCATCCTCAAAGT |
| (SEQ ID NO: 9) |
|
| MO4544 | 5′-CACAATCTAGACACAAATGGATTATAACAGCGCGGAT |
| (SEQ ID NO: 10) |
|
| MO4566 | 5′-CACAAACTAGTTTGCCACCTACAAGCCAGAT |
| (SEQ ID NO: 11) |
|
| MO4568 | 5′-CACAAGGTACCAATGTGAAAGTGCGCGTGAT |
| (SEQ ID NO: 12) |
|
| MO4571 | 5′-CACAAGGTACCAGAGACCGGGTTGGCGG |
| (SEQ ID NO: 13) |
|
| MO4591 | 5′-CACAAGCGGCCGCGCTAGCATGGGGATCGATCTCTTATAT |
| (SEQ ID NO: 14) |
|
| MO4592 | 5′-CACAAGCGGCCGCGCTAGCGAATGATTCTTATACTCAGAAG |
| (SEQ ID NO: 15) |
|
| MO4593 | 5′-CACAAGCGGCCGCACGCGTGCAATTAACAGATAGTTTGCC |
| (SEQ ID NO: 16) |
|
| MO4659 | 5′-CACAAGCTAGCTGGGGATGCGATCTCTTATATC |
| (SEQ ID NO: 17) |
[0117]1A: Production of pMB4628 (tef1p-carRP LEU2) encoding phytoene synthase/lycopene cyclase: Intron-containing carRP was amplified from M. circinelloides (ATCC 90680) genomic DNA using MO4525 and MO4541:
[0118] | MO4525 | 5′-CACAAACGCGTTTAAATGGTATTTAGATTTCTCATT | |
| | (SEQ ID NO: 18) |
| |
| MO4541 | 5′-CACAATCTAGACACAAATGCTGCTCACCTACATGGA |
| | (SEQ ID NO: 19) |
and the resulting 1.9 kb fragment was phosphorylated with T4 polynucleotide kinase. The resulting fragment was blunt-end ligated into pBluescriptSKII-cleaved with EcoRV, yielding pMB4599.The 1.9 kb XbaI-MluI fragment from pMB4599 was inserted into NheI- and MluI-cleaved pMB4603,yielding pMB4628. The intron containing nucleic acid coding sequence, and encoded CarRP protein of pMB4628 are as follows:
[0119]| atgctgctcacctacatggaagtccacctctactacacgctgcctgtgct | |
| gggcgtcctgtcctggctgtcgcggccgtactacacagccaccgatgcgc |
| tcaaattcaaatttctgacactggttgccttcacgaccgcctccgcctgg |
| gacaactacattgtctaccacaaggcgtggtcctactgccccacctgcgt |
| caccgctgtcattggctacgtgcccttggaggagtacatgttcttcatca |
| tcatgactctgttgaccgtggcattcaccaatctggtgatgcgctggcac |
| ctgcacagcttctttatcaggcctgaaacgcccgtcatgcagtccgtcct |
| ggtccgtcttgtccccataacagccttattaatcactgcatacaaggctt |
| gggtaagcaaacaaacaaatgatgtgccgcatcgcattttaatattaacc |
| attgcatacacagcatttggcggtccgctggcggtgctcgtctccattgc |
| gctgcccacgctgtttctctgctgggtcgatgtcgtcgctattggcgccg |
| gcacatgggacatttcgctggccacaagcaccggcaagttcgtcgtgccc |
| cacctgcccgtggaggaattcatgttctttgcgctaattaataccgtttt |
| ggtatttggtacgtgtgcgatcgatcgcacgatggcgatcctccacctgt |
| tcaaaaacaagagtccttatcagcgcccataccagcacagcaagtcgttc |
| ctccaccagatcctcgagatgacctgggccttctgtttacccgaccaagt |
| gctgcattcagacacattccacgacctgtccgtcagctgggacatcctgc |
| gcaaggcctccaagtccttttacacggcctctgctgtctttcccggcgac |
| gtgcgccaagagctcggtgtgctatacgccttttgcagagccacggacga |
| tctctgcgacaacgagcaggtccctgtgcagacgcgaaaggagcagctga |
| tactgacacatcagttcgtcagcgatctgtttggccaaaagacaagcgcg |
| ccgactgccattgactgggacttttacaacgaccaactgcctgcctcgtg |
| catctctgccttcaagtcgttcacccgtttgcgccatgtgctggaagctg |
| gagccatcaaggaactgctcgacgggtacaagtgggatttggagcgtcgc |
| tccatcagggatcaggaggatctcagatattactcagcttgtgtcgccag |
| cagtgttggtgaaatgtgcactcgcatcatactggcccacgccgacaagc |
| ccgcctcccgccagcaaacacagtggatcattcagcgtgcgcgtgaaatg |
| ggtctggtactccaatatacaaacattgcaagagacattgtcaccgacag |
| cgaggaactgggcagatgctacctgcctcaggattggcttaccgagaagg |
| aggtggcgctgattcaaggcggccttgcccgagaaattggcgaggagcga |
| ttgctctcactgtcgcatcgcctcatctaccaggcagacgagctcatggt |
| ggttgccaacaagggcatcgacaagctgcccagccattgtcaaggcggcg |
| tgcgtgcggcctgcaacgtctatgcttccattggcaccaagctcaagtct |
| tacaagcaccactatcccagcagagcacatgtcggcaattcgaaacgagt |
| ggaaattgctcttcttagcgtatacaacctttacaccgcgccaattgcga |
| ctagtagtaccacacattgcagacagggaaaaatgagaaatctaaatacc |
| atttaa |
| (SEQ ID NO: 20) |
|
| mlltymevhlyytlpvlgvlswlsrpyytatdalkfkfltlvafttasaw |
| dnyivyhkawsycptcvtavigyvpleeymffiimtlltvaftnlvmrwh |
| lhsffirpetpvmqsvlvrlvpitallitaykawhlavpgkplfygscil |
| wyacpvlallwfgageymmrrplavlvsialptlflcwvdvvaigagtwd |
| islatstgkfvvphlpveefmffalintvlvfgtcaidrtmailhlfknk |
| spyqrpyqhsksflhqilemtwafclpdqvlhsdtflidlsvswdilrka |
| sksfytasavfpgdvrqelgvlyafcratddlcdneqvpvqtrkeqlilt |
| hqfvsdlfgqktsaptaidwdfyndqlpascisafksftrlrhvleagai |
| kelldgykwdlerrsirdqedlryysacvassvgemctriilahadkpas |
| rqqtqwiiqraremglvlqytniardivtdseelgrcylpqdwltekeva |
| liqgglareigeerllslshrliyqadelmvvankgidklpshcqggvra |
| acnvyasigtklksykhhypsrahvgnskrveiallsvynlytapiatss |
| tthcrqgkmrnlnti |
| (SEQ ID NO: 21) |
[0120]Alternatively, pMB4599 was also used as a template for PCR amplification using MO4318, MO4643, MO4644, and MO4639 and
[0121]| MO4318 | 5′-GTAAAACGACGGCCAGT | |
| (SEQ ID NO: 22) |
|
| MO4643 | 5′-CACACGGTCTCATGCCAAGCCTTGTATGCAGTGATTAA |
| (SEQ ID NO: 23) |
|
| MO4639 | 5′-CCACTGTGTTTGCTGGCGG |
| (SEQ ID NO: 24) |
|
| MO4644 | 5′-CACACGGTCTCTGGCATTTGGCGGTCCCTGGAAA |
| (SEQ ID NO: 25) |
producing fragments of 0.5 and 0.95 kb, that were subsequently cleaved with Acc65I and BsaI, and BsaI and PpuMI, respectively. These fragments were ligated to pMB4599 that had been digested with Acc65I and PpuMI, yielding pMB4613, harboring intronless carRP. The 1.85 kb XbaI-MluI fragment from pMB4613 can be inserted into NheI- and MluI-cleaved pMB4603 to yield pCarRPdelI.
[0122]1B: Production of pMB4638 (tef1p-carB ADE1), encoding phytoene dehydrogenase: Intron-containing carB was amplified from M. circinelloides (ATCC 90680) genomic DNA using MO4530 and MO4542:
[0123]| MO4530 | 5′-CACAAACGCGTTTAAATGACATTAGAGTTATGAAC | |
| (SEQ ID NO: 26) |
|
| MO4542 | 5′-CACAATCTAGACACAAATGTCCAAGAAACACATTGTC |
| (SEQ ID NO: 27) |
and the resulting 1.9 kb fragment was phosphorylated with T4 polynucleotide kinase and blunt-end ligated into pBS-SKII-cleaved with EcoRV, yielding pMB4606. pMB4606 was then used as a template for PCR amplification using MO4318 and MO4648, and MO4646 and MO4647, and MO4343 and MO4645:
[0124] | MO4318 | 5′-GTAAAACGACGGCCAGT | |
| | (SEQ ID NO: 28) |
| |
| MO4648 | 5′-CACAAGGTCTCAAGCACGCATCCCGGAACTG |
| | (SEQ ID NO: 29) |
| |
| MO4646 | 5′-CACACGGTCTCAGGCATGTCGCCCTACGATGC |
| | (SEQ ID NO: 30) |
| |
| MO4647 | 5′-CACACGGTCTCATGCTTGCACCCACAAAGAATAGG |
| | (SEQ ID NO: 31) |
| |
| MO4343 | 5′-CAGGAAACAGCTATGAC |
| | (SEQ ID NO: 32) |
| |
| MO4645 | 5′-CACACGGTCTCTTGCCCATATACATGGTCTGAAACG |
| | (SEQ ID NO: 33) |
producing fragments of 0.4 and 0.85 and 0.7 kb, that were subsequently cleaved with Acc65I and BsaI, and BsaI, and BsaI and BamHI, respectively. These fragments were ligated to pBS-SKII- that had been cut with Acc65I and BamHI, yielding pMB4619, harboring intronless carB. The 1.75 kb XbaI-MluI fragment from pMB4619 was inserted into NheI- and MluI-cleaved pMB4629, yielding pMB4638. The resulting nucleic acid coding sequence and encoded CarB protein of pMB4638 are as follows:
[0125]| atgtccaagaaacacattgtcattatcggtgctggcgtgggtggcacggc | |
| tacagctgctcgtttggcccgcgaaggcttcaaggtcactgtggtggaga |
| aaaacgactttggtggcggccgctgctccttgatccatcaccagggccat |
| cgctttgatcagggcccgtcgctctacctgatgcccaagtactttgagga |
| cgcctttgccgatctggacgagcgcattcaagaccacctggagctgctgc |
| gatgcgacaacaactacaaggtgcactttgacgacggtgagtcgatccag |
| ctgtcgtctgacttgacacgcatgaaggctgaattggaccgcgtggaggg |
| cccccttggttttggccgattcctggatttcatgaaagagacacacatcc |
| actacgaaagcggcaccctgattgcgctcaagaagaatttcgaatccatc |
| tgggacctgattcgcatcaagtacgctccagagatctttcgcttgcacct |
| gtttggcaagatctacgaccgcgcttccaagtacttcaagaccaagaaga |
| tgcgcatggcattcacgtttcagaccatgtatatgggcatgtcgccctac |
| gatgcgcctgctgtctacagcctgttgcagtacaccgagttcgctgaagg |
| catctggtatccccgtggcggcttcaacatggtggttcagaagctagagg |
| cgattgcaaagcaaaagtacgatgccgagtttatctacaatgcgcctgtt |
| gccaagattaacaccgatgatgccaccaaacaagtgacaggtgtaacctt |
| ggaaaatggccacatcatcgatgccgatgcggttgtgtgtaacgcagatc |
| tggtctatgcttatcacaatctgttgcctccctgccgatggacgcaaaac |
| acactggcttccaagaaattgacgtcttcttccatttccttctactggtc |
| catgtccaccaaggtgcctcaattggacgtgcacaacatctttttggccg |
| aggcttatcaggagagctttgacgaaatcttcaaggactttggcctgcct |
| gaagagcaagacgggcgatgcttccaccgagaactacccggccatggtgg |
| acaaggcacgcaagatggtgctggctgtgattgagcgtcgtctgggcatg |
| tcgaatttcgccgacttgattgagcatgagcaagtcaatgatcccgctgt |
| atggcagagcaagttcaatctgtggagaggctcaattctgggtttgtctc |
| atgatgtgcttcaggtgctgtggttccgtcccagcacaaaggattctacc |
| ggtcgttatgataacctattctttgtgggtgcaagcacgcatcccggaac |
| tggtgttcccattgtccttgcaggaagcaagctcacctctgaccaagttg |
| tcaagagctttggaaagacgcccaagccaagaaagatcgagatggagaac |
| acgcaagcacctttggaggagcctgatgctgaatcgacattccctgtgtg |
| gttctggttgcgcgctgccttttgggtcatttaa |
| (SEQ ID NO: 34) |
|
| mskkhiviigagvggtataarlaregfkvtvvekndfgggrcslihhqgh |
| rfdqgpslylmpkyfedafadlderiqdhlellrcdnnykvhfddgesiq |
| lssdltrmkaeldrvegplgfgrfldfmkethihyesgtlialkknfesi |
| wdlirikyapeifrlhlfgkiydraskyfktkkmrmaftfqtmymgmspy |
| dapavysllqytefaegiwyprggfnmvvqkleaiakqkydaefiynapv |
| akintddatkqvtgvtlenghiidadavvcnadlvyayhnllppcrwtqn |
| tlaskkltsssisfywsmstkvpqldvhniflaeayqesfdeiflcdfgl |
| pseasfyvnvpsridpsaapdgkdsvivlvpighmksktgdastenypam |
| vdkarkmvlavierrlgmsnfadlieheqvndpavwqskfnlwrgsilgl |
| shdvlqvlwfrpstkdstgrydnlffvgasthpgtgvpivlagskltsdq |
| vvksfgktpkprkiementqapleepdaestfpvwfwlraafwvmfmffy |
| ffpqsngqtpasfinnllpevfrvhnsnvi |
| (SEQ ID NO: 35) |
[0126]1C. Production of pMB4660 (tef1p-carB URA3) encoding encoding, phytoene dehydrogenase: The 4.3 kb XhoI-NotI fragment and the 1.8 kb NotI-SpeI fragment from pMB4638 were ligated to the 1.9 kb BsaI- and SpeI-cleaved URA3 gene generated by PCR amplification of Y. lipolytica genomic DNA using MO4684 and MO4685 to create pMB4660:
[0127] | MO4684 | 5′-CATTCACTAGTGGTGTGTTCTGTGGAGCATTC | |
| | (SEQ ID NO: 36) |
| |
| MO4685 | 5′-CACACGGTCTCATCGAGGTGTAGTGGTAGTGCAGTG |
| | (SEQ ID NO: 37) |
The resulting nucleic acid coding sequence and encoded CarB(i) protein of pMB4660 are as follows:
[0128]| atgtccaagaaacacattgtcattatcggtgctggcgtgggtggcacggc | |
| tacagctgctcgtttggcccgcgaaggcttcaaggtcactgtggtggaga |
| aaaacgactttggtggcggccgctgctccttgatccatcaccagggccat |
| cgctttgatcagggcccgtcgctctacctgatgcccaagtactttgagga |
| cgcctttgccgatctggacgagcgcattcaagaccacctggagctgctgc |
| gatgcgacaacaactacaaggtgcactttgacgacggtgagtcgatccag |
| ctgtcgtctgacttgacacgcatgaaggctgaattggaccgcgtggaggg |
| cccccttggttttggccgattcctggatttcatgaaagagacacacatcc |
| actacgaaagcggcaccctgattgcgctcaagaagaatttcgaatccatc |
| tgggacctgattcgcatcaagtacgctccagagatctttcgcttgcacct |
| gtttggcaagatctacgaccgcgcttccaagtacttcaagaccaagaaga |
| tgcgcatggcattcacgtttcagaccatgtatatgggcatgtcgccctac |
| gatgcgcctgctgtctacagcctgttgcagtacaccgagttcgctgaagg |
| catctggtatccccgtggcggcttcaacatggtggttcagaagctagagg |
| cgattgcaaagcaaaagtacgatgccgagtttatctacaatgcgcctgtt |
| gccaagattaacaccgatgatgccaccaaacaagtgacaggtgtaacctt |
| ggaaaatggccacatcatcgatgccgatgcggttgtgtgtaacgcagatc |
| tggtctatgcttatcacaatctgttgcctccctgccgatggacgcaaaac |
| acactggcttccaagaaattgacgtcttcttccatttccttctactggtc |
| catgtccaccaaggtgcctcaattggacgtgcacaacatctttttggccg |
| aggcttatcaggagagctttgacgaaatcttcaaggactttggcctgcct |
| gaagagcaagacgggcgatgcttccaccgagaactacccggccatggtgg |
| acaaggcacgcaagatggtgctggctgtgattgagcgtcgtctgggcatg |
| tcgaatttcgccgacttgattgagcatgagcaagtcaatgatcccgctgt |
| atggcagagcaagttcaatctgtggagaggctcaattctgggtttgtctc |
| atgatgtgcttcaggtgctgtggttccgtcccagcacaaaggattctacc |
| ggtcgttatgataacctattctttgtgggtgcaagcacgcatcccggaac |
| tggtgttcccattgtccttgcaggaagcaagctcacctctgaccaagttg |
| tcaagagctttggaaagacgcccaagccaagaaagatcgagatggagaac |
| acgcaagcacctttggaggagcctgatgctgaatcgacattccctgtgtg |
| gttctggttgcgcgctgccttttgggtcatttaa |
| (SEQ ID NO: 38) |
|
| mskkhiviigagvggtataarlaregfkvtvvekndfgggrcslihhqgh |
| rfdqgpslylmpkyfedafadlderiqdhlellrcdnnykvhfddgesiq |
| lssdltrmkaeldrvegplgfgrfldfmkethihyesgtlialkknfesi |
| wdlirikyapeifrlhlfgkiydraskyfktkkmrmaftfqtmymgmspy |
| dapavysllqytefaegiwyprggfnmvvqkleaiakqkydaefiynapv |
| akintddatkqvtgvtIenghiidadavvcnadlvyayhnllppcrwtqn |
| tlaskkltsssisfywsmstkvpqldvhniflaeayqesfdeiflcdfgl |
| pseasfyvnvpsridpsaapdgkdsvivlvpighmksktgdastenypam |
| vdkarkmvlavierrlgmsnfadlieheqvndpavwqskfnlwrgsilgl |
| shdvlqvlwfrpstkdstgrydnlffvgasthpgtgvpivlagskltsdq |
| vvksfgktpkprkiementqapleepdaestfpvwfwlraafwvmfmffy |
| ffpqsngqtpasfinnllpevfrvhnsnvi |
| (SEQ ID NO: 39) |
[0129]1D. Production of pMB4637 and pTef-HMG encoding a truncated HMG1. For production of a truncated variant of the HMG-CoA reductase gene, which also encodes a 77 amino acid leader sequence derived from S. cerevisiae, the following oligonucleotides are synthesized:
[0130]| PRIMER O | 5′-TTCTAGACACAAAAATGGCTGCAGACCAATTGGTGA | |
| (SEQ ID NO: 40) |
|
| PRIMER P | 5′-CATTAATTCTTCTAAAGGACGTATTTTCTTATC |
| (SEQ ID NO: 41) |
|
| PRIMER Q | 5′-GTTCTCTGGACGACCTAGAGG |
| (SEQ ID NO: 42) |
|
| MO4658 | 5′-CACACACGCGTACACCTATGACCGTATGCAAAT |
| (SEQ ID NO: 43) |
Primers O and P are used to amplify a 0.23 kb fragment encoding Met-Ala followed by residues 530 to 604 of the Hmg1 protein of
S. cerevisiae, using genomic DNA as template. Primers Q and MO4658 are used to amplify a 1.4 kb fragment encoding the C-terminal 448 residues of the Hmg1 protein of
Y. lipolytica, using genomic DNA as template. These fragments are ligated to the appropriate cloning vector, and the resultant plasmids, designated pOP and pQMO4658, are verified by sequencing. The OP fragment is liberated with XbaI and AseI, and the QMO4658 fragment is liberated with MaeI and MluI. These fragments are then ligated to the ADE1 TEF1p expression vector pMB4629 cut with XbaI and MluI to produce pTefHMG.
[0131]Alternatively, the native HMG1 gene from Y. lipolytica may be modified without S.cerevisiae sequences as described in the table above using primers MO4658 (described above) and MO4657, to create pMB4637:
[0132]| MO4657 | 5′-CACACTCTAGACACAAAAATGACCCAGTCTGTGAAGGTGG | |
| (SEQ ID NO: 44) |
The resulting nucleic acid coding sequence and encoded Hmg1
truncprotein of pMB4637 are as follows:
[0133]| atgacccagtctgtgaaggtggttgagaagcacgttcctatcgtcattga | |
| gaagcccagcgagaaggaggaggacacctcttctgaagactccattgagc |
| tgactgtcggaaagcagcccaagcccgtgaccgagacccgttctctggac |
| gacctagaggctatcatgaaggcaggtaagaccaagcttctggaggacca |
| cgaggttgtcaagctctctctcgagggcaagcttcctttgtatgctcttg |
| agaagcagcttggtgacaacacccgagctgttggcatccgacgatctatc |
| atctcccagcagtctaataccaagactttagagacctcaaagcttcctta |
| cctgcactacgactacgaccgtgtttttggagcctgttgcgagaacgtta |
| ttggttacatgcctctccccgttggtgttgctggccccatgaacattgat |
| ggcaagaactaccacattcctatggccaccactgagggttgtcttgttgc |
| ctcaaccatgcgaggttgcaaggccatcaacgccggtggcggtgttacca |
| ctgtgcttactcaggacggtatgacacgaggtccttgtgtttccttcccc |
| tctctcaagcgggctggagccgctaagatctggcttgattccgaggaggg |
| tctcaagtccatgcgaaaggccttcaactccacctctcgatttgctcgtc |
| tccagtctcttcactctacccttgctggtaacctgctgtttattcgattc |
| cgaaccaccactggtgatgccatgggcatgaacatgatctccaagggcgt |
| cgaacactctctggccgtcatggtcaaggagtacggcttccctgatatgg |
| acattgtgtctgtctcgggtaactactgcactgacaagaagcccgcagcg |
| atcaactggatcgaaggccgaggcaagagtgttgttgccgaagccaccat |
| ccctgctcacattgtcaagtctgttctcaaaagtgaggttgacgctcttg |
| ttgagctcaacatcagcaagaatctgatcggtagtgccatggctggctct |
| gtgggaggtttcaatgcacacgccgcaaacctggtgaccgccatctacct |
| tgccactggccaggatcctgctcagaatgtcgagtcttccaactgcatca |
| cgctgatgagcaacgtcgacggtaacctgctcatctccgtttccatgcct |
| tctatcgaggtcggtaccattggtggaggtactattttggagccccaggg |
| ggctatgctggagatgcttggcgtgcgaggtcctcacatcgagacccccg |
| gtgccaacgcccaacagcttgctcgcatcattgcttctggagttcttgca |
| gcggagctttcgctgtgttctgctcttgctgccggccatcttgtgcaaag |
| tcatatgacccacaaccggtcccaggctcctactccggccaagcagtctc |
| aggccgatctgcagcgtctacaaaacggttcgaatatttgcatacggtca |
| tag |
| (SEQ ID NO: 45) |
|
| mtqsvkvvekhvpiviekpsekeedtssedsieltvgkqpkpvietrsld |
| dleaimkagktklledhevvklslegklplyalekqlgdntravgirrsi |
| isqqsntktletsklpylhydydrvfgaccenvigymplpvgvagpmnid |
| gknyhipmattegclvastmrgckainagggvttvltqdgmtrgpcvsfp |
| slkragaakiwldseeglksmrkafnstsrfarlqslhstlagnllfirf |
| rtttgdamgmnmiskgvehslavmvkeygfpdmdivsvsgnyctdkkpaa |
| inwiegrgksvvaeatipahivksvlksevdalvelnisknligsamags |
| vggfnahaanlvtaiylatgqdpaqnvessncitlmsnvdgnllisvsmp |
| sievgtigggtilepqgamlemlgvrgphietpganaqqlariiasgvla |
| aelslcsalaaghlvqshmthnrsqaptpakqsqadlqrlqngsnicirs |
| (SEQ ID NO: 46) |
[0134]1E. Production of pMB4692 (URA3 tef1p-crtZ) encoding, carotene hydroxylase. The following carotene hydroxylase (CrtZ) ORF sequence was synthesized; based on protein sequence of Novosphingobium aromaticivorans, using Y. lipolytica codon bias:
[0135]| 5′-ttctagacacaaaaatgggtggagccatgcagaccctcgctgctatc | |
| ctgatcgtcctcggtacagtgctcgctatggagtttgtcgcttgtcttct |
| cataagtatatcatgcatggcttcggatggggatggcatagagaccatca |
| cgagccccatgagggatttcttgagaagaatgacttatacgccatcgttg |
| gcgctgccctctcgatactcatgtttgccctcggctctcccatgatcatg |
| ggcgctgacgcctggtggcccggaacctggatcggactcggtgtcctctt |
| ctatggtgtcatctataccctcgtgcacgacggtctggtgcaccaacgat |
| ggtttagatgggtgcctaaacgaggttacgccaaacgactcgtgcaggcc |
| cataagctgcaccacgccaccattggcaaggaaggaggcgtctcattcgg |
| tttcgtgttcgcccgagatcccgccgttctgaagcaggagcttcgagctc |
| aacgagaagcaggtatcgccgtgctgcgagaggctgtggacggctagacg |
| cgt |
| (SEQ ID NO: 47) |
This sequence was cleaved using XbaI and MluI and ligated, along with an Acc65I-NheI TEF1 promoter fragment from pMB4629, to pMB4662 cut with Acc65I and MluI to produce pMB4692. The nucleic acid coding sequence is depicted in bold underline above. The resulting encoded crtZ protein of pMB4692 is as follows:
[0136]| mggamqtlaailivlgtvlamefvawsshkyimhgfgwgwhrdhhepheg | |
| flekndlyaivgaalsilmfalgspmimgadawwpgtwiglgvlfygviy |
| tlvhdglvhqrwfrwvpkrgyakrlvqahklhhatigkeggvsfgfvfar |
| dpavlkqelraqreagiavlreavdg |
| (SEQ ID NO: 82) |
[0137]1F. Production of pMB4698 (ADE1 tef1p-crtW), encoding carotene ketolase. The following carotene ketolase (CrtW) ORF sequence was synthesized, based on protein sequence of an environmental sequence isolated from the Sargasso Sea (Genbank accession AACY01034193.1):
[0138]| 5′-ttctagacacaaaaatgactcgatctatttcctggccttccacctac | |
| tggcacctccagccctcctgttcttcttgggtcgcaaacgaattctctcc |
| tcaagcccgaaaaggtctcgtcctcgctggtctcattggttccgcttggc |
| tgcttactctcggacttggcttttcccttcccctccatcaaacgagctgg |
| cttctcatcggttgtctcgttctccttagatctttcctgcacaccggact |
| ttttatcgttgcccatgacgctatgcacgcttctcttgttcctgaccacc |
| ctggccttaaccgttggattggacgtgtctgtcttctcatgatatgctgg |
| actctcctacaaaagatgctgccgaaatcaccgtcgacaccaccaagccc |
| ctgaaacagttgaagaccctgactaccaacgatgcactaacaacaatatc |
| ctcgactggtacgttcactttatgggaaattacctcggatggcaacaatt |
| gcttaatctctcttgcgtttggctcgctctcaccttccgtgtttctgact |
| actctgctcaattcttccacctgctccttttctctgtccttcctctcatc |
| gtctcctcctgtcaactcttcctcgtgggaacctggctgccacaccgacg |
| aggcgctactactcgacccggcgttaccactcgatcctgaacttccaccc |
| tgctctttccttcgctgcttgctaccacttcggttaccaccgtgaacacc |
| atgaatctccctctactccttggttccaacttcctaaactccgagaaggt |
| tctctcatctaaacgcgt |
| (SEQ ID NO: 48) |
This sequence was cleaved using XbaI and MluI and ligated to pMB4629 cut with NheI and MluI to produce pMB4698. The nucleic acid coding sequence is depicted in bold underline above. The resulting encoded crtW protein of pMB4698 is as follows:
[0139]| mtrsiswpstywhlqpscsswvanefspqarkglvlagligsawlltlgl | |
| gfslplhqtswlligclvllrsflhtglfivahdamhaslvpdhpglnrw |
| igrvcllmyaglsykrccrnhrrhhqapetvedpdyqrctnnnildwyvh |
| fmgnylgwqqllnlscvwlaltfrvsdysaqffhlllfsvlplivsscql |
| flvgtwlphrrgattrpgvttrslnfbpalsfaacyhfgyhrehhespst |
| pwfqlpklregsli |
| (SEQ ID NO: 83) |
Example 2
Engineering Yarrowia lipolyvtica for Increased Carotenoid Production
[0140]2A. Production of Y. lipolytica expressing geranylgeranylpyrophosphate synthase and phytoene dehydrogenase: MF350 (MATB ura2-21 leu2-35 ade1) was transformed with pMB4591 (tef1p-GGS1) that had been cleaved upstream of URA5 with SspI; a Ura+transformant carrying the plasmid at the ura2 locus was identified and named MF364. It was subsequently transformed with pMB4638 (tef1p-carB) that had been cleaved at ADE1 with SspI and a prototrophic transformant was chosen that harbored the plasmid at the ade1 locus. This strain was named MF502.
[0141]2B. Production of Y. lipolytica expressing geranylgeranylpyrophosphate synthase, phytoene dehydrogenase and phytoene synthase/lycopene cyclase MF502 was transformed with pMB4628 (tef1p-carRP) that had been treated with SspI. Nine prototrophic colonies were chosen that were uncolored, orange, or very orange on the transformation plate (YNB agar with 1% glucose and 0.1% glutamate [YNBglut]) after two to three days of growth. Two, MF597 and MF600 (the very orange ones), produced greater than 4 mg carotene per g dry cell weight (DCW) after four days of growth in YPD at 30° C. Southern analysis reveals a different single KpnI-HindIII band in genomic DNA from MF597 and MF600, neither of which suggested that homologous integration occurred at leu2-270.
[0142]2C. Production of Y. lipolytica expressing phytoene synthase/lycopene cyclase and phytoene dehydrogenase: ATCC201249 (MATA ura3-302 leu2-270 lys8-11) was transformed with SspI-cleaved pMB4628. Hundreds of Leu+colonies were pooled, re-grown, and transformed with pMB4660 (tef1p-carB) that had been cleaved upstream of URA3 with SalI. One colony that was noticeably yellow after 5 days at 30° C. on YNBglut plus 0.6 mM lysine was selected, named MF447, and found to produce 0.2 mg carotene per gram dry cell weight after 4 days of growth in YPD.
[0143]MF447 was challenged with 1 g/L 5-fluoroorotic acid and Ura−segregants selected. Surprisingly, they were all found to retain the identical yellow appearance of their parent, implying that the loss of a functional URA3 gene did not coincide with the loss of a functional CarB enzyme. Southern analysis demonstrates that two fragments from a KpnI-HindlIl digest of MF447 DNA contain URA3p-hybridizing sequences, only one of which also hybridizes to carB. The other is absent in MF578, the Ura3−segregant chosen for further manipulation. Plasmid rescue and analysis of the DNA sequence encompassing the carRP intron in strains MF447, MF597 (example 2c), and MF600 (example 2c) revealed that exons 1 and 2 were contiguous and were each separated by an intron sequence that lacked the original internal SspI site (present in pMB4628).
[0144]2D. Production of Y. lipolytica expressing phytoene synthase/lycopene cyclase, phytoene dehydrogenase and geranylgeranylpyrophosphate synthase: MF578 was transformed with pMB4683 (tef1p-GGS1) that had been cleaved with SalI (upstream of URA3) or with StuI (within the GGS1 ORF). Ura+Leu+colonies in both cases appeared bright orange on YNBglut+Lys and on YPD, and several produced greater than 4 mg carotene per gram of dry cell weight when grown as above. One, MF633, contained a single copy of the plasmid at the GGS1 locus, as inferred from Southern analysis. The others arose by non-homologous or more complex integrations.
[0145]2E. Production of Y. lipolytica expressing phytoene synthase/lycopene cyclase, phytoene dehydrogenase and geranylgeranylpyrophosphate synthase: MF364 is crossed with MF578, and spores from the resulting diploid are plated on YPD for two to three days at 30° C. Orange Leu+Ade−Ura−colonies are screened for the presence of tefp-carB, tefip-carRP, and tefp-GGS1 by PCR, and for high carotenoid (>4 mg/g dry cell weight) production after growth in YPD liquid medium. Colonies meeting these criteria, as well as displaying resistance to 5-fluorootic acid, an indication that they harbor the ura3-302 allele, are chosen for further studies and hereafter referred to as GBRPua strains. Such a strain is selected for further analysis and modification.
Example 3
Extraction of Carotenoids from Yarrowia lipolytica Cells
[0146]Shake-flask testing of generated strains was conducted using YPD medium (1% yeast extract, 2% peptone, 2% glucose). 20 ml cultures in 125 ml flasks were grown at 30° C. Y. lipolytica cells were harvested from 72-96 hour cultures, and extractions were performed to determine carotenoid form and quantity. 1.8 ml of culture was placed into an Eppendorf tube. Cells were pelleted and washed twice with 1 ml H2O. After the second wash, the resuspended cells were transferred to a pre-weighed snap-cap tube with a hole poked in the top, and the cells were lyophilized overnight. After drying to completion, the tube was weighed in order to calculate dry cell weight. 0.25 ml from the same shake flask culture was placed into a 2 ml screw-cap tube for carotenoid extraction. Cells were pelleted and the supernatant was aspirated. Pelleted cells may be frozen at −80° C. and stored. An equal volume of cubic zirconia beads was added to cell pellets, along with 1 ml ice-cold extraction solvent (a 50/50 v/v mix of hexane and ethyl acetate containing 0.01% butylhydroxytoluene (BHT)). The mixture was then agitated (Mini-BeadBeater-8, BioSpec Products, Inc.) at maximum speed for 5 minutes at 4° C. The mixture was then spun at maximum speed for 1 minute, and the supernatant was collected and deposited in a cold 16 ml glass vial. The remaining cell debris was re-extracted at least three times, without the addition of zirconia beads; all supernatants were pooled in the 16 ml glass vial. Following extraction, the glass vial was spun for 5 minutes at 2000 rpm at 4° C. in a Sorvall tabletop centrifuge, and the supernatant was transferred to a new cold 16 ml glass vial. A Speed Vac was used to concentrate the supernatant (room temperature in dark), and the samples were stored at −20° C. or −80° C. until immediately before HPLC analysis. Prior to HPLC analysis, the samples were resuspended in 1 ml ice-cold solvent and then transferred to a cold amber vial. Throughout the protocol, care was taken to avoid contact with oxygen, light, heat, and acids.
Example 4
Quantification of Carotenoid Production by HPLC
[0147]For carotenoid analysis, samples were resuspended in ice-cold extraction solvent (a 50/50 v/v mix of hexane and ethyl acetate containing 0.01% butylhydroxytoluene (BHT)). An Alliance 2795 HPLC (Waters) equipped with a Waters XBridge C18 column (3.5 um, 2.1×50 mm) and Thermo Basic 8 guard column (2.1×10 mm) was used to resolve carotenoid at 25° C.; authentic carotenoid samples were used as standards. The mobile phases and flow rates are shown below (Solvent A=Ethyl Acetate; Solvent B=Water; Solvent C=Methanol; Solvent D=Acetonitrile). The injection volume was 10 μL. The detector is a Waters 996 photodiode array detector. The retention times for lipophilic molecules include astaxanthin (1.159 min), zeaxanthin (1.335), β-apo-8′-carotenal (2.86 min), ergosterol (3.11 min), lycopene (3.69 min), β-Carotene (4.02 min), and phytoene (4.13 min). Astaxanthin, zeaxanthin, β-apo-8′-carotenal, lycopene and β-Carotene are detected at 475 nm, whereas ergosterol and phytoene were detected at 286 nm.
[0148] |
| Retention Times for Lipophilic Molecules |
| Time (min) | Flow (mL/min) | % A | % B | % C | % D | Curve |
|
| 0.50 | 0.0 | 20.0 | 0.0 | 80.0 | |
| 3.00 | 1.00 | 20.0 | 0.0 | 0.0 | 80.0 | 6 |
| 4.50 | 1.00 | 80.0 | 0.0 | 20.0 | 0.0 | 6 |
| 5.50 | 1.00 | 0.0 | 0.0 | 60.0 | 40.0 | 6 |
| 6.50 | 1.00 | 0.0 | 0.0 | 80.0 | 20.0 | 6 |
| 7.50 | 1.00 | 0.0 | 0.0 | 100.0 | 0.0 | 6 |
| 8.50 | 1.00 | 0.0 | 0.0 | 100.0 | 0.0 | 6 |
| 9.50 | 1.00 | 0.0 | 20.0 | 0.0 | 80.0 | 6 |
| 10.50 | 0.50 | 0.0 | 20.0 | 0.0 | 80.0 | 6 |
|
Example 5
Expression of a Truncated form of HMG-CoA Reductase Results in Increased Carotenoid Production
[0149]In order to increase carotenoid production, carbon flow through the isoprenoid pathway is enhanced by introducing a truncated variant of the HMG-CoA reductase gene.
[0150]In one approach, a truncated variant of the HMG-CoA reductase gene which also encodes a 77 amino acid leader sequence derived from S. cerevisiae Hmg1 is introduced into a GRPBua strain (described in Example 2E above). Plasmid pTefHMG can be cleaved with SnaBI, BbvCI, or Bsu36I to direct integration at the ade1 locus, or with BamHI to direct integration at the HMG1 locus, or with EcoRV to promote random integration, in the GRPBua strains, restoring them to adenine prototrophy. Resulting Ade+transformants are screened for increased carotenoid production.
[0151]Alternatively, the native HMG1 gene from Y. lipolytica may be modified without S. cerevisiae sequences as described in Example 1D above, to create pMB4637. This plasmid can be digested as described for pTefHMG and transformed into GRPBua strains, and resulting transformants screened as described for increased carotenoid production.
[0152]In still another approach, a truncated variant of the N. crassa HMG-CoA reductase gene may be utilized and introduced into Y. lipolytica strains. In order to generate a plasmid suitable for expression of the heterologous HMG-CoA reductase, p641P (Yeast 2001; 18 (2001): 97-113) is modified by replacing the ICL1 promoter with the GPD promoter, and by the addition of sequences conferring resistance to phleomycin. Y. lipolytica genomic DNA is amplified with two primers.
[0153]| GPDdist: | |
| 5′ CACACGGTacctgtaggttgggttgggtg |
| (SEQ ID NO: 49) |
|
| GPDprox: |
| 5′ CACACGGATCCtgtttaattcaagaatgaatatagagaagagaag, |
| (SEQ ID NO: 50) |
and the resulting fragment (0.7 kb) is cleaved with BamHI and KpnI, and ligated to BamHI- and KpnI-cleaved p641P, creating the plasmid “p641Pgpd”. The ble gene under the control of the
A. nidulans GPD promoter is then excised from pBCphleo (Silar, Fungal Genetics Newsletter 42:73) as a 3.2 kb BclI-BamHI fragment and inserted into the unique BamHI site of “p641Pgpd”, in the orientation that preserves the BamHI site proximal to the GPD promoter, to create “p641Pgpdble”,
[0154]N. crassa genomic DNA is amplified with two primers:
[0155] | Neuhmg fwd: | |
| 5′ CACACGGATCCACATCAACAatggcatctgccacccttcccc |
| (SEQ ID NO: 51) |
| |
| Neuhmg rev: |
| 5′ CACACGGATCcaagtgctgacgcggaacttg, |
| (SEQ ID NO: 52) |
and the resulting fragment is cleaved with BamHI and inserted into BamHI-digested “p641Pgpdble” in the correct orientation. The resulting plasmid, “pZg”, contains sequences encoding a truncated cytosolic catalytic domain of hydroxymethylglutaryl-CoA reductase from
N. crassa (Genbank accession: XP
—324892) under the control of the constitutive GPD promoter. This plasmid can be introduced into the
Y. lipolytica strain created in Example 2E above, and transformants are selected by their resistance to phleomycin (100 μg/ml). Resulting transformants are tested for β-carotene production, as described above.
Example 6
Introduction of Heterologous Carotene Hydroxylase and Carotene Ketolase Genes Into Y. lipolytica Strains Producing Carotenoid for Production of Astaxanthin
[0156]For introduction of carotene hydroxylase and carotene ketolase into carotenoid producting Y. lipolytica, pMB4692 and pMB4698, described as in Example 1E and 1F above, can be sequentially introduced into the GRPBua strain (described in Example 2E). For the introduction of pMB4692, the plasmid may be cleaved with SalI or BsrGI to direct integration at the ura3 locus, or with XbaI to promote random integration, selecting for uracil prototrophy. GRPBua Ura+transformants harboring pMB4692 are screened for zeaxanthin production in YPD. Zeaxanthin-producing cells are transformed with pMB4698 (which can be cleaved with PpuMI, SspI or BbvCI to direct integration at the ade1 locus, or with EcoRV to promote random integration) and prototrophic colonies are screened for astaxanthin production.
[0157]Alternatively, the order of plasmid transformation may be reversed wherein pMB4698 is transformed first and transformants are selected for adenine prototrophy. GRPBua Ade+transformants harboring pMB4698 are screened for canthaxanthin production. Canthaxanthin-producing GRPBua[pMB4698] cells are transformed with pMB4692 and prototrophic colonies are screened for astaxanthin production.
[0158]In another approach, the carotenoid ketolase and carotenoid hydroxylase genes from P. marcusii can be introduced into the strains described in Example 2 above, in order to convert β-carotene into astaxanthin. P. marcusii genomic DNA is amplified with two primers.
[0159]| CrtZfwd: | 5′ CACACCGTCTCAAatgaccaatttcctgatcgtcgtc | |
| (SEQ ID NO: 53) |
|
| CrtZrev: | 5′ CACACAGATCtcacgtgcgctcctgcgcc, |
| (SEQ ID NO: 54) |
and the resulting fragment is cleaved with BsmBI, modified with the Klenow fragment of DNA polymerase, and cleaved with BglII. This fragment is inserted into PmlI- and BamHI-cleaved pINA1269 (J. Mol. Microbiol. Biotechnol. 2 (2000): 207-216), containing the hp4d promoter, the XPR2 terminator, the selectable LEU2 gene, and sequences necessary for selection and propagation in
E. coli. The resulting plasmid “pA” contains sequences encoding carotene hydroxylase from
P. marcusii (crtZ gene)(Genbank accession: CAB56060.1) under the control of the hp4d promoter.
[0160]“pYEG1TEF” is modified by substituting the LIP2 terminator for the XPR2 terminator as follows. pINA1291 is digested with AvrII, modified with the Klenow fragment of DNA polymerase, and cleaved with EcoRI, and the small LIP2t containing fragment is ligated to “YEG1TEF” that has been digested with SacII, modified with T4 DNA polymerase in the presence of dNTP, and cleaved with EcoRI. The resulting plasmid is named “pYEG1TEF-LIP2t”.
[0161]In order to amplify the carotenoid ketolase gene, P. marcusii genomic DNA is amplified with two primers.
[0162] | CrtWfwd: | 5′ CACACCCTAGGCCatgagcgcacatgccctgc | |
| | (SEQ ID NO: 55) |
| |
| CrtWrev: | 5′ CACACAAGCTTtcatgcggtgtcccccttg, |
| | (SEQ ID NO: 56) |
and the resulting fragment is cleaved with AvrII and HindIII, and inserted into AvrII- and HindIII-cleaved “pYEG1TEF-LIP2t”. The resulting plasmid, “pBt”, contains sequences encoding the carotene ketolase (crtW gene)(Genbank accession: CAB56059.1) under the control of the constitutive TEF1 promoter.
[0163]In order to combine the two expression cassettes into a single plasmid, “pBt” is cleaved with ClaI, modified with the Klenow fragment of DNA polymerase, and cleaved with EcoRI, and the crtW-containing fragment is isolated, mixed with the phosphorylated oligonucleotide adaptor pair:
[0164] | 5′ AATTCGCGGCCGCT | |
| (SEQ ID NO: 57) |
| and |
| |
| 5′ AGCGGCCGCG, |
| (SEQ ID NO: 58) |
cleaved with NotI, and ligated to NotI-digested “pA”. The resulting plasmid, “pABt”, contains both the TEF1p/crtW/LIP2t cassette and the hp4d/crtZ/XPR2t cassette as well as the selectable LEU2 gene.
[0165]“pABt” can be introduced into the Y. lipolytica strain described above in Example 4 (TEF1p/al-1/XPR2t; hp4d/carRP/LIP2t; GPDp/HMGRtrunc), and transformants selected for leucine prototrophy.
Example 7
Partial Inactivation of Y. lipolytica ERG9 Gene Encodinq Squalene Synthase Results in Increased Carotenoid Production
[0166]7A. In order to partially inactivate the ERG9 gene encoding squalene synthase, the neighboring FOL3 gene is disrupted, resulting in a folinic acid requirement. This strain is then transformed with a mutagenized fragment of DNA partially spanning the two genes, and Fol+transformants are screened for decreased squalene synthase activity.
[0167]The following oligonucleotides are synthesized:
[0168] | PRIMER K | 5′-CCTTCTAGTCGTACGTAGTCAGC; | |
| | (SEQ ID NO: 59) |
| |
| PRIMER L | 5′-CCACTGATCTAGAATCTCTTTCTGG |
| | (SEQ ID NO: 60) |
and used to amplify a 2.3 kb fragment from
Y. lipolytica genomic DNA spanning most of the FOL3 gene, using Pfu polymerase. The resulting fragment is cleaved with XbaI and phosphorylated, then ligated into pBluescriptSK
−that has been cleaved with KpnI, treated with T4 DNA polymerase (T4pol) in the presence of dNTPs, and subsequently cleaved with XbaI. The resultant plasmid, designated pBS-fol3, is then cleaved with Acc65I and EcoRI, treated with T4pol as above, and ligated to the 3.4 kb EcoRV-SpeI ADE1 fragment (treated with T4pol) from pMB4529.
[0169]The resulting plasmid, pBSfol3Δade, can be cleaved with BsiWI and XbaI to liberate a 5.5 kb fragment that is used to transform the GRBPua strains described above to adenine prototrophy. Resulting Ade+transformants are screened for a folinic acid requirement, and for homologous integration by PCR analysis.
[0170]Strains that harbor the resultant fol3ΔADE1 allele can be transformed with a 3.5 kb DNA fragment generated by mutagenic PCR amplification using the primers:
[0171] | PRIMER M | 5′-GGCTCATTGCGCATGCTAACATCG; | |
| | (SEQ ID NO: 61) |
| |
| PRIMER N | 5′-CGACGATGCTATGAGCTTCTAGACG, |
| | (SEQ ID NO: 62) |
and
Y. lipolytica genomic DNA as template. The resulting fragment containing the N-terminal three-quarters of the FOL3 ORF and the C-terminal nine-tenths of the ERG9 ORF is used to transform strains. The resulting Fol
+Ade
+transformants are screened for decreased squalene synthase activity by sensitivity to agents such as zaragozic acid, itraconazole, or fluconazole. Additionally, the resulting transformants are screened for increased carotenoid production.
[0172]7B. Alternatively, the PCR fragment produced in 7A could be cloned and altered in such a way as to remove the 3′-untranslated region of ERG9 gene. Replacement of the fol3ΔADE1 disruption by this fragment results in decreased expression of squalene synthase [Schuldiner et al. (2005), Cell 123:507-519][Muhlrad and Parker (1999), RNA 5:1299-1307], which can be confirmed as in 7A. This approach may also be used in a Fol+ Ade−strain, using the ADE1 marker to disrupt the ERG9 3′-UTR.
[0173]7C. In still another approach, partially defective ERG9 alleles can be identified in S. cerevisiae using plasmid shuffling techniques [Boeke et al. (1987), Methods Enzymol. 154:164-175], and using drug sensitivities as a phenotype. Defective genes can be transferred to Y. lipolytica using standard molecular genetic techniques.
Example 8
Treatment of Y. lipolytica Strains Producing Carotenoid With Inhibitor of an Isoprenoid Biosynthesis Competitor Polypeptide Results in Increased Carotenoid Production
[0174]Cultures produced in Example 2 are treated with the squalene synthase inhibitor, zaragozic acid (zaragozic acid at 0.5 μM) and monitored for β-carotene production, as described above.
Example 9
Constructing an Oleaginous Strain of Saccharomvces crevisiae
[0175]The genes encoding the two subunits of ATP-citrate lyase from N. crassa, the AMP deaminase from Saccharomyces cerevisiae, and the cytosolic malic enzyme from M. circinelloides are overexpressed in S. cereviseae strains in order to increase the total lipid content. Similar approaches to enhance lipid production could be employed in other host organisms such as Xanthophyllomyces dendrorhous (Phaffia rhodozyma), using the same, homologous, or functionally similar oleaginic polypeptides.
[0176]Qiagen RNAEasy kits (Qiagen, Valencia, Calif.) are used to prepare messenger RNA from lyophilized biomass prepared from cultures of N. crassa. Subsequently, RT-PCR is performed in two reactions containing the mRNA template and either of the following primer pairs.
[0177]| acl1: | | |
| 1fwd: | 5′ CACACGGATCCTATAatgccttccgcaacgaccg |
| (SEQ ID NO: 63) |
|
| 1rev: | 5′ CACACACTAGttaaatttggacctcaacacgaccc |
| (SEQ ID NO: 64) |
|
| acl2: |
| 2fwd: | 5′ CACACGGATCCAATATAAatgtctgcgaagagcatcctcg |
| (SEQ ID NO: 65) |
|
| 2rev: | 5′ CACACGCATGCttaagcttggaactccaccgcac |
| (SEQ ID NO: 66) |
[0178]The resulting fragment from the acl1 reaction is cleaved with SpeI and BamHI, and that from the acl2 reaction is cleaved with BamHI and SphI, and both are ligated together into YEp24 that has been digested with NheI and SphI, creating the plasmid “p12”. The bi-directional GAL1-10 promoter is amplified from S. cerevisiae genomic DNA using the primers.
[0179]| gal10: | |
| 5′ CACACGGATCCaattttcaaaaattcttactttttttttggatggac |
| (SEQ ID NO: 67) |
|
| gal1: |
| 5′ CACACGGATCCttttttctccttgacgttaaagtatagagg, |
| (SEQ ID NO: 68) |
and the resulting 0.67 kb fragment is cleaved with BamHI and ligated in either orientation to BamHI-digested “p12” to create “p1gal2” and “p2gal1”, containing GAL1-acl1/GAL10-acl2 and GAL10-acl1/GAL1-acl2, respectively (Genbank accession: acl1: CAB91740.2; acl2: CAB91741.2).
[0180]In order to amplify the S. cereviseae gene encoding AMP deaminase and a promoter suitable for expressing this gene, S. cerevisiae genomic DNA is amplified using two primer pairs in separate reactions:
[0181]| AMD1 ORF: | | |
| AMD1FWD: | 5′ CACACGAGCTCAAAAatggacaatcaggctacacagag |
| (SEQ ID NO: 69) |
|
| AMD1rev: | 5′ CACACCCTAGGtcacttttcttcaatggttctcttgaa |
| attg |
| (SEQ ID NO: 70) |
|
| GAL7p: |
| gal7prox: | 5′ CACACGAGCTCggaatattcaactgtttttttttatca |
| tgttgatg |
| (SEQ ID NO: 71) |
|
| gal7dist: | 5′ CACACGGAtccttcttgaaaatatgcactctatatctt |
| ttag, |
| (SEQ ID NO: 72) |
and the resulting fragment from the AMD1 reaction (2.4 kb) is cleaved with SacI and AvrII, and that from the GAL7 reaction (0.7 kb) is cleaved with BamHI and SphI, and both are ligated together into YEp13 that has been digested with NheI and BamHI, creating the plasmid “pAMPD”. This plasmid carries the
S. cerevisiae gene, AMD1, encoding AMP deaminase, under the control of the galactose-inducible GAL7 promoter.
[0182]Messenger RNA is prepared from lyophilized biomass of M. circinelloides, as described above, and the mRNA template is used in a RT-PCR reaction with two primers:
[0183] | MAEfwd: | |
| 5′ CACACGCTAGCTACAAAatgttgtcactcaaacgcatagcaac |
| (SEQ ID NO: 73) |
| |
| MAErev: |
| 5′ CACACGTCGACttaatgatctcggtatacgagaggaac, |
| (SEQ ID NO: 74) |
and the resulting fragment is cleaved with NheI and SalI, and ligated to XbaI- and XhoI-digested pRS413TEF (Mumberg, D. et al. (1995) Gene, 156:119-122), creating the plasmid “pTEFMAE”, which contains sequences encoding the cytosolic NADP
+-dependant malic enzyme from
M. circinelloides (E.C. 1.1.1.40; mce gene; Genbank accession: AY209191) under the control of the constitutive TEF1 promoter.
[0184]The plasmids “p1gal2”, “pAMPD”, and “pTEFMAE” are sequentially transformed into a strain of S. cereviseae to restore prototrophy for uracil (“p1gal2”), leucine (“pAMPD”), and histidine (“pTEFMAE”) (Guthrie and Fink Methods in Enzymology 194:1-933, 1991). The resulting transformants are tested for total lipid content following shake flask testing in either synthetic complete (SC) medium lacking uracil, leucine and histidine, as described in Example 3, or in a 2-step fermentation process. In the 2-step process, 1.5 ml of cells from an overnight 2 ml roll tube culture containing SC medium lacking uracil, leucine and histidine are centrifuged, washed in distilled water, and resuspended in 20 ml of a nitrogen-limiting medium suitable for lipid accumulation (30 g/L glucose, 1.5 g/L yeast extract, 0.5 g/L NH4Cl, 7 g/L KH2PO4, 5 g/L Na2HPO4-12H2O, 1.5 g/L MgSO4-7H2O, 0.08 g/L FeCl3-6H2O, 0.01 g/L ZnSO4-7H2O, 0.1 g/L CaCl2-2H2O, 0.1 mg/L MnSO4-5H2O, 0.1 mg/L CuSO4-5H2O, 0.1 mg/L Co(NO3)2-6H2O; pH 5.5 (J Am Oil Chem Soc 70:891-894 (1993)).
[0185]Intracellular lipid content of the modified and control S. cerevisiae strains is analyzed using the fluorescent probe, Nile Red (J Microbiol Meth (2004) 56:331-338). In brief, cells diluted in buffer are stained with Nile Red, excited at 488 nm, and the fluorescent emission spectra in the wavelength region of 400-700 nm are acquired and compared to the corresponding spectra from cells not stained with Nile Red. To confirm results from the rapid estimation method, the total lipid content is determined by gas chromatographic analysis of the total fatty acids directly transmethylesterified from dried cells, as described (Appl Microbiol Biotechnol. 2002 November;60(3):275-80). Non-transformed S. cerevisiae strains produce 6% and 10% total lipid (dry cell weight basis) after growth in YPD and lipid accumulation medium, respectively. Yeast strains expressing the multiple oleaginic polypeptides produce 17% and 25% total lipid following growth in YPD and lipid accumulation medium, respectively.
Example 10
Introduction of Heterologous Carotene Hydroxylase into Y. lipolytica Strains Producing Carotenoid for Production of Zeaxanthin
[0186]MF578 (tef-carRP tef-carB) was transformed with pMB4692 that had been cleaved with SalI. Several Ura+colonies inferred to contain tef-crtZ by PCR analysis were able to produce zeaxanthin in YPD shake flasks, and in one case, all of the carotene was depleted.
[0187]The following tables are referenced throughout the description:
[0188] |
| Examples of acetyl-CoA carboxylase polypeptides. |
| Gen bank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | XP_410263 | 49097606 |
| 2 | XP_329580 | 32418204 |
| 3 | XP_386756 | 46124405 |
| 4 | XP_367702 | 39972623 |
| 5 | XP_501721 | 50548503 |
| 6 | EAK99708 | 46440402 |
| 7 | XP_457211 | 50413128 |
| 8 | NP_982612 | 45184894 |
| 9 | XP_449236 | 50293649 |
| 10 | NP_593271 | 19114183 |
| 11 | NP_014413 | 6324343 |
| 12 | XP_455355 | 50310667 |
| 13 | T42531 | 11272737 |
| 14 | AAA20073 | 171504 |
| 15 | EAL20176 | 50257469 |
| 16 | XP_571316 | 58268320 |
| 17 | XP_402244 | 49076566 |
| 18 | S60200 | 2133343 |
| 19 | BAA24410 | 2804173 |
| 20 | P32874 | 1708192 |
| 21 | S55089 | 7438088 |
| 22 | NP_990836 | 45382859 |
| 23 | CAE01471 | 32526576 |
| 24 | AAR37018 | 40019048 |
| 25 | NP_001 . . . | 57164283 |
| 26 | NP_776649 | 27806341 |
| 27 | CAI25271 | 56205878 |
| 28 | XP_109883 | 51828611 |
| 29 | NP_942134 | 38679971 |
| 30 | NP_942131 | 38679960 |
| 31 | NP_942135 | 38679974 |
| 32 | NP_942136 | 38679977 |
| 33 | AAP94122 | 33112885 |
| 34 | NP_071529 | 11559962 |
| 35 | 2006242A | 740964 |
| 36 | AAS13685 | 42405896 |
| 37 | NP_598665 | 48976025 |
| 38 | Q13085 | 2493311 |
| 39 | XP_548250 | 57091783 |
| 40 | XP_314071 | 58385597 |
| 41 | CAG08536 | 47226520 |
| 42 | NP_724636 | 24586460 |
| 43 | NP_610342 | 24586458 |
| 44 | NP_001084 | 4501855 |
| 45 | NP_446374 | 16758804 |
| 46 | EAL63219 | 60465120 |
| 47 | NP_921034 | 37533464 |
| 48 | T07084 | 7438099 |
| 49 | AAP78896 | 32264940 |
| 50 | AAO62903 | 29123370 |
| 51 | BAA07012 | 1100253 |
| 52 | AAL02056 | 15558947 |
| 53 | AAG40563 | 11869927 |
| 54 | D86483 | 25293894 |
| 55 | T07920 | 7438090 |
| 56 | A57710 | 2130099 |
| 57 | AAO62902 | 29123376 |
| 58 | 2208491A | 1588584 |
| 59 | T09538 | 7438102 |
| 60 | CAC19875 | 12057067 |
| 61 | AAP78897 | 32264942 |
| 62 | T02235 | 7438095 |
| 63 | AAG40564 | 11869928 |
| 64 | E86483 | 25293893 |
| 65 | CAC84161 | 20975574 |
| 66 | T07081 | 7438097 |
| 67 | CAC19876 | 12057069 |
|
[0189] |
| Examples of pyruvate decarboxylase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | 1QPBB | 7245977 |
| 2 | CAA54522 | 871533 |
| 3 | 1PYDB | 515237 |
| 4 | CAA28380 | 4109 |
| 5 | 1PVDB | 1127233 |
| 6 | CAA33709 | 4114 |
| 7 | AAN77243 | 25992752 |
| 8 | NP_013235 | 6323163 |
| 9 | Q6FJA3 | 57012668 |
| 10 | S36363 | 486942 |
| 11 | Q12629 | 52788279 |
| 12 | AAP75898 | 37359468 |
| 13 | S70684 | 2131152 |
| 14 | NP_011601 | 6321524 |
| 15 | AAQ73618 | 34500072 |
| 16 | NP_983270 | 45185554 |
| 17 | AAF78895 | 8745337 |
| 18 | CAB65554 | 6689662 |
| 19 | AAP75899 | 37359470 |
| 20 | NP_982469 | 45184751 |
| 21 | CAA97091 | 1945321 |
| 22 | S50700 | 1086157 |
| 23 | XP_446491 | 50288125 |
| 24 | XP_462338 | 50427451 |
| 25 | AAC03164 | 17066784 |
| 26 | EAK96569 | 46437219 |
| 27 | XP_457131 | 50412425 |
| 28 | AAC03165 | 2734883 |
| 29 | XP_459224 | 50421349 |
| 30 | CAH56494 | 52673248 |
| 31 | XP_502647 | 50550349 |
| 32 | NP_010203 | 6320123 |
| 33 | BAA04886 | 1786148 |
| 34 | XP_449074 | 50293325 |
| 35 | EAL04098 | 46444826 |
| 36 | CAD60727 | 27803024 |
| 37 | T38759 | 25777585 |
| 38 | XP_331173 | 32421459 |
| 39 | NP_594083 | 19114995 |
| 40 | XP_401609 | 49075036 |
| 41 | XP_390010 | 46136637 |
| 42 | XP_409025 | 49095128 |
| 43 | NP_984350 | 45188127 |
| 44 | AAD16178 | 4323053 |
| 45 | P87208 | 2501326 |
| 46 | EAL18331 | 50255598 |
| 47 | XP_567475 | 58260130 |
| 48 | AAM73540 | 21666011 |
| 49 | AAM73539 | 21666009 |
| 50 | XP_502508 | 50550071 |
| 51 | CAA93158 | 1177659 |
| 52 | XP_412533 | 49123327 |
| 53 | P51844 | 1706333 |
| 54 | XP_455842 | 50311631 |
| 55 | CAA61155 | 3688422 |
| 56 | XP_444902 | 50284947 |
| 57 | CAA47319 | 4118 |
|
[0190] |
| Examples of isocitrate dehydrogenase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | O13285 | 3023996 |
| 2 | EAK91676 | 46432179 |
| 3 | O13285 | 3023996 |
| 4 | EAK94305 | 46434909 |
| 5 | XP_451683 | 50303483 |
| 6 | XP_459772 | 50422415 |
| 7 | O13294 | 27805482 |
| 8 | XP_460289 | 50423413 |
| 9 | XP_390523 | 46137663 |
| 10 | XP_367343 | 39971905 |
| 11 | XP_323176 | 32405126 |
| 12 | XP_445447 | 50286037 |
| 13 | AAK76730 | 15027826 |
| 14 | NP_010217 | 6320137 |
| 15 | NP_984921 | 45190667 |
| 16 | AAK76731 | 15027827 |
| 17 | P79089 | 3023999 |
| 18 | NP_013275 | 6323203 |
| 19 | XP_407136 | 49091350 |
| 20 | NP_982520 | 45184802 |
| 21 | XP_446953 | 50289047 |
| 22 | XP_445184 | 50285511 |
| 23 | XP_455638 | 50311227 |
| 24 | AAA64516 | 736722 |
| 25 | NP_970434 | 42525054 |
| 26 | AAT93173 | 51013759 |
| 27 | XP_569233 | 58264154 |
| 28 | XP_569234 | 58264156 |
| 29 | XP_403726 | 49080406 |
| 30 | XP_503571 | 50552322 |
| 31 | XP_458151 | 50428131 |
| 32 | O13302 | 13124301 |
| 33 | XP_409927 | 49096934 |
| 34 | XP_385909 | 46122711 |
| 35 | XP_365293 | 39967489 |
| 36 | NP_983873 | 45187650 |
| 37 | XP_455266 | 50310493 |
| 38 | NP_594397 | 19115309 |
| 39 | XP_324955 | 32408949 |
| 40 | CAE81942 | 38636405 |
| 41 | NP_014361 | 6324291 |
| 42 | XP_446479 | 50288101 |
| 43 | XP_567378 | 58259936 |
| 44 | XP_398944 | 49069310 |
| 45 | XP_502479 | 50550013 |
| 46 | EAK96238 | 46436883 |
| 47 | EAK96305 | 46436951 |
| 48 | XP_461797 | 50426401 |
| 49 | XP_328403 | 32415850 |
| 50 | CAF31997 | 42820684 |
| 51 | XP_389756 | 46136129 |
| 52 | XP_363786 | 39952139 |
| 53 | AAL73035 | 18463935 |
| 54 | XP_405140 | 49086142 |
| 55 | NP_595203 | 19111995 |
| 56 | NP_014779 | 6324709 |
| 57 | XP_447564 | 50290265 |
| 58 | NP_985684 | 45198655 |
| 59 | XP_566837 | 58258849 |
| 60 | XP_454086 | 50308171 |
| 61 | XP_398943 | 49069308 |
|
[0191] |
| Examples of ATP-citrate lyase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | XP_327071 | 32413182 |
| 2 | O93988 | 30912679 |
| 3 | XP_370222 | 39977669 |
| 4 | XP_406573 | 49090008 |
| 5 | XP_504787 | 50554757 |
| 6 | Q9P7W3 | 30912748 |
| 7 | XP_398620 | 49068662 |
| 8 | NP_596202 | 19112994 |
| 9 | XP_567460 | 58260100 |
| 10 | NP_001008 | 56118260 |
| 11 | XP_418154 | 50760837 |
| 12 | AAH84253 | 54038148 |
| 13 | NP_942127 | 38569423 |
| 14 | NP_001087 | 38569421 |
| 15 | P53396 | 20141248 |
| 16 | AAL34316 | 17028103 |
| 17 | NP_001002 | 50540366 |
| 18 | AAH84776 | 54311201 |
| 19 | S21173 | 105392 |
| 20 | AAT94429 | 51092031 |
| 21 | AAD34754 | 28372804 |
| 22 | AAH21502 | 18204829 |
| 23 | XP_319323 | 58392375 |
| 24 | NP_725514 | 24653990 |
| 25 | EAL26601 | 54637198 |
| 26 | CAE56725 | 39579419 |
| 27 | CAE64663 | 39593194 |
| 28 | XP_511495 | 55645405 |
| 29 | CAF95829 | 47210997 |
| 30 | AAO22565 | 27754223 |
| 31 | AAL33788 | 17065616 |
| 32 | CAB46077 | 5304837 |
| 33 | CAF96044 | 47204726 |
| 34 | AAK13318 | 13160653 |
| 35 | AAQ75159 | 34558815 |
| 36 | AAQ75128 | 34558783 |
| 37 | XP_537640 | 57091075 |
| 38 | XP_327069 | 32413178 |
| 39 | CAB76164 | 7160184 |
| 40 | XP_370223 | 39977671 |
| 41 | XP_386215 | 46123323 |
| 42 | CAA10666 | 7159697 |
| 43 | XP_406572 | 49090004 |
| 44 | XP_503231 | 50551515 |
| 45 | NP_593246 | 19114158 |
| 46 | XP_398620 | 49068662 |
| 47 | XP_567460 | 58260100 |
| 48 | AAT94429 | 51092031 |
| 49 | NP_725514 | 24653990 |
| 50 | AAD34754 | 28372804 |
| 51 | EAL26601 | 54637198 |
| 52 | XP_319323 | 58392375 |
| 53 | AAH84776 | 54311201 |
| 54 | BAB00624 | 9229902 |
| 55 | NP_001008 | 56118260 |
| 56 | AAH84253 | 54038148 |
| 57 | AAH56378 | 38614162 |
| 58 | NP_001087 | 38569421 |
| 59 | NP_942127 | 38569423 |
| 60 | P53396 | 20141248 |
| 61 | XP_511495 | 55645405 |
| 62 | NP_058683 | 8392839 |
| 63 | NP_001002 | 50540366 |
| 64 | S21173 | 105392 |
| 65 | NP_508280 | 17551266 |
| 66 | CAE64663 | 39593194 |
| 67 | CAE56725 | 39579419 |
| 68 | NP_506267 | 17557344 |
| 69 | XP_537640 | 57091075 |
| 70 | CAF96059 | 47204551 |
| 71 | F96633 | 25404292 |
| 72 | AAM91141 | 22136126 |
| 73 | NP_849634 | 30681854 |
| 74 | AAO23582 | 27764922 |
| 75 | AAM65078 | 21593129 |
| 76 | CAC86996 | 15919089 |
| 77 | AAQ75158 | 34558814 |
| 78 | AAQ75127 | 34558782 |
|
[0192] |
| Examples of malic enzyme polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | NP_012896 | 6322823 |
| 2 | XP_448858 | 50292851 |
| 3 | XP_454793 | 50309563 |
| 4 | NP_986598 | 45201028 |
| 5 | XP_460887 | 50424595 |
| 6 | EAK97738 | 46438407 |
| 7 | XP_504112 | 50553402 |
| 8 | XP_330094 | 32419237 |
| 9 | XP_380981 | 46107844 |
| 10 | XP_411070 | 49102552 |
| 11 | XP_362875 | 39946676 |
| 12 | NP_587760 | 19075260 |
| 13 | NP_978189 | 42780942 |
| 14 | YP_035982 | 49481098 |
| 15 | YP_027934 | 49184682 |
| 16 | YP_018438 | 47527089 |
| 17 | ZP_002365 | 47565532 |
| 18 | YP_083209 | 52143619 |
| 19 | XP_571672 | 58269032 |
| 20 | NP_391586 | 16080758 |
| 21 | YP_092693 | 52786864 |
| 22 | NP_831516 | 30019885 |
| 23 | YP_093460 | 52787631 |
| 24 | YP_081030 | 52082239 |
| 25 | NP_822689 | 29828055 |
| 26 | O34389 | 33517449 |
| 27 | EAL19111 | 50256386 |
| 28 | NP_825047 | 29830413 |
| 29 | ZP_002340 | 47096498 |
| 30 | NP_928837 | 37525493 |
| 31 | NP_230833 | 15641201 |
| 32 | NP_934257 | 37679648 |
| 33 | NP_761613 | 27366085 |
| 34 | AC1314 | 25283688 |
| 35 | YP_055602 | 50842375 |
| 36 | YP_095310 | 52841511 |
| 37 | ZP_002315 | 47093832 |
| 38 | AC1686 | 25283689 |
| 39 | YP_126594 | 54294179 |
| 40 | YP_123567 | 54297198 |
| 41 | EAJ76260 | 44510091 |
| 42 | YP_114273 | 53803890 |
| 43 | NP_797637 | 28898032 |
| 44 | YP_040250 | 49483026 |
| 45 | ZP_001276 | 53693400 |
| 46 | YP_044961 | 50083451 |
| 47 | YP_128226 | 54295811 |
| 48 | NP_719387 | 24375344 |
| 49 | XP_572853 | 58271394 |
| 50 | NP_252161 | 15598667 |
| 51 | ZP_001368 | 46164263 |
| 52 | YP_125345 | 54298976 |
| 53 | NP_793695 | 28871076 |
| 54 | YP_096964 | 52843165 |
| 55 | EAH92280 | 44245125 |
| 56 | YP_154988 | 56459707 |
| 57 | EAI68195 | 44354928 |
| 58 | YP_070054 | 51595863 |
| 59 | YP_133025 | 54303032 |
| 60 | NP_969623 | 42524243 |
| 61 | NP_856009 | 31793516 |
| 62 | DECARBOXY | ATING)) |
| 63 | NP_935035 | 37680426 |
| 64 | YP_050922 | 50121755 |
| 65 | E70705 | 7431223 |
| 66 | NP_216848 | 57116971 |
| 67 | DECARBOXY | ATING)) |
| 68 | YP_143786 | 55980489 |
| 69 | YP_130202 | 54309182 |
| 70 | NP_415996 | 16129438 |
| 71 | NP_819843 | 29654151 |
| 72 | NP_753809 | 26247769 |
| 73 | NP_707611 | 56479957 |
| 74 | F85728 | 25283682 |
| 75 | YP_163690 | 56552851 |
| 76 | YP_150562 | 56413487 |
| 77 | NP_720610 | 24378655 |
| 78 | NP_460525 | 16764910 |
| 79 | ZP_003193 | 48865537 |
| 80 | NP_784797 | 28377905 |
| 81 | T13496 | 7431227 |
| 82 | AAV65766 | 55793550 |
| 83 | A97096 | 25283683 |
| 84 | YP_193951 | 58337366 |
| 85 | H97096 | 25283684 |
| 86 | ZP_003237 | 48870993 |
| 87 | ZP_001460 | 41689468 |
| 88 | D86737 | 25283676 |
| 89 | ZP_002870 | 48825851 |
| 90 | ZP_001439 | 34762975 |
| 91 | 1922245A | 737262 |
| 92 | YP_169914 | 56708018 |
| 93 | YP_055027 | 50841800 |
| 94 | ZP_000625 | 23023297 |
| 95 | NP_296302 | 15807565 |
| 96 | NP_285599 | 15807938 |
| 97 | YP_132069 | 54302076 |
| 98 | CAA50716 | 467569 |
| 99 | ZP_002906 | 48833596 |
| 100 | ZP_003155 | 48861632 |
| 101 | NP_773109 | 27381580 |
| 102 | AAQ95658 | 37622953 |
| 103 | CAC19505 | 56204311 |
| 104 | AAH80660 | 51873855 |
| 105 | P40927 | 729986 |
| 106 | AAT02533 | 46850200 |
| 107 | BAC37086 | 26346875 |
| 108 | T02763 | 7431235 |
| 109 | XP_387367 | 46125627 |
| 110 | AAC50613 | 1465733 |
| 111 | CAA39421 | 669118 |
| 112 | CAA39420 | 669117 |
| 113 | NP_032641 | 6678912 |
| 114 | CAA39419 | 581228 |
| 115 | AAB01380 | 1335389 |
| 116 | JC4160 | 1085347 |
| 117 | E96828 | 25283677 |
| 118 | BAD87910 | 57899974 |
| 119 | EAJ77083 | 44511304 |
| 120 | P13697 | 266504 |
| 121 | NP_036732 | 7106353 |
| 122 | YP_065939 | 51246055 |
| 123 | CAC18164 | 16944467 |
| 124 | XP_322953 | 32404680 |
| 125 | AAK91502 | 18460985 |
| 126 | AAQ88396 | 37147841 |
| 127 | NP_001003 | 57525624 |
| 128 | 1GQ2P | 21465488 |
| 129 | AAO26053 | 28195290 |
| 130 | AAH84250 | 54038006 |
| 131 | XP_362590 | 39946106 |
| 132 | AAH03287 | 13096987 |
| 133 | Q29558 | 2497785 |
| 134 | XP_532217 | 57094622 |
| 135 | P28227 | 126734 |
| 136 | NP_496968 | 17537199 |
| 137 | NP_914533 | 34906372 |
| 138 | AAD10504 | 4096786 |
| 139 | AAO67523 | 50897495 |
| 140 | P43279 | 1170871 |
| 141 | AAK83074 | 15077109 |
| 142 | AAP33011 | 30575690 |
| 143 | AAN86690 | 27357017 |
| 144 | P78715 | 41017288 |
| 145 | AAP32204 | 30526303 |
| 146 | AAV31249 | 54287505 |
| 147 | T06402 | 7431232 |
| 148 | Q99KE1 | 55583978 |
| 149 | XP_399922 | 49071266 |
| 150 | P36444 | 547886 |
| 151 | AAO30034 | 28059162 |
| 152 | AAK83073 | 15077107 |
| 153 | NP_002387 | 4505145 |
| 154 | AAA33487 | 168528 |
| 155 | BAA74735 | 4239891 |
| 156 | NP_989634 | 45383538 |
| 157 | 1GZ3D | 31615316 |
| 158 | AAW56450 | 57791240 |
| 159 | AAT02534 | 46850202 |
| 160 | S29742 | 422339 |
| 161 | 1O0SB | 34811253 |
| 162 | P27443 | 126732 |
| 163 | T06401 | 7431231 |
| 164 | AAL16175 | 16226466 |
| 165 | AAF73006 | 8118507 |
| 166 | AAK97530 | 15420975 |
| 167 | EAI90348 | 44385841 |
| 168 | P51615 | 1708924 |
| 169 | AAA19575 | 169327 |
| 170 | S43718 | 1084300 |
| 171 | P34105 | 1346485 |
| 172 | AAS38597 | 42733630 |
| 173 | BAC54101 | 27530932 |
| 174 | AAT02535 | 46850204 |
| 175 | CAB66003 | 6706333 |
| 176 | AAH84860 | 54311418 |
| 177 | CAA39422 | 669119 |
| 178 | NP_916713 | 34910732 |
| 179 | CAA56354 | 510876 |
| 180 | DEFBC | 7427668 |
| 181 | JC5967 | 7431234 |
| 182 | NP_197960 | 15239517 |
| 183 | NP_651959 | 21356279 |
| 184 | CAB64263 | 6634090 |
| 185 | BAB20887 | 54606800 |
| 186 | EAL27424 | 54638022 |
| 187 | NP_006671 | 5729920 |
| 188 | AAB08874 | 1561774 |
| 189 | 1PJLH | 33358128 |
| 190 | 1GZ4D | 22218682 |
| 191 | 1QR6B | 5822327 |
| 192 | 1PJ3D | 39654475 |
| 193 | P22178 | 126736 |
| 194 | XP_410305 | 49097690 |
| 195 | AAH22472 | 18490280 |
|
[0193] |
| Examples of AMP deaminase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | AAA34420 | 171053 |
| 2 | XP_446684 | 50288509 |
| 3 | NP_983153 | 45185436 |
| 4 | XP_453337 | 50306727 |
| 5 | EAL02322 | 46443037 |
| 6 | XP_460211 | 50423261 |
| 7 | XP_503822 | 50552824 |
| 8 | XP_413009 | 49131023 |
| 9 | XP_360256 | 39941438 |
| 10 | XP_381547 | 46108978 |
| 11 | XP_330167 | 32419447 |
| 12 | CAB97316 | 16945394 |
| 13 | T50996 | 11359582 |
| 14 | NP_595153 | 19111945 |
| 15 | EAL22226 | 50259553 |
| 16 | XP_402237 | 49076548 |
| 17 | CAA62797 | 995562 |
| 18 | AAF65407 | 7638159 |
| 19 | XP_537039 | 57088163 |
| 20 | AAH49119 | 29145073 |
| 21 | XP_569691 | 58265070 |
| 22 | AAD56303 | 5922018 |
| 23 | NP_004028 | 21264318 |
| 24 | A44313 | 345738 |
| 25 | CAI19307 | 56206061 |
| 26 | AAA62126 | 644509 |
| 27 | CAI19305 | 56206059 |
| 28 | XP_310497 | 58424203 |
| 29 | CAI19306 | 56206060 |
| 30 | AAC50308 | 608499 |
| 31 | CAG06825 | 47229629 |
| 32 | NP_727741 | 45551453 |
| 33 | NP_727739 | 45551452 |
| 34 | NP_727740 | 24641890 |
| 35 | AAN09337 | 22832227 |
| 36 | T01259 | 7484807 |
| 37 | XP_506591 | 51963676 |
| 38 | NP_850294 | 30687456 |
| 39 | CAG07509 | 47228777 |
| 40 | NP_494974 | 32564190 |
| 41 | T15771 | 7497030 |
| 42 | CAE59064 | 39596837 |
| 43 | NP_494973 | 32564194 |
| 44 | BAA06505 | 1321635 |
| 45 | NP_000471 | 4502079 |
| 46 | S68147 | 2134756 |
| 47 | AAH56380 | 38614134 |
| 48 | O08739 | 2494043 |
| 49 | NP_113732 | 13928736 |
| 50 | O09178 | 2494044 |
| 51 | XP_420973 | 50747746 |
| 52 | NP_956142 | 41054127 |
| 53 | CAG01709 | 47222742 |
| 54 | NP_957187 | 41053780 |
| 55 | XP_392957 | 48104570 |
| 56 | AAH07183 | 13938134 |
| 57 | CAG05605 | 47220579 |
| 58 | NP_620231 | 20302047 |
| 59 | XP_540247 | 57098851 |
| 60 | CAF99638 | 47230445 |
| 61 | XP_513671 | 55587796 |
| 62 | CAI18828 | 56203368 |
| 63 | CAI18829 | 56203369 |
| 64 | CAI18830 | 56203370 |
| 65 | EAA19931 | 23484684 |
| 66 | CAH99706 | 56500932 |
| 67 | XP_131103 | 38076931 |
| 68 | CAH77387 | 56523366 |
|
[0194] |
| Examples of acetoacetyl-CoA thiolase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | P10551 | 135758 |
| 2 | Q04677 | 418002 |
| 3 | Q12598 | 34925109 |
| 4 | T10247 | 7433657 |
| 5 | T42741 | 11257345 |
| 6 | AAL18924 | 16417944 |
| 7 | AAM67058 | 21618008 |
| 8 | AAO51605 | 28829030 |
| 9 | AAU95618 | 53854350 |
| 10 | AAU95619 | 53854352 |
| 11 | BAA97003 | 8777413 |
| 12 | CAE76429 | 38567134 |
| 13 | EAK90852 | 46431255 |
| 14 | EAL32264 | 54643520 |
| 15 | NP_015297 | 6325229 |
| 16 | NP_568694 | 30695411 |
| 17 | NP_572414 | 24640423 |
| 18 | NP_596686 | 19113478 |
| 19 | NP_851154 | 30695409 |
| 20 | NP_908411 | 34894172 |
| 21 | NP_974900 | 42573608 |
| 22 | NP_974901 | 42573610 |
| 23 | NP_984262 | 45188039 |
| 24 | XP_389497 | 46134945 |
| 25 | XP_401186 | 49074048 |
| 26 | XP_405546 | 49087148 |
| 27 | XP_449306 | 50293789 |
| 28 | XP_449306 | 50293789 |
| 29 | XP_450298 | 50899020 |
| 30 | XP_453599 | 50307241 |
| 31 | XP_460741 | 50424309 |
| 32 | XP_500646 | 50546253 |
|
[0195] |
| Examples of HMG-CoA synthase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | B55729 | 1083370 |
| 2 | P54869 | 1708235 |
| 3 | S13887 | 86312 |
| 4 | S27197 | 284048 |
| 5 | AAA37076 | 387072 |
| 6 | AAF89580 | 9621905 |
| 7 | AAH00297 | 33991031 |
| 8 | AAH31363 | 21618633 |
| 9 | AAH42929 | 27552834 |
| 10 | AAH79694 | 50925193 |
| 11 | AAH83543 | 54035469 |
| 12 | AAO52569 | 28830079 |
| 13 | AAP35966 | 30583443 |
| 14 | BAB23657 | 12836439 |
| 15 | BAC04559 | 21754758 |
| 16 | BAC05233 | 21758044 |
| 17 | CAA52032 | 1772495 |
| 18 | CAC18553 | 11602786 |
| 19 | CAG33131 | 48145817 |
| 20 | CAH92111 | 55730782 |
| 21 | CAI22408 | 56205097 |
| 22 | EAK97451 | 46438115 |
| 23 | EAL25034 | 54635631 |
| 24 | NP_002121 | 54020720 |
| 25 | NP_013580 | 6323509 |
| 26 | NP_032282 | 31560689 |
| 27 | NP_058964 | 8393538 |
| 28 | NP_593859 | 19114771 |
| 29 | NP_666054 | 31981842 |
| 30 | NP_725570 | 24654139 |
| 31 | NP_775117 | 27465521 |
| 32 | NP_957379 | 41055180 |
| 33 | NP_983739 | 45187516 |
| 34 | NP_990742 | 45382279 |
| 35 | NP_999545 | 47523816 |
| 36 | XP_315872 | 58387870 |
| 37 | XP_323241 | 32405256 |
| 38 | XP_368218 | 39973655 |
| 39 | XP_389442 | 46134253 |
| 40 | XP_397202 | 48141273 |
| 41 | XP_402977 | 49078452 |
| 42 | XP_409060 | 49095198 |
| 43 | XP_446972 | 50289085 |
| 44 | XP_453529 | 50307101 |
| 45 | XP_456470 | 50405663 |
| 46 | XP_506052 | 50557288 |
| 47 | XP_513693 | 55587844 |
| 48 | XP_536483 | 57085299 |
| 49 | XP_569805 | 58265298 |
| 50 | XP_571930 | 58269548 |
|
[0196] |
| Examples of HMG-CoA reductase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | A23586 | 90238 |
| 2 | O74164 | 11132850 |
| 3 | P51639 | 1708252 |
| 4 | P54960 | 1708251 |
| 5 | Q12649 | 18276268 |
| 6 | Q29512 | 2495262 |
| 7 | Q9Y7D2 | 11133211 |
| 8 | S30338 | 422383 |
| 9 | S72194 | 7450066 |
| 10 | AAA36989 | 387052 |
| 11 | AAA37077 | 305355 |
| 12 | AAA49740 | 214237 |
| 13 | AAD20975 | 9817458 |
| 14 | AAH74197 | 49257596 |
| 15 | AAL09351 | 15824453 |
| 16 | AAO85434 | 29468180 |
| 17 | AAP72015 | 32165622 |
| 18 | AAR02862 | 45272118 |
| 19 | AAT92819 | 51013051 |
| 20 | BAC20567 | 23574646 |
| 21 | CAA63970 | 4376229 |
| 22 | CAE47850 | 41581201 |
| 23 | CAF92135 | 47213283 |
| 24 | CAH92577 | 55731745 |
| 25 | EAK94577 | 46435190 |
| 26 | EAL20195 | 50257490 |
| 27 | AAF80374 | 8886086 |
| 28 | NP_013555 | 6323483 |
| 29 | NP_013636 | 6323565 |
| 30 | NP_032281 | 56119096 |
| 31 | NP_037266 | 40538852 |
| 32 | NP_588235 | 19075735 |
| 33 | NP_985010 | 45190756 |
| 34 | NP_989816 | 45383193 |
| 35 | NP_999724 | 47551099 |
| 36 | XP_324892 | 32408825 |
| 37 | XP_364130 | 39955070 |
| 38 | XP_389373 | 46134115 |
| 39 | XP_400629 | 49072680 |
| 40 | XP_405730 | 49087632 |
| 41 | XP_407954 | 49092986 |
| 42 | XP_449268 | 50293713 |
| 43 | XP_451740 | 50303597 |
| 44 | XP_458872 | 50420671 |
| 45 | XP_503558 | 50552167 |
| 46 | XP_536323 | 57084803 |
| 47 | XP_571450 | 58268588 |
|
[0197] |
| Examples of mevalonate kinase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | XP_386088 | 46123069 |
| 2 | XP_408006 | 49093090 |
| 3 | XP_370449 | 39978123 |
| 4 | EAL04797 | 46445529 |
| 5 | XP_322935 | 32404644 |
| 6 | NP_001007 | 55925207 |
| 7 | XP_460851 | 50424525 |
| 8 | XP_567851 | 58260882 |
| 9 | XP_567850 | 58260880 |
| 10 | AAQ02416 | 33303805 |
| 11 | CAA53059 | 450346 |
| 12 | AAH16140 | 16359371 |
| 13 | AAH05606 | 13542811 |
| 14 | XP_403111 | 49078786 |
| 15 | XP_452532 | 50305147 |
| 16 | CAG08527 | 47226511 |
| 17 | XP_446138 | 50287417 |
| 18 | AAO51522 | 28828936 |
| 19 | NP_985191 | 45190937 |
| 20 | XP_500956 | 50546973 |
| 21 | NP_013935 | 6323864 |
| 22 | AAD45421 | 5578718 |
| 23 | NP_920723 | 37532842 |
| 24 | NP_851084 | 30690651 |
| 25 | AAL18925 | 16417946 |
| 26 | NP_788338 | 28573850 |
| 27 | AAU20834 | 51988124 |
| 28 | AAU87813 | 52839819 |
| 29 | AAU20835 | 51988125 |
| 30 | YP_183887 | 57641409 |
| 31 | NP_143478 | 14591399 |
| 32 | BAA24409 | 2804172 |
| 33 | NP_126232 | 14520757 |
| 34 | XP_522574 | 55639331 |
| 35 | NP_071114 | 11499870 |
| 36 | XP_423949 | 50797461 |
| 37 | NP_633786 | 21227864 |
| 38 | ZP_002971 | 48840229 |
| 39 | EAH50787 | 44170778 |
| 40 | NP_615566 | 20089491 |
| 41 | 1VISA | 40890012 |
| 42 | EAK03559 | 44549994 |
| 43 | NP_248080 | 15669275 |
| 44 | 1KKHA | 20150886 |
| 45 | Q50559 | 2497518 |
| 46 | CAF88123 | 47200914 |
| 47 | NP_275189 | 15678075 |
| 48 | EAI88745 | 44383877 |
| 49 | ZP_002040 | 46141948 |
| 50 | XP_543435 | 57105916 |
| 51 | EAI38920 | 44313360 |
| 52 | NP_148611 | 14602065 |
| 53 | EAD08953 | 43286228 |
| 54 | EAD45697 | 43361720 |
| 55 | YP_134862 | 55377012 |
| 56 | NP_720650 | 24378695 |
| 57 | NP_614276 | 20094429 |
| 58 | E84270 | 25409931 |
| 59 | NP_691146 | 23097680 |
| 60 | ZP_003233 | 48870579 |
| 61 | AAG02440 | 9937386 |
| 62 | EAD12278 | 43292898 |
| 63 | NP_498328 | 17555862 |
| 64 | EAB31483 | 42928976 |
| 65 | ZP_003319 | 50590618 |
| 66 | NP_814642 | 29375488 |
| 67 | AC1434 | 25514495 |
| 68 | ZP_003577 | 53796847 |
| 69 | EAD82048 | 43454743 |
| 70 | CAE73618 | 39586491 |
| 71 | YP_012624 | 46906235 |
| 72 | NP_988455 | 45358898 |
| 73 | ZP_002348 | 47097293 |
| 74 | ZP_002862 | 48824993 |
| 75 | ZP_002307 | 47093020 |
| 76 | NP_597102 | 19173299 |
| 77 | CAD24422 | 20429111 |
| 78 | NP_785308 | 28378416 |
| 79 | EAA39098 | 29247539 |
| 80 | NP_819638 | 29653946 |
| 81 | EAH49746 | 44168765 |
| 82 | EAH49745 | 44168764 |
| 83 | NP_378182 | 15922513 |
| 84 | ZP_000459 | 23002259 |
| 85 | H90181 | 25393827 |
| 86 | YP_054120 | 50405028 |
| 87 | BAB07790 | 9695270 |
| 88 | AAG02435 | 9937379 |
| 89 | NP_560495 | 18313828 |
| 90 | YP_187834 | 57866187 |
| 91 | EAK40782 | 44602942 |
| 92 | CAC51370 | 15212070 |
| 93 | AAG02424 | 9937364 |
| 94 | YP_185521 | 57651465 |
| 95 | YP_040044 | 49482820 |
| 96 | YP_194037 | 58337452 |
| 97 | D86675 | 25400965 |
| 98 | NP_763916 | 27467279 |
| 99 | CAF89434 | 47197810 |
| 100 | EAF38333 | 43767792 |
| 101 | EAK46841 | 44611394 |
| 102 | H89827 | 25507776 |
| 103 | ZP_003149 | 48861061 |
| 104 | EAK17824 | 44570143 |
| 105 | EAH86276 | 44235719 |
| 106 | YP_118418 | 54024176 |
| 107 | ZP_003196 | 48865749 |
| 108 | AAG02430 | 9937372 |
| 109 | NP_269075 | 15674901 |
| 110 | NP_802520 | 28896170 |
| 111 | AAL97579 | 19748102 |
| 112 | ZP_003666 | 56808907 |
| 113 | NP_965060 | 42519130 |
| 114 | NP_819639 | 29653947 |
| 115 | EAD97024 | 43484567 |
| 116 | BAD86800 | 57753870 |
|
[0198] |
| Examples of phosphomevalonate kinase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | AAA34596 | 171479 |
| 2 | XP_452514 | 50305111 |
| 3 | NP_985210 | 45190956 |
| 4 | XP_446144 | 50287429 |
| 5 | XP_462340 | 50427455 |
| 6 | EAL04096 | 46444824 |
| 7 | EAL03941 | 46444668 |
| 8 | XP_503619 | 50552418 |
| 9 | XP_389940 | 46136497 |
| 10 | XP_329795 | 32418634 |
| 11 | XP_369652 | 39976529 |
| 12 | XP_406448 | 49089559 |
| 13 | NP_593421 | 19114333 |
| 14 | XP_568385 | 58261950 |
| 15 | EAL17628 | 50254887 |
| 16 | AAL18926 | 16417948 |
| 17 | BAD43274 | 51969164 |
| 18 | BAD44652 | 51971975 |
| 19 | XP_398375 | 49068172 |
| 20 | BAD44486 | 51971643 |
| 21 | F90479 | 25393214 |
| 22 | YP_194039 | 58337454 |
|
[0199] |
| Examples of mevalonate pyrophosphate decarboxylase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | AAT93171 | 51013755 |
| 2 | 1FI4A | 13786942 |
| 3 | XP_455548 | 50311049 |
| 4 | XP_445335 | 50285813 |
| 5 | XP_456912 | 50409853 |
| 6 | NP_986435 | 45200865 |
| 7 | AAF19399 | 6625790 |
| 8 | XP_328845 | 32416734 |
| 9 | XP_505041 | 50555265 |
| 10 | NP_594027 | 19114939 |
| 11 | XP_364905 | 39963452 |
| 12 | XP_390600 | 46137817 |
| 13 | XP_408551 | 49094180 |
| 14 | AAA34506 | 7544604 |
| 15 | EAL18927 | 50256200 |
| 16 | XP_568247 | 58261674 |
| 17 | XP_402794 | 49077992 |
| 18 | AAH81784 | 51980639 |
| 19 | EAL00166 | 46440864 |
| 20 | NP_619597 | 20149736 |
| 21 | NP_112324 | 13592005 |
| 22 | BAC40852 | 26354448 |
| 23 | XP_546783 | 57087071 |
| 24 | Q99JF5 | 23814095 |
| 25 | AAH63907 | 39645379 |
| 26 | CAF99534 | 47230341 |
| 27 | AAP35576 | 30582699 |
| 28 | AAP36301 | 30584105 |
| 29 | AAL18927 | 16417950 |
| 30 | AAV32433 | 54292590 |
| 31 | AAP68208 | 31711704 |
| 32 | AAM64988 | 21593039 |
| 33 | NP_566995 | 18410026 |
| 34 | XP_423130 | 50771155 |
| 35 | AAM65192 | 21593243 |
| 36 | NP_001007 | 55925435 |
| 37 | NP_573068 | 28571205 |
| 38 | BAD27942 | 50252009 |
| 39 | T47584 | 11281655 |
| 40 | XP_307373 | 31196851 |
| 41 | CAE73245 | 39591192 |
| 42 | NP_496966 | 17537201 |
| 43 | XP_393230 | 48121058 |
| 44 | G90479 | 25393662 |
| 45 | NP_496967 | 17537203 |
| 46 | NP_691147 | 23097681 |
| 47 | EAL29282 | 54640164 |
| 48 | AD1434 | 25515042 |
| 49 | ZP_002308 | 47093021 |
| 50 | YP_012625 | 46906236 |
| 51 | ZP_002348 | 47097294 |
| 52 | NP_819637 | 29653945 |
| 53 | NP_376888 | 15921219 |
| 54 | ZP_003319 | 50590617 |
| 55 | NP_585805 | 19074299 |
| 56 | YP_187835 | 57866188 |
| 57 | CAD24423 | 20429112 |
| 58 | AAG02431 | 9937373 |
| 59 | NP_763917 | 27467280 |
| 60 | AAG02446 | 9937394 |
| 61 | ZP_002863 | 48824994 |
| 62 | AAG02441 | 9937387 |
| 63 | YP_185522 | 57651466 |
| 64 | A89828 | 25505863 |
| 65 | NP_814641 | 29375487 |
| 66 | YP_040045 | 49482821 |
| 67 | NP_785307 | 28378415 |
| 68 | ZP_003196 | 48865750 |
| 69 | ZP_003233 | 48870580 |
| 70 | E86675 | 25400967 |
| 71 | EAE31110 | 43552684 |
| 72 | BAB07791 | 9695271 |
| 73 | CAC51371 | 15212071 |
| 74 | ZP_000459 | 23002258 |
| 75 | NP_965061 | 42519131 |
| 76 | BAD86801 | 57753871 |
| 77 | YP_194038 | 58337453 |
| 78 | YP_118419 | 54024177 |
| 79 | EAK18820 | 44571499 |
| 80 | EAI85935 | 44379784 |
| 81 | NP_721336 | 24379381 |
| 82 | D95044 | 25388338 |
| 83 | AAG02456 | 9937408 |
| 84 | C97914 | 25511486 |
| 85 | EAK47683 | 44612560 |
| 86 | EAB86425 | 43039778 |
| 87 | YP_140971 | 55822530 |
| 88 | YP_139081 | 55820639 |
| 89 | BAD07376 | 40882372 |
| 90 | NP_968512 | 42523132 |
| 91 | EAI06705 | 44265427 |
| 92 | YP_060018 | 50914046 |
| 93 | AAG02451 | 9937401 |
| 94 | NP_269076 | 15674902 |
| 95 | ZP_003666 | 56808906 |
| 96 | NP_688323 | 22537472 |
| 97 | NP_735832 | 25011437 |
| 98 | EAC40267 | 43149093 |
| 99 | AAL97580 | 19748103 |
| 100 | EAI76915 | 44367119 |
| 101 | EAD35042 | 43339207 |
| 102 | YP_073129 | 51598941 |
| 103 | EAI90092 | 44385501 |
| 104 | BAB07818 | 9711347 |
| 105 | EAD72850 | 43433025 |
| 106 | NP_212820 | 15595031 |
| 107 | YP_124337 | 54297968 |
| 108 | YP_096056 | 52842257 |
| 109 | EAA39903 | 29248368 |
| 110 | EAH06252 | 44088237 |
| 111 | YP_127354 | 54294939 |
| 112 | EAD45753 | 43361830 |
| 113 | NP_802519 | 28896169 |
|
[0200] |
| Examples of IPP isomerase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | NP_015208 | 6325140 |
| 2 | XP_448008 | 50291151 |
| 3 | NP_983828 | 45187605 |
| 4 | XP_455121 | 50310203 |
| 5 | XP_462358 | 50427491 |
| 6 | EAL01685 | 46442395 |
| 7 | XP_504974 | 50555131 |
| 8 | XP_328425 | 32415894 |
| 9 | XP_367200 | 39971619 |
| 10 | XP_389898 | 46136413 |
| 11 | XP_404716 | 49085144 |
| 12 | CAD37150 | 21627818 |
| 13 | NP_595164 | 19111956 |
| 14 | XP_566641 | 58258457 |
| 15 | XP_402453 | 49077100 |
| 16 | O35586 | 6225528 |
| 17 | AAP36609 | 30584713 |
| 18 | AAF37873 | 7188790 |
| 19 | NP_445991 | 16758306 |
| 20 | O42641 | 6225529 |
| 21 | BAA33979 | 3790386 |
| 22 | Q13907 | 6225527 |
| 23 | AAH22418 | 48257241 |
| 24 | AAH19227 | 48257312 |
| 25 | AAH57827 | 35505325 |
| 26 | NP_004499 | 40018633 |
| 27 | AAH89786 | 58477715 |
| 28 | CAH91844 | 55730243 |
| 29 | XP_418561 | 50732281 |
| 30 | AAH06999 | 48257093 |
| 31 | CAF98782 | 47225155 |
| 32 | NP_808875 | 29366820 |
| 33 | XP_507622 | 55633353 |
| 34 | AAH82648 | 52139082 |
| 35 | NP_001011 | 58332496 |
| 36 | AAF29976 | 6856556 |
| 37 | AAG10423 | 9971806 |
| 38 | O48964 | 6225525 |
| 39 | AAF29973 | 6856550 |
| 40 | AAF29977 | 6856558 |
| 41 | AAQ84167 | 35186998 |
| 42 | AAF29974 | 6856552 |
| 43 | Q39472 | 6225526 |
| 44 | S49588 | 1085973 |
| 45 | AAL91980 | 19568939 |
| 46 | BAB40973 | 13603406 |
| 47 | AAF29975 | 6856554 |
| 48 | T52027 | 25493162 |
| 49 | AAL91979 | 19568937 |
| 50 | T46812 | 11362218 |
| 51 | T51248 | 11362217 |
| 52 | BAB40974 | 13603408 |
| 53 | O48965 | 6225532 |
| 54 | XP_225509 | 34877710 |
| 55 | XP_506401 | 51963472 |
| 56 | AAF29978 | 6856560 |
| 57 | AAH76541 | 50369278 |
| 58 | AAT94033 | 51038230 |
| 59 | XP_225502 | 34876517 |
| 60 | Q39471 | 6225533 |
| 61 | AAB67743 | 1213450 |
| 62 | NP_197148 | 22326844 |
| 63 | BAB09611 | 9759126 |
| 64 | AAD41766 | 5305669 |
| 65 | AAB67741 | 1213442 |
| 66 | XP_395125 | 48101420 |
| 67 | AAN28784 | 23505849 |
| 68 | AAF36996 | 7110585 |
| 69 | BAB16690 | 15289752 |
| 70 | AAQ14869 | 33340598 |
| 71 | BAC65421 | 28971819 |
| 72 | S71369 | 2129625 |
| 73 | AAF29979 | 6856562 |
| 74 | AAF29980 | 6856564 |
| 75 | AAP21674 | 30267831 |
| 76 | Q39664 | 6225534 |
| 77 | NP_650962 | 24648688 |
| 78 | AAM50284 | 21429130 |
| 79 | XP_321388 | 58395620 |
| 80 | Q9BXS1 | 20978506 |
| 81 | T07979 | 7484383 |
| 82 | XP_225508 | 34876527 |
| 83 | AAT92102 | 51011386 |
| 84 | XP_225507 | 34876555 |
| 85 | XP_344623 | 34876537 |
| 86 | S44843 | 630677 |
| 87 | XP_225498 | 27687955 |
| 88 | AAT08468 | 47013849 |
| 89 | EAI79636 | 44370808 |
| 90 | CAE75055 | 39587401 |
| 91 | EAL04047 | 46444775 |
| 92 | XP_225528 | 34876543 |
| 93 | XP_544282 | 57040602 |
| 94 | XP_225511 | 27688013 |
| 95 | P26173 | 114853 |
| 96 | EAJ04069 | 44405322 |
| 97 | EAH27496 | 44127513 |
| 98 | AAF91499 | 9653280 |
| 99 | AAM48661 | 21328655 |
| 100 | EAK17826 | 44570145 |
| 101 | EAD59515 | 43391069 |
| 102 | YP_128702 | 54307682 |
| 103 | EAK66656 | 44639203 |
| 104 | YP_118189 | 54023947 |
| 105 | T50740 | 11282665 |
| 106 | ZP_002077 | 46193541 |
| 107 | EAK16470 | 44568229 |
| 108 | YP_165403 | 56695056 |
| 109 | EAD08775 | 43285885 |
| 110 | YP_195623 | 58616494 |
| 111 | EAI38918 | 44313358 |
| 112 | NP_930583 | 37527239 |
| 113 | YP_160254 | 56478665 |
| 114 | EAH69842 | 44206571 |
| 115 | EAK26254 | 44582307 |
| 116 | AAR24381 | 38569721 |
| 117 | AAM48607 | 21328600 |
| 118 | EAD82049 | 43454744 |
| 119 | ZP_001924 | 45914126 |
| 120 | YP_056780 | 50843553 |
| 121 | YP_050880 | 50121713 |
| 122 | EAF29235 | 43749645 |
| 123 | NP_630823 | 21225044 |
| 124 | Q82MJ7 | 34582349 |
| 125 | ZP_003374 | 52010110 |
| 126 | AAS75819 | 45737905 |
| 127 | Q8KP37 | 30913023 |
| 128 | XP_507621 | 55633351 |
| 129 | XP_344621 | 34876521 |
| 130 | XP_346322 | 34880719 |
| 131 | YP_152060 | 56414985 |
| 132 | AAT42442 | 48429280 |
| 133 | Q9KK75 | 13878536 |
| 134 | NP_806649 | 29143307 |
| 135 | YP_063124 | 50955836 |
| 136 | Q8FND7 | 46395593 |
| 137 | CAF20647 | 41326485 |
| 138 | Q8NN99 | 23821718 |
| 139 | Q7X5H2 | 46395586 |
| 140 | NP_336246 | 15841209 |
| 141 | Q83MJ9 | 46395588 |
| 142 | P60923 | 46395576 |
| 143 | Q8FE75 | 31563050 |
| 144 | 1R67A | 38493022 |
| 145 | Q9KWD1 | 13878537 |
| 146 | Q7VEU0 | 46395585 |
| 147 | B84333 | 25410326 |
| 148 | NP_417365 | 16130791 |
| 149 | E85944 | 25355426 |
| 150 | 1HZTA | 15826050 |
| 151 | 1PVFB | 50513321 |
| 152 | EAD63579 | 43403471 |
| 153 | 1I9AB | 13786886 |
| 154 | YP_012992 | 46906603 |
| 155 | ZP_002293 | 47091503 |
| 156 | EAI37194 | 44310821 |
| 157 | YP_137864 | 55380014 |
| 158 | CAD92056 | 42516867 |
| 159 | 1OW2B | 42543244 |
|
[0201] |
| Examples of FPP synthase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | Q92250 | 2497455 |
| 2 | XP_363065 | 39948036 |
| 3 | XP_386960 | 46124813 |
| 4 | Q92235 | 3122099 |
| 5 | XP_412149 | 49116518 |
| 6 | XP_503599 | 50552378 |
| 7 | NP_593299 | 19114211 |
| 8 | CAD42869 | 21955860 |
| 9 | XP_448787 | 50292709 |
| 10 | NP_012368 | 6322294 |
| 11 | T42081 | 7433997 |
| 12 | EAK93751 | 46434339 |
| 13 | XP_451300 | 50302727 |
| 14 | XP_571137 | 58267962 |
| 15 | XP_460720 | 50424267 |
| 16 | NP_984739 | 45190485 |
| 17 | BAD15361 | 46367743 |
| 18 | S71433 | 7433991 |
| 19 | CAA65643 | 1523990 |
| 20 | XP_399061 | 49069544 |
| 21 | S71432 | 7433990 |
| 22 | AAH68912 | 46249832 |
| 23 | 1FPS | 1065289 |
| 24 | P08836 | 3915686 |
| 25 | AAH83515 | 53733369 |
| 26 | 1UBX | 1942050 |
| 27 | 1UBY | 1942051 |
| 28 | AAF37872 | 7188788 |
| 29 | NP_803463 | 29135293 |
| 30 | AAK63847 | 14488053 |
| 31 | AAV58896 | 55710092 |
| 32 | T06272 | 7433988 |
| 33 | JC4846 | 2117737 |
| 34 | P05369 | 120478 |
| 35 | O24241 | 25452945 |
| 36 | O24242 | 25452946 |
| 37 | AAH59125 | 37590777 |
| 38 | AAH48497 | 28913418 |
| 39 | AAP74720 | 32329199 |
| 40 | CAG11850 | 47225367 |
| 41 | AAM51429 | 21436457 |
| 42 | AAP74719 | 32329197 |
| 43 | AAM08927 | 20135548 |
| 44 | XP_537252 | 57089113 |
| 45 | AAQ56011 | 34013692 |
| 46 | AAQ14872 | 33340604 |
| 47 | AAQ14871 | 33340602 |
| 48 | AAD17204 | 4324960 |
| 49 | AAH87886 | 56789674 |
| 50 | AAK68152 | 14573639 |
| 51 | AAA52423 | 182399 |
| 52 | S66470 | 2129849 |
| 53 | CAA29064 | 4725 |
| 54 | CAI12715 | 55957735 |
| 55 | BAA03523 | 40788949 |
| 56 | P14324 | 1346031 |
| 57 | S66471 | 2129850 |
| 58 | AAA35820 | 182405 |
| 59 | CAA59170 | 1491641 |
| 60 | BAB16687 | 15289750 |
| 61 | CAA72793 | 1922251 |
| 62 | CAH91070 | 55728661 |
| 63 | AAK58594 | 14279425 |
| 64 | AAB07264 | 1146159 |
| 65 | Q09152 | 21431776 |
| 66 | O64905 | 6016044 |
| 67 | BAB60822 | 14422406 |
| 68 | S52009 | 1076319 |
| 69 | NP_917118 | 34911542 |
| 70 | AAD32648 | 4894899 |
| 71 | AAA40960 | 203582 |
| 72 | AAR27053 | 38684029 |
| 73 | AAU43998 | 52353430 |
| 74 | AAL82595 | 18958450 |
| 75 | NP_917069 | 34911444 |
| 76 | XP_228802 | 34879769 |
| 77 | BAD81810 | 56785155 |
| 78 | AAN62522 | 24796660 |
| 79 | NP_595334 | 19112126 |
| 80 | T52066 | 25458583 |
| 81 | AAL49067 | 17946048 |
| 82 | CAA08919 | 3395483 |
| 83 | XP_547662 | 57089869 |
| 84 | EAL26135 | 54636732 |
| 85 | BAB60821 | 14422404 |
| 86 | AAP74721 | 32329201 |
| 87 | XP_496902 | 51466663 |
| 88 | XP_474182 | 50929309 |
| 89 | CAA87327 | 1160178 |
| 90 | BAD20729 | 47776234 |
| 91 | BAC53873 | 30984142 |
| 92 | BAB69490 | 15991313 |
| 93 | NP_974565 | 42572937 |
| 94 | CAA08918 | 5678609 |
| 95 | AAP86267 | 32527731 |
| 96 | AAO17735 | 30522953 |
| 97 | AAK71861 | 14647139 |
| 98 | AAL73357 | 18478919 |
| 99 | AAO63552 | 29124957 |
| 100 | CAI00471 | 56498227 |
| 101 | NP_701155 | 23508486 |
| 102 | XP_474180 | 50929305 |
| 103 | AAL73358 | 18478922 |
| 104 | EAH48995 | 44167328 |
| 105 | NP_493027 | 17508563 |
| 106 | CAE71711 | 39580204 |
| 107 | XP_487220 | 51766977 |
|
[0202] |
| Examples of GGPP synthase polypetides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | AAT92871 | 51013155 |
| 2 | XP_447025 | 50289191 |
| 3 | NP_984623 | 45190369 |
| 4 | XP_390273 | 46137163 |
| 5 | XP_404791 | 49085320 |
| 6 | XP_368486 | 39974191 |
| 7 | Q92236 | 6831550 |
| 8 | AAO85432 | 29468176 |
| 9 | XP_572774 | 58271236 |
| 10 | XP_502923 | 50550901 |
| 11 | AAK11525 | 13021716 |
| 12 | XP_326920 | 32412880 |
| 13 | CAF32032 | 42820719 |
| 14 | BAD29965 | 50355599 |
| 15 | XP_384767 | 46117498 |
| 16 | BAD29970 | 50355631 |
| 17 | CAB89115 | 7649674 |
| 18 | CAG09545 | 47229030 |
| 19 | CAI13753 | 55960163 |
| 20 | AAH69913 | 47124116 |
| 21 | AAH67768 | 45709211 |
| 22 | XP_455003 | 50309979 |
| 23 | P56966 | 9296978 |
| 24 | NP_001007 | 56090562 |
| 25 | AAT65717 | 49409613 |
| 26 | NP_956329 | 41053321 |
| 27 | BAA90525 | 6899844 |
| 28 | XP_405729 | 49087630 |
| 29 | AAK11531 | 13021724 |
| 30 | XP_412280 | 49119197 |
| 31 | AAC05273 | 2944400 |
| 32 | NP_523958 | 24660002 |
| 33 | XP_402074 | 49076128 |
| 34 | EAL30191 | 54641441 |
| 35 | XP_536340 | 57084951 |
| 36 | XP_424685 | 50811194 |
| 37 | AAH06798 | 13905030 |
| 38 | AAP06018 | 29841005 |
| 39 | XP_460338 | 50423511 |
| 40 | AAC05595 | 2957271 |
| 41 | EAK92197 | 46432727 |
| 42 | XP_535573 | 57108760 |
| 43 | AAH83212 | 53734594 |
| 44 | XP_486466 | 51827552 |
| 45 | CAH18006 | 51469024 |
| 46 | CAA75568 | 3549881 |
| 47 | XP_397455 | 48143654 |
| 48 | XP_410947 | 49101294 |
| 49 | XP_381914 | 46109712 |
| 50 | XP_364478 | 39959279 |
| 51 | XP_360889 | 39942704 |
| 52 | XP_369218 | 39975655 |
| 53 | XP_406544 | 49089926 |
| 54 | XP_367595 | 39972409 |
| 55 | XP_363775 | 39952117 |
| 56 | XP_368486 | 39974191 |
| 57 | XP_390273 | 46137163 |
| 58 | Q92236 | 6831550 |
| 59 | AAK11525 | 13021716 |
| 60 | CAF32032 | 42820719 |
| 61 | XP_404791 | 49085320 |
| 62 | AAO85432 | 29468176 |
| 63 | BAD29965 | 50355599 |
| 64 | BAD29970 | 50355631 |
| 65 | BAA90525 | 6899844 |
| 66 | AAT65717 | 49409613 |
| 67 | XP_384767 | 46117498 |
| 68 | CAB89115 | 7649674 |
| 69 | XP_572774 | 58271236 |
| 70 | AAK11531 | 13021724 |
| 71 | XP_502923 | 50550901 |
| 72 | CAI13753 | 55960163 |
| 73 | CAG09545 | 47229030 |
| 74 | XP_412280 | 49119197 |
| 75 | P56966 | 9296978 |
| 76 | NP_001007 | 56090562 |
| 77 | AAH69913 | 47124116 |
| 78 | AAH67768 | 45709211 |
| 79 | NP_956329 | 41053321 |
| 80 | EAL30191 | 54641441 |
| 81 | XP_424685 | 50811194 |
| 82 | XP_536340 | 57084951 |
| 83 | NP_523958 | 24660002 |
| 84 | AAC05273 | 2944400 |
| 85 | XP_405729 | 49087630 |
| 86 | AAC05595 | 2957271 |
| 87 | XP_402074 | 49076128 |
| 88 | AAP06018 | 29841005 |
| 89 | AAH06798 | 13905030 |
| 90 | XP_535573 | 57108760 |
| 91 | AAH83212 | 53734594 |
| 92 | AAP21085 | 30097620 |
| 93 | NP_984623 | 45190369 |
| 94 | XP_447025 | 50289191 |
| 95 | AAT92871 | 51013155 |
| 96 | XP_486466 | 51827552 |
| 97 | XP_410947 | 49101294 |
| 98 | XP_397455 | 48143654 |
| 99 | XP_455003 | 50309979 |
| 100 | EAK92197 | 46432727 |
| 101 | XP_381914 | 46109712 |
| 102 | XP_460338 | 50423511 |
| 103 | CAH18006 | 51469024 |
| 104 | XP_360889 | 39942704 |
| 105 | XP_406544 | 49089926 |
| 106 | XP_364478 | 39959279 |
| 107 | XP_363775 | 39952117 |
| 108 | XP_367595 | 39972409 |
| 109 | XP_369218 | 39975655 |
| 110 | C39273 | 483124 |
| 111 | BAB79600 | 18143445 |
| 112 | BAA14124 | 216682 |
| 113 | AAN85596 | 27228290 |
| 114 | AAA32797 | 413730 |
| 115 | Q08291 | 585326 |
| 116 | S52584 | 1073293 |
| 117 | S53722 | 1076576 |
| 118 | AAC44848 | 1842242 |
| 119 | BAA19583 | 1944371 |
| 120 | S71230 | 2129674 |
| 121 | BAA23157 | 2578822 |
| 122 | AAC77874 | 3885426 |
| 123 | CAB38744 | 4490594 |
| 124 | BAA78047 | 4958920 |
| 125 | BAA82613 | 5631295 |
| 126 | CAB56064 | 5912297 |
| 127 | BAA86284 | 6277254 |
| 128 | T11021 | 7447356 |
| 129 | AAF78199 | 8650415 |
| 130 | AAG10424 | 9971808 |
| 131 | CAC10561 | 10637876 |
| 132 | T50879 | 11279298 |
| 133 | BAB01343 | 11994221 |
| 134 | Q42698 | 13431546 |
| 135 | Q43133 | 13431547 |
| 136 | P54976 | 13878921 |
| 137 | BAB50600 | 14023995 |
| 138 | BAB60678 | 14325238 |
| 139 | BAB60820 | 14422402 |
| 140 | NP_189589 | 15228704 |
| 141 | NP_188651 | 15231055 |
| 142 | NP_188069 | 15231869 |
| 143 | NP_188073 | 15231881 |
| 144 | AAL01997 | 15553715 |
| 145 | AAL01998 | 15553717 |
| 146 | NP_252732 | 15599238 |
| 147 | NP_245470 | 15602398 |
| 148 | NP_390308 | 16079484 |
| 149 | NP_440010 | 16329282 |
| 150 | NP_440010 | 16329282 |
| 151 | AAL17614 | 17352451 |
| 152 | NP_520343 | 17546941 |
| 153 | AAL76349 | 18645048 |
| 154 | AAM21638 | 20386366 |
| 155 | AAM21639 | 20386368 |
| 156 | NP_622916 | 20807745 |
| 157 | AAM48650 | 21328644 |
| 158 | NP_659794 | 21492720 |
| 159 | AAM64496 | 21592547 |
| 160 | AAM65107 | 21593158 |
| 161 | NP_680811 | 22297564 |
| 162 | ZP_000474 | 23003800 |
| 163 | ZP_001252 | 23469933 |
| 164 | NP_698760 | 23502633 |
| 165 | E84566 | 25313373 |
| 166 | F85434 | 25313385 |
| 167 | AC1245 | 25313389 |
| 168 | E83997 | 25313393 |
| 169 | G84566 | 25313395 |
| 170 | AH2910 | 25315863 |
| 171 | D87505 | 25398795 |
| 172 | A89932 | 25505949 |
| 173 | F97685 | 25520741 |
| 174 | AI3285 | 25527013 |
| 175 | BAC42571 | 26450928 |
| 176 | NP_785195 | 28378303 |
| 177 | NP_790546 | 28867927 |
| 178 | AAO63392 | 28950937 |
| 179 | AAO93113 | 29893480 |
| 180 | NP_833891 | 30022260 |
| 181 | AAP59037 | 31621279 |
| 182 | ZP_001374 | 32039216 |
| 183 | NP_864766 | 32471772 |
| 184 | NP_875521 | 33240579 |
| 185 | NP_881399 | 33593755 |
| 186 | NP_884694 | 33597051 |
| 187 | NP_888456 | 33600896 |
| 188 | NP_893187 | 33861626 |
| 189 | NP_894940 | 33863380 |
| 190 | NP_896835 | 33865276 |
| 191 | NP_896835 | 33865276 |
| 192 | AAQ65086 | 34365549 |
| 193 | NP_945877 | 39933601 |
| 194 | NP_946867 | 39934591 |
| 195 | NP_952815 | 39996864 |
| 196 | AAR37805 | 40062934 |
| 197 | AAR37858 | 40062988 |
| 198 | AAR98495 | 41018904 |
| 199 | AAR99082 | 41059107 |
| 200 | NP_965349 | 42519419 |
| 201 | NP_980544 | 42783297 |
| 202 | EAA96348 | 42858148 |
| 203 | EAB36506 | 42939031 |
| 204 | EAB36642 | 42939300 |
| 205 | EAC39208 | 43146996 |
| 206 | EAD26007 | 43320598 |
| 207 | EAE43084 | 43576643 |
| 208 | EAE70061 | 43630884 |
| 209 | EAF70308 | 43832107 |
| 210 | EAG88494 | 44055952 |
| 211 | EAH52060 | 44173220 |
| 212 | EAH78354 | 44221788 |
| 213 | EAH84117 | 44231960 |
| 214 | EAI11762 | 44272832 |
| 215 | EAI49391 | 44328289 |
| 216 | EAI54846 | 44336042 |
| 217 | EAI68356 | 44355138 |
| 218 | EAI68713 | 44355672 |
| 219 | EAI69401 | 44356609 |
| 220 | EAI73873 | 44362658 |
| 221 | EAJ73634 | 44506168 |
| 222 | EAJ77351 | 44511694 |
| 223 | EAK70639 | 44644254 |
| 224 | ZP_001751 | 45523854 |
| 225 | AAS76253 | 45752710 |
| 226 | ZP_001957 | 45916757 |
| 227 | 1RTRB | 46015556 |
| 228 | ZP_001863 | 46105954 |
| 229 | ZP_002002 | 46107045 |
| 230 | ZP_001711 | 46132567 |
| 231 | ZP_002073 | 46192680 |
| 232 | ZP_002074 | 46192861 |
| 233 | AAS82860 | 46241274 |
| 234 | ZP_002108 | 46308696 |
| 235 | YP_010568 | 46579760 |
| 236 | BAD18313 | 47076770 |
| 237 | ZP_002315 | 47093750 |
| 238 | ZP_002335 | 47095946 |
| 239 | AAT35222 | 47531118 |
| 240 | ZP_002401 | 47569437 |
| 241 | ZP_002435 | 47573473 |
| 242 | ZP_002626 | 48728941 |
| 243 | ZP_002702 | 48765678 |
| 244 | ZP_002705 | 48766028 |
| 245 | ZP_002732 | 48768894 |
| 246 | ZP_002914 | 48834438 |
| 247 | ZP_003024 | 48848203 |
| 248 | ZP_003129 | 48858958 |
| 249 | ZP_003177 | 48863841 |
| 250 | ZP_003225 | 48869790 |
| 251 | AAT51323 | 49086036 |
| 252 | ZP_003301 | 49236117 |
| 253 | YP_034222 | 49476181 |
| 254 | YP_040995 | 49483771 |
| 255 | YP_043579 | 49486358 |
| 256 | AAT71982 | 50253560 |
| 257 | AAT90315 | 50952782 |
| 258 | YP_066435 | 51246551 |
| 259 | YP_075673 | 51892982 |
| 260 | YP_085511 | 52141318 |
| 261 | YP_092166 | 52786337 |
| 262 | ZP_001298 | 53691368 |
| 263 | YP_105136 | 53716444 |
| 264 | YP_111769 | 53722784 |
| 265 | ZP_003630 | 54030933 |
| 266 | YP_129021 | 54308001 |
| 267 | AAV74395 | 56122554 |
| 268 | AAV74396 | 56122556 |
| 269 | YP_148246 | 56420928 |
| 270 | YP_156518 | 56461237 |
| 271 | YP_162590 | 56551751 |
| 272 | YP_171470 | 56750769 |
| 273 | YP_175959 | 56964228 |
| 274 | YP_186407 | 57650478 |
| 275 | YP_190690 | 58038726 |
| 276 | AAW66658 | 58201026 |
| 277 | YP_194187 | 58337602 |
| 278 | YP_197469 | 58579257 |
| 279 | YP_201938 | 58582922 |
| 280 | YP_196510 | 58617311 |
|
[0203] |
| Examples of squalene synthase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | AAA34597 | 171481 |
| 2 | CAA42583 | 3686 |
| 3 | Q9HGZ6 | 51704336 |
| 4 | BAB12207 | 9955387 |
| 5 | XP_453457 | 50306959 |
| 6 | Q752X9 | 51701405 |
| 7 | O74165 | 51701378 |
| 8 | XP_458579 | 50420093 |
| 9 | EAK95451 | 46436082 |
| 10 | P78589 | 2499979 |
| 11 | Q9Y753 | 51701459 |
| 12 | XP_407513 | 49092104 |
| 13 | XP_364394 | 39958237 |
| 14 | Q7S4Z6 | 51701416 |
| 15 | CAD60581 | 27764301 |
| 16 | XP_389557 | 46135731 |
| 17 | NP_595363 | 19112155 |
| 18 | B48057 | 477750 |
| 19 | NP_034321 | 34328173 |
| 20 | CAH92517 | 55731622 |
| 21 | AAF00038 | 6002565 |
| 22 | P53798 | 1706773 |
| 23 | NP_004453 | 31542632 |
| 24 | AAP36671 | 30584837 |
| 25 | 1EZFC | 11514497 |
| 26 | AAH09251 | 14328083 |
| 27 | AAH84016 | 54035372 |
| 28 | I52090 | 2136196 |
| 29 | XP_420043 | 50745256 |
| 30 | AAH81810 | 51858605 |
| 31 | CAE48363 | 50841455 |
| 32 | XP_569783 | 58265254 |
| 33 | XP_569782 | 58265252 |
| 34 | XP_534557 | 57105080 |
| 35 | XP_401989 | 49075920 |
|
[0204] |
| Examples of phytoene dehydrogenase polypeptides. |
| Genbank |
| Row | ACCESSION |
|
| 1 | 1613414B |
| 2 | 1613414F |
| 3 | 1904206A |
| 4 | 2121278A |
| 5 | A86203 |
| 6 | A96612 |
| 7 | A99470 |
| 8 | AAA24820 |
| 9 | AAA34001 |
| 10 | AAA50313 |
| 11 | AAA64981 |
| 12 | AAA91161 |
| 13 | AAA99519 |
| 14 | AAC44798 |
| 15 | AAC44850 |
| 16 | AAC48983 |
| 17 | AAF78201 |
| 18 | AAG10426 |
| 19 | AAG14399 |
| 20 | AAG28700 |
| 21 | AAG50743 |
| 22 | AAH85048 |
| 23 | AAK51545 |
| 24 | AAK51557 |
| 25 | AAK64299 |
| 26 | AAL02000 |
| 27 | AAL15300 |
| 28 | AAL38046 |
| 29 | AAL73986 |
| 30 | AAL80005 |
| 31 | AAL91366 |
| 32 | AAM45380 |
| 33 | AAM48646 |
| 34 | AAM63349 |
| 35 | AAM94364 |
| 36 | AAN75037 |
| 37 | AAN85599 |
| 38 | AAO24235 |
| 39 | AAO46892 |
| 40 | AAO46894 |
| 41 | AAO53257 |
| 42 | AAO53258 |
| 43 | AAO64750 |
| 44 | AAO93135 |
| 45 | AAP59036 |
| 46 | AAP79175 |
| 47 | AAQ04224 |
| 48 | AAQ04225 |
| 49 | AAQ65246 |
| 50 | AAQ65246 |
| 51 | AAQ88931 |
| 52 | AAR37797 |
| 53 | AAR37802 |
| 54 | AAR37850 |
| 55 | AAR37855 |
| 56 | AAR86105 |
| 57 | AAR98491 |
| 58 | AAR98494 |
| 59 | AAR98733 |
| 60 | AAS17750 |
| 61 | AAT01639 |
| 62 | AAT35222 |
| 63 | AAT74579 |
| 64 | AAT74580 |
| 65 | AAT76050 |
| 66 | AAT76434 |
| 67 | AAT90316 |
| 68 | AAU34019 |
| 69 | AAW23161 |
| 70 | AB2035 |
| 71 | AB2064 |
| 72 | AC2446 |
| 73 | AF1557 |
| 74 | AF2029 |
| 75 | AG2103 |
| 76 | AG2509 |
| 77 | AH1199 |
| 78 | AI2185 |
| 79 | AI2273 |
| 80 | B55548 |
| 81 | B84327 |
| 82 | B90061 |
| 83 | BAA14127 |
| 84 | BAA20276 |
| 85 | BAA76534 |
| 86 | BAB10768 |
| 87 | BAB50520 |
| 88 | BAB51896 |
| 89 | BAB68552 |
| 90 | BAB79603 |
| 91 | BAB82461 |
| 92 | BAB82462 |
| 93 | BAB98016 |
| 94 | BAC75676 |
| 95 | BAC77668 |
| 96 | BAC77671 |
| 97 | BAD07279 |
| 98 | BAD07280 |
| 99 | BAD07287 |
| 100 | BAD07288 |
| 101 | CAA52098 |
| 102 | CAA60479 |
| 103 | CAA66626 |
| 104 | CAB38739 |
| 105 | CAB38743 |
| 106 | CAB40843 |
| 107 | CAB56041 |
| 108 | CAB56062 |
| 109 | CAB59726 |
| 110 | CAB65434 |
| 111 | CAB94794 |
| 112 | CAC85667 |
| 113 | CAD19989 |
| 114 | CAD27442 |
| 115 | CAD55814 |
| 116 | CAE00192 |
| 117 | CAE83576 |
| 118 | CAF19330 |
| 119 | CAF21094 |
| 120 | CAF21337 |
| 121 | CAH91165 |
| 122 | E90061 |
| 123 | EAA90383 |
| 124 | EAA98598 |
| 125 | EAB09790 |
| 126 | EAB14136 |
| 127 | EAB18725 |
| 128 | EAB29729 |
| 129 | EAB30992 |
| 130 | EAB41377 |
| 131 | EAB54727 |
| 132 | EAB76679 |
| 133 | EAB87028 |
| 134 | EAB92587 |
| 135 | EAB94459 |
| 136 | EAB96864 |
| 137 | EAC01884 |
| 138 | EAC38895 |
| 139 | EAC60360 |
| 140 | EAD05874 |
| 141 | EAD05999 |
| 142 | EAD20520 |
| 143 | EAE06978 |
| 144 | EAE70773 |
| 145 | EAF04985 |
| 146 | EAF51354 |
| 147 | EAF62819 |
| 148 | EAF75453 |
| 149 | EAG09111 |
| 150 | EAG19412 |
| 151 | EAG23070 |
| 152 | EAG25053 |
| 153 | EAG25054 |
| 154 | EAG29279 |
| 155 | EAG39845 |
| 156 | EAG56100 |
| 157 | EAG63013 |
| 158 | EAG68633 |
| 159 | EAG71574 |
| 160 | EAG89835 |
| 161 | EAH04928 |
| 162 | EAH04936 |
| 163 | EAH08586 |
| 164 | EAH22597 |
| 165 | EAH22853 |
| 166 | EAH31648 |
| 167 | EAH55579 |
| 168 | EAH68071 |
| 169 | EAH73302 |
| 170 | EAH79041 |
| 171 | EAH86965 |
| 172 | EAH97108 |
| 173 | EAH99977 |
| 174 | EAI01660 |
| 175 | EAI03576 |
| 176 | EAI06784 |
| 177 | EAI11087 |
| 178 | EAI15261 |
| 179 | EAI15547 |
| 180 | EAI17521 |
| 181 | EAI21398 |
| 182 | EAI29728 |
| 183 | EAI38468 |
| 184 | EAI43591 |
| 185 | EAI51589 |
| 186 | EAI58453 |
| 187 | EAI72974 |
| 188 | EAI77885 |
| 189 | EAI78272 |
| 190 | EAI80262 |
| 191 | EAI83937 |
| 192 | EAI86664 |
| 193 | EAJ00517 |
| 194 | EAJ05570 |
| 195 | EAJ08238 |
| 196 | EAJ15524 |
| 197 | EAJ18144 |
| 198 | EAJ20649 |
| 199 | EAJ21683 |
| 200 | EAJ24413 |
| 201 | EAJ28774 |
| 202 | EAJ30522 |
| 203 | EAJ35157 |
| 204 | EAJ37407 |
| 205 | EAJ39929 |
| 206 | EAJ54356 |
| 207 | EAJ54959 |
| 208 | EAJ56207 |
| 209 | EAJ58447 |
| 210 | EAJ59958 |
| 211 | EAJ63347 |
| 212 | EAJ66054 |
| 213 | EAJ67637 |
| 214 | EAJ69812 |
| 215 | EAJ74441 |
| 216 | EAJ76472 |
| 217 | EAJ76473 |
| 218 | EAJ80355 |
| 219 | EAJ80839 |
| 220 | EAJ81408 |
| 221 | EAJ86174 |
| 222 | EAJ87600 |
| 223 | EAJ88203 |
| 224 | EAJ88682 |
| 225 | EAJ92341 |
| 226 | EAJ94774 |
| 227 | EAJ97555 |
| 228 | EAJ97958 |
| 229 | EAK07654 |
| 230 | EAK08513 |
| 231 | EAK08529 |
| 232 | EAK10609 |
| 233 | EAK10614 |
| 234 | EAK12902 |
| 235 | EAK13034 |
| 236 | EAK15092 |
| 237 | EAK22483 |
| 238 | EAK23222 |
| 239 | EAK24187 |
| 240 | EAK24674 |
| 241 | EAK28785 |
| 242 | EAK34731 |
| 243 | EAK34742 |
| 244 | EAK36883 |
| 245 | EAK37522 |
| 246 | EAK42705 |
| 247 | EAK43213 |
| 248 | EAK52580 |
| 249 | EAK53452 |
| 250 | EAK58759 |
| 251 | EAK62665 |
| 252 | EAK63558 |
| 253 | F84187 |
| 254 | F90272 |
| 255 | G87635 |
| 256 | G90413 |
| 257 | H83880 |
| 258 | H84320 |
| 259 | JC7723 |
| 260 | NP_060220 |
| 261 | NP_080435 |
| 262 | NP_193157 |
| 263 | NP_214383 |
| 264 | NP_276913 |
| 265 | NP_293819 |
| 266 | NP_294534 |
| 267 | NP_294585 |
| 268 | NP_295972 |
| 269 | NP_338490 |
| 270 | NP_376437 |
| 271 | NP_377056 |
| 272 | NP_388895 |
| 273 | NP_441167 |
| 274 | NP_441254 |
| 275 | NP_442491 |
| 276 | NP_442727 |
| 277 | NP_562475 |
| 278 | NP_568712 |
| 279 | NP_601630 |
| 280 | NP_601630 |
| 281 | NP_616426 |
| 282 | NP_624522 |
| 283 | NP_626360 |
| 284 | NP_630834 |
| 285 | NP_643053 |
| 286 | NP_647302 |
| 287 | NP_659552 |
| 288 | NP_661086 |
| 289 | NP_661546 |
| 290 | NP_661701 |
| 291 | NP_662300 |
| 292 | NP_681023 |
| 293 | NP_681127 |
| 294 | NP_682351 |
| 295 | NP_693380 |
| 296 | NP_693382 |
| 297 | NP_737250 |
| 298 | NP_763380 |
| 299 | NP_786524 |
| 300 | NP_822198 |
| 301 | NP_822828 |
| 302 | NP_827278 |
| 303 | NP_851528 |
| 304 | NP_857496 |
| 305 | NP_868798 |
| 306 | NP_869339 |
| 307 | NP_870237 |
| 308 | NP_874530 |
| 309 | NP_874561 |
| 310 | NP_874977 |
| 311 | NP_892236 |
| 312 | NP_892265 |
| 313 | NP_892458 |
| 314 | NP_893232 |
| 315 | NP_894882 |
| 316 | NP_895385 |
| 317 | NP_895793 |
| 318 | NP_895829 |
| 319 | NP_896854 |
| 320 | NP_896994 |
| 321 | NP_898304 |
| 322 | NP_898346 |
| 323 | NP_902647 |
| 324 | NP_923340 |
| 325 | NP_923639 |
| 326 | NP_923813 |
| 327 | NP_925079 |
| 328 | NP_931515 |
| 329 | NP_936379 |
| 330 | NP_940208 |
| 331 | NP_945754 |
| 332 | NP_946860 |
| 333 | NP_946866 |
| 334 | NP_948851 |
| 335 | NP_962004 |
| 336 | NP_968600 |
| 337 | NP_974222 |
| 338 | NP_974545 |
| 339 | O49901 |
| 340 | P17059 |
| 341 | P54971 |
| 342 | P54978 |
| 343 | P54979 |
| 344 | P54981 |
| 345 | P54982 |
| 346 | P74306 |
| 347 | Q01671 |
| 348 | Q02861 |
| 349 | Q38893 |
| 350 | Q40406 |
| 351 | Q9FV46 |
| 352 | Q9SE20 |
| 353 | Q9SMJ3 |
| 354 | Q9ZTN9 |
| 355 | Q9ZTP4 |
| 356 | S29314 |
| 357 | S32171 |
| 358 | S49624 |
| 359 | S52586 |
| 360 | S65060 |
| 361 | T10701 |
| 362 | T31463 |
| 363 | T46822 |
| 364 | T48646 |
| 365 | T50745 |
| 366 | T50749 |
| 367 | T50893 |
| 368 | T50910 |
| 369 | T51119 |
| 370 | T51123 |
| 371 | XP_324732 |
| 372 | XP_383241 |
| 373 | XP_401825 |
| 374 | XP_470568 |
| 375 | XP_473486 |
| 376 | XP_477063 |
| 377 | XP_525801 |
| 378 | XP_540198 |
| 379 | YP_006049 |
| 380 | YP_013621 |
| 381 | YP_024310 |
| 382 | YP_041986 |
| 383 | YP_041988 |
| 384 | YP_044561 |
| 385 | YP_044564 |
| 386 | YP_062471 |
| 387 | YP_117947 |
| 388 | YP_120612 |
| 389 | YP_135077 |
| 390 | YP_136483 |
| 391 | YP_145331 |
| 392 | YP_145348 |
| 393 | YP_171014 |
| 394 | YP_172823 |
| 395 | YP_173078 |
| 396 | YP_173207 |
| 397 | YP_184572 |
| 398 | YP_187368 |
| 399 | YP_187371 |
| 400 | YP_187371 |
| 401 | YP_187371 |
| 402 | ZP_000490 |
| 403 | ZP_000509 |
| 404 | ZP_000518 |
| 405 | ZP_000566 |
| 406 | ZP_000627 |
| 407 | ZP_000627 |
| 408 | ZP_001073 |
| 409 | ZP_001081 |
| 410 | ZP_001091 |
| 411 | ZP_001116 |
| 412 | ZP_001117 |
| 413 | ZP_001119 |
| 414 | ZP_001124 |
| 415 | ZP_001510 |
| 416 | ZP_001591 |
| 417 | ZP_001593 |
| 418 | ZP_001602 |
| 419 | ZP_001614 |
| 420 | ZP_001645 |
| 421 | ZP_001650 |
| 422 | ZP_001722 |
| 423 | ZP_001746 |
| 424 | ZP_001752 |
| 425 | ZP_001770 |
| 426 | ZP_001777 |
| 427 | ZP_001787 |
| 428 | ZP_001837 |
| 429 | ZP_001867 |
| 430 | ZP_002073 |
| 431 | ZP_002077 |
| 432 | ZP_002339 |
| 433 | ZP_002680 |
| 434 | ZP_002705 |
| 435 | ZP_002771 |
| 436 | ZP_002892 |
| 437 | ZP_002916 |
| 438 | ZP_002963 |
| 439 | ZP_003022 |
| 440 | ZP_003036 |
| 441 | ZP_003107 |
| 442 | ZP_003202 |
| 443 | ZP_003258 |
| 444 | ZP_003268 |
| 445 | ZP_003269 |
| 446 | ZP_003276 |
| 447 | ZP_003283 |
| 448 | ZP_003557 |
| 449 | ZP_003559 |
| 450 | ZP_003565 |
| 451 | ZP_003577 |
| 452 | ZP_003593 |
| 453 | ZP_003595 |
| 441 | ZP_003685 |
|
[0205] |
| Examples of phytoene synthase and lycopene cyclase polypeptides. |
| Genbank | |
| Row | Accession | Genbank GI |
|
| 1 | 1613414C | 227040 |
| 2 | A49558 | 1076590 |
| 3 | AAA19428 | 506623 |
| 4 | AAA32836 | 413732 |
| 5 | AAA64982 | 148413 |
| 6 | AAB87738 | 29893495 |
| 7 | AAC44849 | 1842243 |
| 8 | AAD38051 | 13542332 |
| 9 | AAF78202 | 8650418 |
| 10 | AAF82616 | 9081847 |
| 11 | AAG10427 | 9971814 |
| 12 | AAG28701 | 11066678 |
| 13 | AAK07734 | 18476085 |
| 14 | AAK07735 | 18476089 |
| 15 | AAK15621 | 13195243 |
| 16 | AAL02001 | 15553721 |
| 17 | AAL76346 | 18645045 |
| 18 | AAL82578 | 21326700 |
| 19 | AAM45379 | 21360353 |
| 20 | AAM48647 | 21328641 |
| 21 | AAM62787 | 21553694 |
| 22 | AAM94363 | 22296799 |
| 23 | AAN85600 | 27228294 |
| 24 | AAO24767 | 27903500 |
| 25 | AAO39835 | 28403302 |
| 26 | AAO46895 | 37729028 |
| 27 | AAO47570 | 33465823 |
| 28 | AAO73816 | 33465821 |
| 29 | AAP22038 | 30349414 |
| 30 | AAP55451 | 32350232 |
| 31 | AAP55453 | 32350236 |
| 32 | AAP55461 | 32350252 |
| 33 | AAP55471 | 32350272 |
| 34 | AAP55484 | 32350298 |
| 35 | AAP55486 | 32350302 |
| 36 | AAP56083 | 32349564 |
| 37 | AAP56124 | 32349646 |
| 38 | AAP56127 | 32349652 |
| 39 | AAP56136 | 32349670 |
| 40 | AAP56148 | 32349694 |
| 41 | AAP56155 | 32349708 |
| 42 | AAP56156 | 32349710 |
| 43 | AAP56157 | 32349712 |
| 44 | AAP56158 | 32349714 |
| 45 | AAP79176 | 32307542 |
| 46 | AAQ91837 | 37499616 |
| 47 | AAR08445 | 38037628 |
| 48 | AAR31885 | 39842609 |
| 49 | AAR37803 | 40062932 |
| 50 | AAR37856 | 40062986 |
| 51 | AAR86104 | 40456029 |
| 52 | AAR87868 | 40557193 |
| 53 | AAR98492 | 41018901 |
| 54 | AAS02284 | 41394357 |
| 55 | AAS17009 | 42491736 |
| 56 | AAS18307 | 42521626 |
| 57 | AAT28184 | 47498515 |
| 58 | AAT35222 | 47531118 |
| 59 | AAT38473 | 47779181 |
| 60 | AAT46069 | 48686711 |
| 61 | AAT74581 | 50313418 |
| 62 | AAT90319 | 50952786 |
| 63 | AAV74394 | 56122551 |
| 64 | AAW23162 | 56698928 |
| 65 | AC2035 | 25366683 |
| 66 | AC2035 | 25366683 |
| 67 | BAB18514 | 11344507 |
| 68 | BAB79604 | 18143449 |
| 69 | BAD07278 | 40809739 |
| 70 | BAD07286 | 40809755 |
| 71 | BAD62106 | 54291340 |
| 72 | BAD62107 | 54291341 |
| 73 | C90061 | 25506636 |
| 74 | CAA47625 | 19347 |
| 75 | CAA68575 | 19341 |
| 76 | CAB07958 | 1934837 |
| 77 | CAB38740 | 4490590 |
| 78 | CAB51949 | 5690074 |
| 79 | CAB56063 | 5912296 |
| 80 | CAB86388 | 7453011 |
| 81 | CAB93661 | 8250520 |
| 82 | CAB94795 | 8574392 |
| 83 | CAC19567 | 11990226 |
| 84 | CAC27383 | 12584564 |
| 85 | CAD19988 | 18307500 |
| 86 | CAD29284 | 57282088 |
| 87 | CAE76609 | 38567321 |
| 88 | E37802 | 95606 |
| 89 | E84320 | 25410251 |
| 90 | EAA98758 | 42863045 |
| 91 | EAB01965 | 42869439 |
| 92 | EAB04170 | 42873822 |
| 93 | EAB07138 | 42879858 |
| 94 | EAB09791 | 42885235 |
| 95 | EAB19826 | 42905452 |
| 96 | EAB35029 | 42936011 |
| 97 | EAB41375 | 42948740 |
| 98 | EAB78706 | 43024004 |
| 99 | EAB92586 | 43052355 |
| 100 | EAC06949 | 43081493 |
| 101 | EAC18360 | 43104624 |
| 102 | EAC25793 | 43119723 |
| 103 | EAC29883 | 43128092 |
| 104 | EAC32813 | 43133973 |
| 105 | EAC33105 | 43134560 |
| 106 | EAC38486 | 43145552 |
| 107 | EAC52233 | 43173313 |
| 108 | EAC60029 | 43189028 |
| 109 | EAC68026 | 43204953 |
| 110 | EAC96197 | 43261031 |
| 111 | EAD08701 | 43285745 |
| 112 | EAD20866 | 43310220 |
| 113 | EAD32755 | 43334458 |
| 114 | EAD38008 | 43345761 |
| 115 | EAD50152 | 43370658 |
| 116 | EAD50402 | 43371147 |
| 117 | EAD81123 | 43452903 |
| 118 | EAD93882 | 43478303 |
| 119 | EAE12860 | 43516265 |
| 120 | EAE16121 | 43522884 |
| 121 | EAE31084 | 43552634 |
| 122 | EAE35665 | 43561764 |
| 123 | EAE44717 | 43579862 |
| 124 | EAE46627 | 43583580 |
| 125 | EAE47846 | 43586023 |
| 126 | EAE72264 | 43635190 |
| 127 | EAE76009 | 43642573 |
| 128 | EAE86335 | 43662748 |
| 129 | EAE89581 | 43669163 |
| 130 | EAF18881 | 43728007 |
| 131 | EAF64277 | 43819669 |
| 132 | EAF67931 | 43827263 |
| 133 | EAF84745 | 43861327 |
| 134 | EAF94004 | 43880040 |
| 135 | EAG06083 | 43903395 |
| 136 | EAG21950 | 43933540 |
| 137 | EAG43625 | 43973477 |
| 138 | EAG50171 | 43985555 |
| 139 | EAG57517 | 43999205 |
| 140 | EAG62787 | 44009110 |
| 141 | EAG65580 | 44014171 |
| 142 | EAG68110 | 44018715 |
| 143 | EAG72283 | 44026322 |
| 144 | EAG78750 | 44037938 |
| 145 | EAG80445 | 44041116 |
| 146 | EAG93220 | 44064453 |
| 147 | EAH04927 | 44085694 |
| 148 | EAH08972 | 44093217 |
| 149 | EAH10377 | 44095788 |
| 150 | EAH22151 | 44117864 |
| 151 | EAH31461 | 44134654 |
| 152 | EAH50033 | 44169323 |
| 153 | EAH64480 | 44196848 |
| 154 | EAH79040 | 44223009 |
| 155 | EAH99976 | 44255671 |
| 156 | EAI02786 | 44259828 |
| 157 | EAI02787 | 44259829 |
| 158 | EAI03575 | 44260943 |
| 159 | EAI05900 | 44264266 |
| 160 | EAI61004 | 44344824 |
| 161 | EAI70669 | 44358327 |
| 162 | EAI83938 | 44377067 |
| 163 | EAJ05110 | 44406802 |
| 164 | EAJ05569 | 44407471 |
| 165 | EAJ08876 | 44412338 |
| 166 | EAJ35156 | 44449986 |
| 167 | EAJ38900 | 44455130 |
| 168 | EAJ49645 | 44470504 |
| 169 | EAJ54357 | 44477026 |
| 170 | EAJ60475 | 44485647 |
| 171 | EAJ64125 | 44492007 |
| 172 | EAJ67499 | 44497025 |
| 173 | EAJ76471 | 44510405 |
| 174 | EAJ76950 | 44511114 |
| 175 | EAJ78637 | 44513596 |
| 176 | EAJ78787 | 44513824 |
| 177 | EAJ79616 | 44515082 |
| 178 | EAJ80356 | 44516200 |
| 179 | EAJ81914 | 44518489 |
| 180 | EAJ87417 | 44526623 |
| 181 | EAK08514 | 44557109 |
| 182 | EAK08523 | 44557119 |
| 183 | EAK12901 | 44563097 |
| 184 | EAK22180 | 44576315 |
| 185 | EAK24859 | 44580262 |
| 186 | EAK28345 | 44585276 |
| 187 | EAK34732 | 44594324 |
| 188 | EAK34736 | 44594329 |
| 189 | EAK37296 | 44597942 |
| 190 | EAK37521 | 44598256 |
| 191 | EAK56335 | 44624430 |
| 192 | G84363 | 25410528 |
| 193 | NP_274195 | 15677043 |
| 194 | NP_284085 | 15794263 |
| 195 | NP_294586 | 15805888 |
| 196 | NP_388961 | 16078144 |
| 197 | NP_441168 | 16330440 |
| 198 | NP_443763 | 16519643 |
| 199 | NP_624523 | 21218744 |
| 200 | NP_630832 | 21225053 |
| 201 | NP_662273 | 21674208 |
| 202 | NP_682350 | 22299103 |
| 203 | NP_693381 | 23099915 |
| 204 | NP_786525 | 28379633 |
| 205 | NP_822199 | 29827565 |
| 206 | NP_822829 | 29828195 |
| 207 | NP_851527 | 30795077 |
| 208 | NP_868799 | 32475805 |
| 209 | NP_874560 | 33239618 |
| 210 | NP_879992 | 33592348 |
| 211 | NP_884101 | 33596458 |
| 212 | NP_889809 | 33602249 |
| 213 | NP_892264 | 33860703 |
| 214 | NP_895828 | 33864268 |
| 215 | NP_898345 | 33866786 |
| 216 | NP_902648 | 34498433 |
| 217 | NP_902649 | 34498434 |
| 218 | NP_924690 | 37521313 |
| 219 | NP_931516 | 37528171 |
| 220 | NP_946861 | 39934585 |
| 221 | NP_949079 | 39936803 |
| 222 | NP_962005 | 41409169 |
| 223 | NP_968601 | 42523221 |
| 224 | O07333 | 3913360 |
| 225 | P08196 | 585746 |
| 226 | P21683 | 30923192 |
| 227 | P37269 | 585009 |
| 228 | P37271 | 27735222 |
| 229 | P37272 | 585749 |
| 230 | P53797 | 1709885 |
| 231 | P54975 | 1706137 |
| 232 | P54977 | 1706139 |
| 233 | P65860 | 54041032 |
| 234 | Q9SSU8 | 8928282 |
| 235 | Q9UUQ6 | 34922667 |
| 236 | S22474 | 7489041 |
| 237 | S32170 | 321671 |
| 238 | S52587 | 1073300 |
| 239 | S56668 | 2129505 |
| 240 | S68307 | 2130144 |
| 241 | T10702 | 7484346 |
| 242 | T46594 | 11291807 |
| 243 | T50746 | 11356347 |
| 244 | T50895 | 11291816 |
| 245 | XP_324765 | 32408567 |
| 246 | XP_383242 | 46114448 |
| 247 | XP_403902 | 49080862 |
| 248 | YP_006040 | 46255128 |
| 249 | YP_103126 | 53723680 |
| 250 | YP_112342 | 53723357 |
| 251 | YP_117945 | 54023703 |
| 252 | YP_120611 | 54026369 |
| 253 | YP_136628 | 55378778 |
| 254 | YP_136629 | 55378779 |
| 255 | YP_145340 | 55978284 |
| 256 | YP_145343 | 55978287 |
| 257 | YP_160917 | 56479328 |
| 258 | YP_160918 | 56479329 |
| 259 | YP_162605 | 56551766 |
| 260 | YP_172822 | 56752121 |
| 261 | YP_187369 | 57652299 |
| 262 | YP_192648 | 58040684 |
| 263 | ZP_000044 | 22956752 |
| 264 | ZP_001091 | 53688068 |
| 265 | ZP_001591 | 53763709 |
| 266 | ZP_001657 | 45514234 |
| 267 | ZP_001690 | 46132223 |
| 268 | ZP_001746 | 45523280 |
| 269 | ZP_001837 | 53771530 |
| 270 | ZP_001867 | 45546711 |
| 271 | ZP_002096 | 46204978 |
| 272 | ZP_002248 | 46324513 |
| 273 | ZP_002450 | 47575031 |
| 274 | ZP_002680 | 48763469 |
| 275 | ZP_002710 | 48766450 |
| 276 | ZP_002791 | 48782680 |
| 277 | ZP_002892 | 48832182 |
| 278 | ZP_002916 | 48834623 |
| 279 | ZP_003036 | 48849426 |
| 280 | ZP_003269 | 48893702 |
| 281 | ZP_003351 | 52007802 |
| 282 | ZP_003487 | 53730362 |
| 283 | ZP_003501 | 53759405 |
| 284 | ZP_003591 | 53798896 |
| 285 | ZP_003628 | 54030691 |
|
[0206] |
| Examples of carotenoid ketolase polypeptides. |
| Accession | |
| Row | Number | GI Number |
|
| 1 | AAA99932 | 609575 |
| 2 | AAB48668 | 1870215 |
| 3 | AAC25611 | 2541936 |
| 4 | AAF78203 | 8650419 |
| 5 | AAH16427 | 16741158 |
| 6 | AAN03484 | 22597194 |
| 7 | AAN85497 | 26541510 |
| 8 | AAN86030 | 33439708 |
| 9 | AAO64399 | 28976134 |
| 10 | AAQ23139 | 33621091 |
| 11 | AAT35222 | 47531118 |
| 12 | AAT35555 | 47558911 |
| 13 | AAV41372 | 55139370 |
| 14 | AB2307 | 25530134 |
| 15 | AF2204 | 25533132 |
| 16 | BAB54999 | 14028447 |
| 17 | BAB58879 | 14270087 |
| 18 | BAC98366 | 37360914 |
| 19 | CAA60478 | 2654318 |
| 20 | CAB56059 | 5912292 |
| 21 | D87673 | 25398945 |
| 22 | EAA79304 | 42823978 |
| 23 | EAA80363 | 42826055 |
| 24 | EAA81403 | 42828115 |
| 25 | EAA84711 | 42834481 |
| 26 | EAB82380 | 43031476 |
| 27 | EAB86624 | 43040184 |
| 28 | EAC05755 | 43079085 |
| 29 | EAD12219 | 43292778 |
| 30 | EAD71182 | 43427899 |
| 31 | EAD94927 | 43480380 |
| 32 | EAF11582 | 43712986 |
| 33 | EAF98072 | 43888329 |
| 34 | EAG19345 | 43928738 |
| 35 | EAG38273 | 43963688 |
| 36 | EAG79800 | 44039853 |
| 37 | EAG96474 | 44070318 |
| 38 | EAH00349 | 44077315 |
| 39 | EAH36448 | 44143633 |
| 40 | EAH40683 | 44151265 |
| 41 | EAH53180 | 44175316 |
| 42 | EAH96648 | 44250729 |
| 43 | EAI05260 | 44263397 |
| 44 | EAI17468 | 44281329 |
| 45 | EAI53009 | 44333409 |
| 46 | EAI54054 | 44334878 |
| 47 | EAI67818 | 44354362 |
| 48 | EAI68153 | 44354875 |
| 49 | EAI89684 | 44384943 |
| 50 | EAJ27674 | 44439188 |
| 51 | EAJ45589 | 44464684 |
| 52 | EAJ45589 | 44464684 |
| 53 | EAJ67118 | 44496466 |
| 54 | EAJ74221 | 44507022 |
| 55 | EAJ74653 | 44507662 |
| 56 | EAJ88396 | 44528064 |
| 57 | EAJ88887 | 44528792 |
| 58 | EAK06069 | 44553531 |
| 59 | EAK11467 | 44561166 |
| 60 | EAK16824 | 44568733 |
| 61 | EAK28828 | 44585942 |
| 62 | EAK28828 | 44585942 |
| 63 | EAK31112 | 44589271 |
| 64 | EAK42591 | 44605441 |
| 65 | NP_045063 | 11465545 |
| 66 | NP_081575 | 27754029 |
| 67 | NP_338204 | 15843167 |
| 68 | NP_440788 | 16330060 |
| 69 | NP_441220 | 16330492 |
| 70 | NP_682690 | 22299443 |
| 71 | NP_770721 | 27379192 |
| 72 | NP_848964 | 30468077 |
| 73 | NP_857223 | 31794730 |
| 74 | NP_881760 | 33594116 |
| 75 | NP_882469 | 33594826 |
| 76 | NP_886657 | 33599097 |
| 77 | NP_895643 | 33864083 |
| 78 | NP_896386 | 33864827 |
| 79 | NP_897461 | 33865902 |
| 80 | NP_924674 | 37521297 |
| 81 | NP_927525 | 37524181 |
| 82 | NP_947075 | 39934799 |
| 83 | P54972 | 1706150 |
| 84 | Q39982 | 2498257 |
| 85 | Q44261 | 2498256 |
| 86 | T31123 | 11361063 |
| 87 | XP_330780 | 32420673 |
| 88 | XP_368852 | 39974923 |
| 89 | XP_380194 | 46102628 |
| 90 | XP_383758 | 46115480 |
| 91 | XP_405100 | 49086048 |
| 92 | XP_409222 | 49095522 |
| 93 | YP_102417 | 53725671 |
| 94 | YP_108945 | 53719959 |
| 95 | YP_132414 | 54302421 |
| 96 | YP_154670 | 56459389 |
| 97 | YP_166682 | 56696325 |
| 98 | YP_168846 | 56698471 |
| 99 | YP_172377 | 56751676 |
| 100 | ZP_001068 | 23124870 |
| 101 | ZP_001112 | 53688676 |
| 102 | ZP_001607 | 53764743 |
| 103 | ZP_001757 | 46118877 |
| 104 | ZP_001787 | 53736018 |
| 105 | ZP_002218 | 46321435 |
| 106 | ZP_002456 | 47575608 |
| 107 | ZP_003028 | 48848557 |
| 108 | ZP_003107 | 48856640 |
| 109 | ZP_003264 | 48893204 |
| 110 | ZP_003458 | 53688805 |
| 111 | ZP_003513 | 53763576 |
|
[0207] |
| Examples of carotenoid hydroxylase polypetides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | AAC44852 | 1842246 |
| 2 | AAC49443 | 1575296 |
| 3 | AAD54243 | 5852870 |
| 4 | AAG10430 | 9971820 |
| 5 | AAG10793 | 9988836 |
| 6 | AAG33636 | 11245486 |
| 7 | AAL80006 | 19071768 |
| 8 | AAM44971 | 21280903 |
| 9 | AAM51300 | 21436107 |
| 10 | AAM77007 | 21734857 |
| 11 | AAN85601 | 27228295 |
| 12 | AAO53295 | 28911949 |
| 13 | AAS48097 | 44887642 |
| 14 | AAS55552 | 45184599 |
| 15 | AAS88426 | 46326968 |
| 16 | AAT48741 | 49036137 |
| 17 | AAT84408 | 50844570 |
| 18 | AAV85452 | 56267980 |
| 19 | AAV85453 | 56267982 |
| 20 | BAA14129 | 216687 |
| 21 | BAB79605 | 18143450 |
| 22 | BAC77670 | 31790567 |
| 23 | BAD07283 | 40809749 |
| 24 | BAD07291 | 40809765 |
| 25 | CAA70427 | 2956671 |
| 26 | CAA70888 | 2956717 |
| 27 | CAB55625 | 5870598 |
| 28 | CAB55626 | 5870600 |
| 29 | CAB56060 | 5912293 |
| 30 | CAC06712 | 9968545 |
| 31 | CAC95130 | 33145986 |
| 32 | EAB30128 | 42926157 |
| 33 | EAC49462 | 43167766 |
| 34 | EAC86129 | 43241003 |
| 35 | EAD61089 | 43395962 |
| 36 | EAD76156 | 43443111 |
| 37 | EAD88640 | 43467793 |
| 38 | EAE27903 | 43546376 |
| 39 | EAE28203 | 43546980 |
| 40 | EAE78743 | 43647896 |
| 41 | EAF12173 | 43714211 |
| 42 | EAH29370 | 44130906 |
| 43 | EAH44202 | 44158360 |
| 44 | EAI00766 | 44256844 |
| 45 | EAI29017 | 44298625 |
| 46 | EAJ30844 | 44443849 |
| 47 | EAJ72524 | 44504516 |
| 48 | EAK10611 | 44559981 |
| 49 | EAK53455 | 44620561 |
| 50 | EAK63955 | 44635271 |
| 51 | H90469 | 25394049 |
| 52 | NP_745389 | 26989964 |
| 53 | NP_922503 | 37536402 |
| 54 | P54973 | 1706152 |
| 55 | Q44262 | 2498258 |
| 56 | S52982 | 1073291 |
| 57 | XP_473611 | 50928167 |
| 58 | YP_024309 | 48478603 |
| 59 | ZP_003055 | 48851297 |
| 60 | ZP_003107 | 48856620 |
|
[0208] |
| Examples of astaxanthin synthase polypeptides and putative |
| astaxanthin synthase polypeptides. |
| Genbank | |
| Row | ACCESSION | Genbank GI |
|
| 1 | AAM56288 | 21501451 |
| 2 | XP_571276 | 58268240 |
| 3 | EAL20013 | 50257304 |
| 4 | XP_401804 | 49075484 |
| 5 | XP_397817 | 49067054 |
| 6 | XP_399595 | 49070612 |
| 7 | XP_403279 | 49079218 |
| 8 | XP_382294 | 46110473 |
| 9 | XP_406021 | 49088382 |
| 10 | XP_381224 | 46108332 |
| 11 | XP_391479 | 46139577 |
| 12 | XP_569261 | 58264210 |
| 13 | EAL22841 | 50260180 |
| 14 | XP_359866 | 39940658 |
|
[0209] |
| Examples of carotenoid epsilon hydroxylase polypeptides. |
| ACCESSION | GI | PROTEIN DESCRIPTION |
|
| ABB52076 | 79155148 | putative epsilon-ring carotene hydroxylase [Daucus carota |
| | subsp. sativus] |
| BAD94136 | 62319017 | Cytochrom P450-like protein [Arabidopsis thaliana] |
| ABD28565 | 87162770 | E-class P450, group I [Medicago truncatula] |
| AAT28222 | 47498772 | putative 97B2-like cytochrome P450 [Ginkgo biloba] |
| ABC68396 | 85001685 | cytochrome P450 monooxygenase CYP97A [Glycine max] |
| ABC59110 | 84514203 | cytochrome P450 monooxygenase CYP97B [Medicago |
| | truncatula] |
| NP_190881 | 42565881 | LUT1 (LUTEIN DEFICIENT 1); oxygen binding |
| | [Arabidopsis thaliana] |
| ABB47954 | 78708979 | cytochrome P450 monooxygenase, putative [Oryza sativa |
| | (japonica cultivar-group)] |
| NP_922604 | 37536604 | putative cytochrome P450 monooxygenase [Oryza sativa |
| | (japonica cultivar-group)] |
|
[0210] |
| Examples of lycopene cyclase polypeptides, beta and epsilon subunits. |
| ACCESSION | GI | PROTEIN DESCRIPTION |
|
| AAK07431 | 12746307 | lycopene epsilon-cyclase [Adonis palaestina] |
| ABB52073 | 79154988 | putative lycopene epsilon cyclase [Daucus carota subsp. |
| | sativus] |
| Q38932 | 27735211 | Lycopene epsilon cyclase, chloroplast precursor |
| AAB53336 | 1399181 | lycopene epsilon cyclase |
| AAG10428 | 9971816 | epsilon cyclase [Tagetes erecta] |
| AAK07434 | 12746313 | lycopene epsilon-cyclase [Lactuca sativa] |
| AAM45382 | 21360359 | epsilon cyclase [Tagetes erecta] |
| O65837 | 11132841 | Lycopene epsilon cyclase, chloroplast precursor |
| AAL69394 | 18419661 | lycopene epsilon-cyclase [Spinacia oleracea] |
| BAE79549 | 87299433 | lycopene epsilon-cyclase [Chrysanthemum x morifolium] |
| XP_463351 | 50901836 | putative lycopene epsilon-cyclase [Oryza sativa (japonica |
| | cultivar-group)] |
| AAS48096 | 44887640 | epsilon lycopene cyclase [Citrus sinensis] |
| AAX92679 | 62638188 | lycopene epsilon cyclase [Citrus maxima] |
| AAL92114 | 19569601 | lycopene epsilon-cyclase [Citrus x paradisi] |
| AAK07433 | 12746311 | lycopene epsilon-cyclase [Solanum tuberosum] |
| AAL47019 | 17864021 | lycopene epsilon-cyclase [Citrus sinensis] |
| AAT46065 | 48686703 | chloroplast lycopene epsilon-cyclase precursor |
| | [Chlamydomonas reinhardtii] |
| BAD07293 | 40809769 | lycopene epsilon-cyclase [Citrus limon] |
| BAD07285 | 40809753 | lycopene epsilon-cyclase [Citrus sinensis] |
| BAD07277 | 40809737 | lycopene epsilon-cyclase [Citrus unshiu] |
| EAJ62839 | 44489138 | unknown [environmental sequence] |
| BAE43547 | 73993068 | putative lycopene beta cyclase [Taxodium distichum var. |
| | distichum] |
| BAE43550 | 73993074 | putative lycopene beta cyclase [Taxodium distichum var. |
| | distichum] |
| BAE43557 | 73993088 | putative lycopene beta cyclase [Taxodium distichum var. |
| | imbricarium] |
| BAE43558 | 73993090 | putative lycopene beta cyclase [Taxodium distichum var. |
| | imbricarium] |
| BAE43553 | 73993080 | putative lycopene beta cyclase [Taxodium distichum var. |
| | imbricarium] |
| BAE43545 | 73993064 | putative lycopene beta cyclase [Taxodium distichum var. |
| | distichum] |
| BAE43556 | 73993086 | putative lycopene beta cyclase [Taxodium distichum var. |
| | imbricarium] |
| BAE43552 | 73993078 | putative lycopene beta cyclase [Taxodium distichum var. |
| | distichum] |
| BAE43560 | 73993094 | putative lycopene beta cyclase [Taxodium distichum var. |
| | imbricarium] |
| BAE43554 | 73993082 | putative lycopene beta cyclase [Taxodium distichum var. |
| | imbricarium] |
| BAE43551 | 73993076 | putative lycopene beta cyclase [Taxodium distichum var. |
| | distichum] |
| BAE43519 | 73993012 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43535 | 73993044 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43541 | 73993056 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43542 | 73993058 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43517 | 73993008 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43534 | 73993042 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43537 | 73993048 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43533 | 73993040 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAD02774 | 38603277 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAD02766 | 38603261 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43540 | 73993054 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43514 | 73993002 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43544 | 73993062 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43538 | 73993050 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43528 | 73993030 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43546 | 73993066 | putative lycopene beta cyclase [Taxodium distichum var. |
| | distichum] |
| BAE43526 | 73993026 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43543 | 73993060 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAD02742 | 38603213 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAD02770 | 38603269 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43522 | 73993018 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43559 | 73993092 | putative lycopene beta cyclase [Taxodium distichum var. |
| | imbricarium] |
| BAE43527 | 73993028 | putative lycopene beta cyclase [Cryptomeria japonica] |
| BAE43548 | 73993070 | putative lycopene beta cyclase [Taxodium distichum var. |
| | distichum] |
| AAF44700 | 14550425 | lycopene beta-cyclase [Citrus sinensis] |
| BAE43555 | 73993084 | putative lycopene beta cyclase [Taxodium distichum var. |
| | imbricarium] |
| BAE43549 | 73993072 | putative lycopene beta cyclase [Taxodium distichum var. |
| | distichum] |
| AAU14144 | 51922063 | lycopene beta-cyclase [Citrus sinensis] |
| AAN86060 | 27261727 | lycopene cyclase [Citrus unshiu] |
| AAR89632 | 40756518 | lycopene-beta-cyclase [Citrus maxima] |
| AAM21152 | 20530862 | lycopene beta-cyclase [Citrus sinensis] |
| AAD38049 | 13959731 | lycopene cyclase [Citrus x paradisi] |
| AAU05146 | 51511939 | lycopene beta-cyclase [Citrus sinensis] |
| AAU05145 | 51511937 | lycopene beta-cyclase [Citrus sinensis] |
| AAK07430 | 12746305 | lycopene beta-cyclase [Adonis palaestina] |
| ABB72443 | 82394885 | lycopene beta-cyclase [Citrus sinensis] |
| BAE79544 | 87299423 | lycopene beta-cyclase [Chrysanthemum x morifolium] |
| BAE78471 | 85717882 | lycopene beta cyclase [Taraxacum officinale] |
| Q43415 | 11133019 | Lycopene beta cyclase, chloroplast precursor |
| AAF23013 | 6665782 | lycopene epsilon-cyclase [Daucus carota] |
| ABB52071 | 79154899 | putative lycopene beta cyclase [Daucus carota subsp. sativus] |
| AAW88382 | 59665024 | lycopene beta-cyclase [Lycium barbarum] |
| AAG10429 | 9971818 | beta cyclase [Tagetes erecta] |
| AAM45381 | 21360357 | beta cyclase [Tagetes erecta] |
| AAM14335 | 20259239 | putative lycopene beta cyclase [Arabidopsis thaliana] |
| AAO18661 | 27728515 | lycopene beta-cyclase [Zea mays] |
| AAA81880 | 735882 | lycopene cyclase |
| Q43503 | 11133022 | Lycopene beta cyclase, chloroplast precursor |
| S66350 | 2129931 | lycopene beta-cyclase (EC 5.5.1.—) - tomato |
| XP_464409 | 50905841 | putative lycopene beta-cyclase [Oryza sativa (japonica |
| | cultivar-group)] |
| CAD70565 | 45237491 | lycopene cyclase [Bixa orellana] |
| Q43578 | 11133025 | Lycopene beta cyclase, chloroplast precursor |
| AAL92175 | 19569782 | beta-lycopene cyclase [Sandersonia aurantiaca] |
| AAX54906 | 61742130 | putative chloroplast lycopene beta cyclase precursor |
| | [Chlamydomonas reinhardtii] |
| S66349 | 2129954 | lycopene beta-cyclase (EC 5.5.1.—) - common tobacco |
| AAG21133 | 10644119 | chromoplast-specific lycopene beta-cyclase [Lycopersicon |
| | esculentum] |
| CAB92977 | 8247354 | neoxanthin synthase [Solanum tuberosum] |
| CAB93342 | 8249885 | neoxanthin synthase [Lycopersicon esculentum] |
| Q9SEA0 | 11131528 | Capsanthin/capsorubin synthase, chloroplast precursor |
| Q42435 | 12643508 | Capsanthin/capsorubin synthase, chloroplast precursor |
| AAO64977 | 37730608 | lycopene beta cyclase [Haematococcus pluvialis] |
| Q40424 | 11133011 | Lycopene beta cyclase, chloroplast precursor |
| ABB52072 | 79154940 | putative capsanthin-capsorubin synthase [Daucus carota |
| | subsp. sativus] |
| AAQ02668 | 33304511 | lycopene cyclase [Setaria italica] |
| CAA54961 | 840729 | putative chromoplastic oxydo-reductase [Capsicum annuum] |
| EAJ62838 | 44489136 | unknown [environmental sequence] |
| YP_401079 | 81300871 | Lycopene cyclase, beta and epsilon [Synechococcus |
| | elongatus PCC 7942] |
| YP_172741 | 56752040 | lycopene cyclase [Synechococcus elongatus PCC 6301] |
| ZP_011 . . . | 88808972 | lycopene beta cyclase [Synechococcus sp. WH 7805] |
| EAK50052 | 44615956 | unknown [environmental sequence] |
| NP_892751 | 33861190 | putative lycopene epsilon cyclase [Prochlorococcus marinus |
| | subsp. pastoris str. CCMP1986] |
| NP_875182 | 33240240 | Lycopene epsilon cyclase [Prochlorococcus marinus subsp. |
| | marinus str. CCMP1375] |
| YP_382237 | 78213458 | Lycopene cyclase, beta and epsilon [Synechococcus sp. |
| | CC9605] |
| YP_397130 | 78779018 | Lycopene cyclase, beta and epsilon [Prochlorococcus marinus |
| | str. MIT 9312] |
| NP_896821 | 33865262 | lycopene beta cyclase [Synechococcus sp. WH 8102] |
| YP_397570 | 78779458 | Lycopene cyclase, beta and epsilon [Prochlorococcus marinus |
| | str. MIT 9312] |
| ZP_010 . . . | 87302144 | lycopene cyclase [Synechococcus sp. WH 5701] |
| EAK17149 | 44569190 | unknown [environmental sequence] |
| YP_291882 | 72382527 | lycopene cyclase, beta and epsilon [Prochlorococcus marinus |
| | str. NATL2A] |
| NP_875528 | 33240586 | Lycopene beta cyclase related dehydrogenase |
| | [Prochlorococcus marinus subsp. marinus str. CCMP1375] |
| NP_893181 | 33861620 | putative lycopene beta cyclase [Prochlorococcus marinus |
| | subsp. pastoris str. CCMP1986] |
| NP_895600 | 33864040 | putative lycopene epsilon cyclase [Prochlorococcus marinus |
| | str. MIT 9313] |
| EAI47456 | 44325573 | unknown [environmental sequence] |
| YP_291268 | 72381913 | lycopene cyclase, beta and epsilon [Prochlorococcus marinus |
| | str. NATL2A] |
| ZP_010 . . . | 84517806 | Lycopene beta cyclase related dehydrogenase |
| | [Prochlorococcus marinus str. MIT 9211] |
| AAF34191 | 6970079 | lycopene epsilon cyclase [Daucus carota] |
| ZP_010 . . . | 84518202 | Lycopene epsilon cyclase [Prochlorococcus marinus str. MIT |
| | 9211] |
| YP_376736 | 78184301 | Lycopene cyclase, beta and epsilon [Synechococcus sp. |
| | CC9902] |
| ZP_003 . . . | 66796756 | Lycopene cyclase, beta and epsilon [Deinococcus |
| | geothermalis DSM 11300] |
| NP_894954 | 33863394 | putative lycopene beta cyclase [Prochlorococcus marinus str. |
| | MIT 9313] |
| AAT76051 | 50365502 | lycopene cyclase [Citrus clementina] |
| EAK22047 | 44576122 | unknown [environmental sequence] |
| NP_294525 | 15805827 | lycopene cyclase [Deinococcus radiodurans R1] |
|
[0211] |
| Examples of carotenoid glucosyltransferase polypeptides. |
| ACCESSION | GI | PROTEIN DESCRIPTION |
|
| AAA21261 | 148395 | CrtX [Pantoea agglomerans] |
| AAN85597 | 27228291 | Zeaxanthin Glucosyl Transferase [Pantoea stewartii] |
| BAB79601 | 18143446 | crtX [Pantoea agglomerans pv. milletiae] |
| AAZ73147 | 72536082 | zeaxanthin glucosyl transferase [Enterobacteriaceae bacterium |
| | DC413] |
| AAZ73128 | 72536060 | zeaxanthin glucosyl transferase [Enterobacteriaceae bacterium |
| | DC260] |
| AAZ73140 | 72536074 | zeaxanthin glucosyl transferase [Enterobacteriaceae bacterium |
| | DC416] |
| Q01330 | 231911 | Zeaxanthin glucosyl transferase |
| ZP_006 . . . | 71674312 | UDP-glycosyltransferase, MGT [Trichodesmium erythraeum |
| | IMS101] |
| NP_439972 | 16329244 | zeaxanthin glucosyl transferase [Synechocystis sp. PCC 6803] |
| EAH29368 | 44130903 | unknown [environmental sequence] |
| ZP_005 . . . | 67926135 | zeaxanthin glucosyl transferase, hypothetical protein |
| | [Crocosphaera watsonii WH 8501] |
| YP_378763 | 78188425 | hypothetical protein Cag_0447 [Chlorobium chlorochromatii |
| | CaD3] |
| ZP_005 . . . | 68549418 | Glycosyl transferase, group 1 [Pelodictyon phaeoclathratiforme |
| | BU-1] |
| ZP_010 . . . | 85713606 | glycosyl transferase, group 1 [Nitrobacter sp. Nb-311A] |
| YP_317171 | 75674750 | glycosyl transferase, group 1 [Nitrobacter winogradskyi Nb- |
| | 255] |
| ZP_006 . . . | 69929171 | Glycosyl transferase, group 1 [Nitrobacter hamburgensis X14] |
| ZP_009 . . . | 84500589 | hypothetical protein OB2597_11541 [Oceanicola batsensis |
| | HTCC2597] |
| ZP_009 . . . | 83953176 | hypothetical protein NAS141_12746 [Sulfitobacter sp. NAS- |
| | 14.1] |
| ZP_009 . . . | 83942121 | hypothetical protein EE36_07793 [Sulfitobacter sp. EE-36] |
| YP_508020 | 89052569 | glycosyl transferase, group 1 [Jannaschia sp. CCS1] |
| ZP_010 . . . | 85704103 | hypothetical protein ROS217_13931 [Roseovarius sp. 217] |
| ZP_009 . . . | 83370850 | probable glycosyltransferase [Rhodobacter sphaeroides ATCC |
| | 17025] |
| ZP_006 . . . | 69934465 | Glycosyl transferase, group 1 [Paracoccus denitrificans |
| | PD1222] |
| ZP_009 . . . | 83949880 | probable glycosyltransferase [Roseovarius nubinhibens ISM] |
| YP_376237 | 78183803 | putative glycosyltransferase [Synechococcus sp. CC9902] |
| YP_376129 | 78183695 | probable glycosyltransferase [Synechococcus sp. CC9902] |
| YP_374296 | 78186253 | hypothetical protein Plut_0365 [Pelodictyon luteolum DSM |
| | 273] |
| ZP_010 . . . | 87301651 | Putative glycosyltransferase [Synechococcus sp. WH 5701] |
| ZP_011 . . . | 88809938 | Putative glycosyltransferase [Synechococcus sp. WH 7805] |
| BAE47471 | 78483937 | carotenoid glucosyltransferase [Paracoccus sp. N81106] |
| ZP_010 . . . | 87303273 | probable glycosyltransferase [Synechococcus sp. WH 5701] |
| YP_376127 | 78183693 | probable glycosyltransferase [Synechococcus sp. CC9902] |
| YP_501334 | 88196509 | hypothetical protein SAOUHSC_02880 [Staphylococcus |
| | aureus subsp. aureus NCTC 8325] |
| YP_187370 | 57652300 | glycosyl transferase, group 2 family protein [Staphylococcus |
| | aureus subsp. aureus COL] |
| CAA66627 | 1340131u | nnamed protein product [Staphylococcus aureus] |
| YP_041987 | 49484763 | putative glycosyl transferase [Staphylococcus aureus subsp. |
| | aureus MRSA252] |
| YP_417885 | 82752144 | hypothetical protein SAB2436c [Staphylococcus aureus |
| | RF122] |
| YP_252404 | 70725490 | hypothetical protein SH0489 [Staphylococcus haemolyticus |
| | JCSC1435] |
| NP_693379 | 23099913 | hypothetical protein OB2458 [Oceanobacillus iheyensis |
| | HTE831] |
| ZP_008 . . . | 82501285 | conserved hypothetical protein [Caldicellulosiruptor |
| | saccharolyticus DSM 8903] |
| ZP_010 . . . | 87303565 | hypothetical protein WH5701_09900 [Synechococcus sp. WH |
| | 5701] |
|
[0212] |
| Examples of acyl CoA: diacyglycerol acyltransferase (DGAT) polypeptides. |
| ACCESSION | GI | PROTEIN DESCRIPTION |
|
| XP_957022 | 85082953 | hypothetical protein [Neurospora crassa N150] |
| XP_386864 | 46124621 | hypothetical protein FG06688.1 [Gibberella zeae PH-1] |
| XP_755172 | 71000982 | diacylglycerol O-acyltransferase DGAT [Aspergillus |
| | fumigatus Af293] |
| XP_663763 | 67539978 | hypothetical protein AN6159.2 [Aspergillus nidulans FGSC |
| | A4] |
| BAE65302 | 83775179 | unnamed protein product [Aspergillus oryzae] |
| XP_502557 | 50550169 | hypothetical protein [Yarrowia lipolytica] |
| AAS78662 | 56199782 | diacylglycerol acyltransferase [Glycine max] |
| ABB84383 | 82582915 | diacylglycerol acyltransferase [Jatropha curcas] |
| AAV31083 | 54145459 | 1,2-diacyl-sn-glycerol: acyl-CoA acyltransferase [Euonymus |
| | alatus] |
| AAG23696 | 10803053 | diacylglycerol acyltransferase [Perilla frutescens] |
| AAF64065 | 7576941 | putative diacylglycerol acyltransferase [Brassica napus] |
| AAS01606 | 41387497 | acyl-CoA: diacylglycerol acyltransferase 1 [Olea europaea] |
| AAT73629 | 50299542 | acyl CoA: diacylglycerol acyltransferase [Glycine max] |
| AAM03340 | 67043496 | putative diacylglycerol acyltransferase [Tropaeolum majus] |
| XP_645633 | 66824557 | hypothetical protein DDB0202877 [Dictyostelium |
| | discoideum] |
| AAF19345 | 6625653 | diacylglycerol acylCoA acyltransferase [Nicotiana tabacum] |
| AAY40785 | 63376239 | diacylglycerol acyltransferase DGAT2 [Brassica juncea] |
| AAW47581 | 57231736 | diacylglycerol acyltransferase [Oryza sativa (japonica |
| | cultivar-group)] |
| AAR11479 | 38146080 | diacylglycerol acyltransferase [Ricinus communis] |
| AAY40784 | 63376226 | diacylglycerol acyltransferase DGAT1 [Brassica juncea] |
| AAP68322 | 31711932 | At2g19450 [Arabidopsis thaliana] |
| AAW51456 | 57545061 | diacylglycerol acyltransferase [Lotus corniculatus var. |
| | japonicus] |
| AAD45536 | 5579408 | putative diacylglycerol acyltransferase [Brassica napus] |
| BAD53762 | 53791817 | putative acyl-CoA: diacylglycerol acyltransferase [Oryza |
| | sativa (japonica cultivar-group)] |
| NP_956024 | 41054343 | hypothetical protein LOC325875 [Danio rerio] |
| AAL49962 | 18642598 | diacylglycerol acyltransferase 1 [Bos taurus] |
| XP_930884 | 89028385 | similar to Diacylglycerol O-acyltransferase 1 (Diglyceride |
| | acyltransferase) (ACAT-related gene) [Homo sapiens] |
| NP_777118 | 27819636 | diacylglycerol O-acyltransferase 1 [Bos taurus] |
| Q9GMF1 | 18202926 | Diacylglycerol O-acyltransferase 1 (Diglyceride |
| | acyltransferase) |
| NP_036211 | 6912332 | diacylglycerol O-acyltransferase 1 [Homo sapiens] |
| AAH06263 | 34782946 | DGAT1 protein [Homo sapiens] |
| XP_780515 | 72006039 | similar to Diacylglycerol O-acyltransferase 1 |
| | [Strongylocentrotus purpuratus] |
| AAD40881 | 5225382 | putative diacylglycerol acyltransferase [Brassica napus] |
| XP_539214 | 73974769 | similar to Diacylglycerol O-acyltransferase 1 (ACAT related |
| | gene product 1) isoform 1 [Canis familiaris] |
| AAZ22403 | 71063860 | diacylglycerol O-acyltransferase 1 [Bubalus bubalis] |
| NP_999216 | 47522918 | diacylglycerol acyltransferase [Sus scrofa] |
| NP_001 . . . | 50539976 | hypothetical protein LOC436731 [Danio rerio] |
| XP_849176 | 73974767 | similar to Diacylglycerol O-acyltransferase 1 (ACAT related |
| | gene product 1) isoform 2 [Canis familiaris] |
| NP_505828 | 71997360 | H19N07.4 [Caenorhabditis elegans] |
| AAF82410 | 9049538 | diacylglycerol acyltransferase [Caenorhabditis elegans] |
| CAE75170 | 39591950 | Hypothetical protein CBG23107 [Caenorhabditis briggsae] |
| XP_626337 | 66358318 | diacylglycerol acyltransferase 1 [Cryptosporidium parvum |
| | Iowa II] |
| XP_668402 | 67624239 | acyl-CoA: diacylglycerol acyltransferase 1-related enzyme |
| | [Cryptosporidium hominis TU502] |
| AAP94208 | 33113253 | acyl-CoA: diacylglycerol acyltransferase 1-related enzyme |
| | [Toxoplasma gondii] |
| AAP94209 | 33113255 | acyl-CoA: diacylglycerol acyltransferase 1-related enzyme |
| | [Toxoplasma gondii] |
| XP_579557 | 62652535 | PREDICTED: diacylglycerol O-acyltransferase 1 [Rattus |
| | norvegicus] |
| BAC66171 | 29170489 | diacylglycerol acyltransferase [Mus musculus] |
| Q9ERM3 | 18202872 | Diacylglycerol O-acyltransferase 1 (Diglyceride |
| | acyltransferase) |
| AAL78366 | 18698659 | acyl coenzyme A: diacylglycerol acyltransferase [Drosophila |
| | melanogaster] |
| NP_995724 | 45552403 | CG31991-PD, isoform D [Drosophila melanogaster] |
| NP_724017 | 24584734 | CG31991-PC, isoform C [Drosophila melanogaster] |
| XP_858062 | 73974765 | similar to Diacylglycerol O-acyltransferase 1 (ACAT related |
| | gene product 1) isoform 3 [Canis familiaris] |
| XP_728984 | 82915156 | hypothetical protein PY01256 [Plasmodium yoelii yoelii str. |
| | 17XNL] |
| CAG11944 | 47225461 | unnamed protein product [Tetraodon nigroviridis] |
| BAD27526 | 50199438 | acyl-CoA: diacylglycerol acyltransferase [eukaryotic synthetic |
| | construct] |
| XP_317656 | 31226099 | ENSANGP00000002281 [Anopheles gambiae str. PEST] |
| AAV59457 | 55733950 | putative diacylglycerol acyltransferase [Oryza sativa |
| | (japonica cultivar-group)] |
| EAL33593 | 54644853 | GA16599-PA [Drosophila pseudoobscura] |
| XP_678753 | 68073677 | diacylglycerol O-acyltransferase [Plasmodium berghei strain |
| | ANKA] |
| XP_520014 | 55631434 | PREDICTED: similar to Diacylglycerol O-acyltransferase 1 |
| | (Diglyceride acyltransferase) [Pan troglodytes] |
| CAG10815 | 47219451 | unnamed protein product [Tetraodon nigroviridis] |
| XP_624754 | 66522700 | PREDICTED: similar to ENSANGP00000002281 [Apis |
| | mellifera] |
| CAC69884 | 15620769 | diacylglycerol acyltransferase I [Rattus norvegicus] |
| XP_686181 | 68363630 | PREDICTED: similar to Diacylglycerol O-acyltransferase 1 |
| | (Diglyceride acyltransferase) [Danio rerio] |
| XP_734008 | 70921323 | diacylglycerol O-acyltransferase [Plasmodium chabaudi |
| | chabaudi] |
| XP_673128 | 68062248 | hypothetical protein PB300300.00.0 [Plasmodium berghei |
| | strain ANKA] |
| AAS72376 | 45642963 | acyl-CoA: cholesterol acyltransferase beta [Toxoplasma |
| | gondii] |
| AAS72375 | 45642961 | acyl-CoA: cholesterol acyltransferase alpha [Toxoplasma |
| | gondii] |
| NP_586145 | 19074639 | STEROL O-ACYLTRANSFERASE [Encephalitozoon |
| | cuniculi GB-M1] |
| XP_640280 | 66812202 | hypothetical protein DDB0205259 [Dictyostelium |
| | discoideum] |
| AAY40783 | 63376221 | diacylglycerol acyltransferase [Brassica juncea] |
| XP_765774 | 71032265 | diacylglycerol O-acyltransferase [Theileria parva strain |
| | Muguga] |
| Q876L2 | 34582301 | Sterol O-acyltransferase 2 (Sterol-ester synthase 2) |
| XP_571260 | 58268208 | sterol O-acyltransferase [Cryptococcus neoformans var. |
| | neoformans JEC21] |
| EAL20032 | 50257323 | hypothetical protein CNBF3580 [Cryptococcus neoformans |
| | var. neoformans B-3501A] |
| XP_954478 | 84999514 | acyl transferase [Theileria annulata strain Ankara] |
| XP_505086 | 50555355 | hypothetical protein [Yarrowia lipolytica] |
| NP_588558 | 19076058 | hypothetical protein SPCP1E11.05c [Schizosaccharomyces |
| | pombe 972h-] |
| AAC49441 | 1389739 | acyl-CoA: sterol acyltransferase |
| NP_014416 | 6324346 | Acyl-CoA: sterol acyltransferase, isozyme of Are1p; Are2p |
| | [Saccharomyces cerevisiae] |
| XP_750354 | 70991010 | sterol o-acyltransferase APE2 [Aspergillus fumigatus Af293] |
| XP_382192 | 46110268 | hypothetical protein FG02016.1 [Gibberella zeae PH-1] |
| BAE54934 | 83764790 | unnamed protein product [Aspergillus oryzae] |
| XP_885914 | 76617939 | similar to Sterol O-acyltransferase 2 (Cholesterol |
| | acyltransferase 2) (ACAT-2) isoform 2 [Bos taurus] |
| XP_591251 | 76617937 | similar to Sterol O-acyltransferase 2 (Cholesterol |
| | acyltransferase 2) (ACAT-2) isoform 1 [Bos taurus] |
| BAC00846 | 21392392 | AcylCoA: Cholesterol Acyltransferase 2 [Rattus norvegicus] |
| NP_649816 | 28571583 | CG8112-PA [Drosophila melanogaster] |
| NP_666176 | 22122547 | sterol O-acyltransferase 2 [Mus musculus] |
| O88908 | 18202245 | Sterol O-acyltransferase 2 (Cholesterol acyltransferase 2) |
| | (ACAT-2) |
| XP_761502 | 71022545 | hypothetical protein UM05355.1 [Ustilago maydis 521] |
| NP_714950 | 40254723 | sterol O-acyltransferase 2 [Rattus norvegicus] |
| EAQ86094 | 88178626 | hypothetical protein CHGG_07347 [Chaetomium globosum |
| | CBS 148.51] |
| XP_461395 | 50425599 | hypothetical protein DEHA0F25652g [Debaryomyces |
| | hansenii CBS767] |
| XP_661812 | 67527926 | hypothetical protein AN4208.2 [Aspergillus nidulans FGSC |
| | A4] |
| AAH96091 | 64654094 | Sterol O-acyltransferase 2 [Homo sapiens] |
| O75908 | 18202149 | Sterol O-acyltransferase 2 (Cholesterol acyltransferase 2) |
| | (ACAT-2) |
| AAH96090 | 64652990 | Sterol O-acyltransferase 2 [Homo sapiens] |
| AAK48829 | 13898623 | acyl coenzyme A: cholesterol acyltransferase-2 [Homo |
| | sapiens] |
| XP_543637 | 73996435 | PREDICTED: similar to sterol O-acyltransferase 2 [Canis |
| | familiaris] |
| O77759 | 18202176 | Sterol O-acyltransferase 2 (Cholesterol acyltransferase 2) |
| | (ACAT-2) |
| AAO32474 | 28564191 | ARE2 [Saccharomyces castellii] |
| XP_323485 | 32405744 | hypothetical protein [Neurospora crassa] |
| NP_982606 | 45184888 | AAR065Cp [Eremothecium gossypii] |
| NP_593708 | 19114620 | hypothetical protein SPAC13G7.06 [Schizosaccharomyces |
| | pombe 972h-] |
| AAO32554 | 28564940 | ARE2 [Saccharomyces kluyveri] |
| EAL28962 | 54639560 | GA20833-PA [Drosophila pseudoobscura] |
| XP_449806 | 50294790 | hypothetical protein CAGL0M10571g [Candida glabrata |
| | CBS138] |
| NP_033256 | 84619697 | sterol O-acyltransferase 1 [Mus musculus] |
| Q61263 | 18202591 | Sterol O-acyltransferase 1 (Cholesterol acyltransferase 1) |
| | (ACAT-1) |
| BAC34925 | 26342537 | unnamed protein product [Mus musculus] |
| XP_452607 | 50305295 | unnamed protein product [Kluyveromyces lactis] |
| NP_001 . . . | 77735363 | hypothetical protein LOC504287 [Bos taurus] |
| Q60457 | 18202585 | Sterol O-acyltransferase 1 (Cholesterol acyltransferase 1) |
| | (ACAT-1) |
| XP_320321 | 58393811 | ENSANGP00000016512 [Anopheles gambiae str. PEST] |
| XP_320320 | 58393809 | ENSANGP00000016486 [Anopheles gambiae str. PEST] |
| O70536 | 18202126 | Sterol O-acyltransferase 1 (Cholesterol acyltransferase 1) |
| | (ACAT-1) |
| XP_714776 | 68482533 | acyl-CoA cholesterol acyltransferase [Candida albicans |
| | SC5314] |
| P84285 | 56404462 | Sterol O-acyltransferase 2 (Sterol-ester synthase) (ASAT) |
| AAH77916 | 50416229 | Soat1-prov protein [Xenopus laevis] |
| XP_692855 | 68364838 | PREDICTED: similar to Soat1-prov protein [Danio rerio] |
| CAI13574 | 55960156 | sterol O-acyltransferase (acyl-Coenzyme A: cholesterol |
| | acyltransferase) 1 [Homo sapiens] |
| AAL56227 | 18028942 | cholesterol acyltransferase 1 [Gorilla gorilla] |
| AAL56228 | 18028944 | cholesterol acyltransferase 1 [Pongo pygmaeus] |
| AAC37532 | 4878022 | acyl-coenzyme A: cholesterol acyltransferase [Homo sapiens] |
| 2201440A | 1585676 | acyl-CoA/cholesterol acyltransferase |
| Q876L3 | 34582302 | Sterol O-acyltransferase 1 (Sterol-ester synthase 1) |
| BAE01048 | 67969393 | unnamed protein product [Macaca fascicularis] |
| XP_514030 | 55588858 | PREDICTED: hypothetical protein XP_514030 [Pan |
| | troglodytes] |
| XP_547445 | 73961286 | similar to Sterol O-acyltransferase 1 (Cholesterol |
| | acyltransferase 1) (ACAT-1) [Canis familiaris] |
| EAQ84619 | 88177151 | hypothetical protein CHGG_08633 [Chaetomium globosum |
| | CBS 148.51] |
| O77761 | 18202178 | Sterol O-acyltransferase 1 (Cholesterol acyltransferase 1) |
| | (ACAT-1) |
| XP_422267 | 50751122 | PREDICTED: similar to Sterol O-acyltransferase 1 |
| | (Cholesterol acyltransferase 1) (ACAT-1) [Gallus gallus] |
| XP_693284 | 68392980 | PREDICTED: similar to Sterol O-acyltransferase 1 |
| | (Cholesterol acyltransferase 1) (ACAT-1) [Danio rerio] |
| AAT92940 | 51013293 | YCR048W [Saccharomyces cerevisiae] |
| XP_956576 | 85080625 | hypothetical protein [Neurospora crassa N150] |
| XP_624691 | 66564061 | PREDICTED: similar to ENSANGP00000016486 [Apis |
| | mellifera] |
| CAF96514 | 47222847 | unnamed protein product [Tetraodon nigroviridis] |
| XP_788209 | 72085563 | PREDICTED: similar to sterol O-acyltransferase 1 |
| | [Strongylocentrotus purpuratus] |
| XP_445307 | 50285757 | unnamed protein product [Candida glabrata] |
| CAE70002 | 39596364 | Hypothetical protein CBG16409 [Caenorhabditis briggsae] |
| CAG07990 | 47225647 | unnamed protein product [Tetraodon nigroviridis] |
| NP_510623 | 17549960 | B0395.2 [Caenorhabditis elegans] |
| AAX28331 | 76157393 | SJCHGC04421 protein [Schistosoma japonicum] |
| CAI96158 | 66347204 | Diacylglycerol O-acyltransferase [Bubalus bubalis] |
| XP_390039 | 46136695 | hypothetical protein FG09863.1 [Gibberella zeae PH-1] |
| XP_643169 | 66819019 | hypothetical protein DDB0203882 [Dictyostelium |
| | discoideum] |
| AAO53095 | 28850306 | hypothetical protein [Dictyostelium discoideum] |
| AAB06959 | 1515472 | acyl-CoA: cholesterol acyltransferase [Oryctolagus cuniculus] |
| NP_945619 | 39933343 | putative alginate o-acetyltransferase AlgI |
| | [Rhodopseudomonas palustris CGA009] |
| ZP_008 . . . | 77691302 | Membrane bound O-acyl transferase, MBOAT |
| | [Rhodopseudomonas palustris BisB5] |
| XP_465546 | 50908115 | putative wax synthase [Oryza sativa (japonica cultivar- |
| | group)] |
|
[0213] |
| Examples of Prenyldiphosphate synthase polypeptides |
| Accession | GI | Description |
|
| 29A: Bacteria Proteins that require a mitochondrial targeting sequence |
| ZP_009 . . . | 83373595 | Trans-hexaprenyltranstransferase [Rhodobacter sphaeroides ATCC |
| | 17029] |
| ZP_009 . . . | 83371280 | Trans-hexaprenyltranstransferase [Rhodobacter sphaeroides ATCC |
| | 17025] |
| CAD24417 | 20429105 | decaprenyl diphosphate synthase [Paracoccus zeaxanthinifaciens] |
| ZP_010 . . . | 85705714 | Geranylgeranyl pyrophosphate synthase/Polyprenyl synthetase |
| | [Roseovarius sp. 217] |
| ZP_010 . . . | 84515724 | decaprenyl diphosphate synthase [Loktanella vestfoldensis SKA53] |
| YP_165582 | 56695234 | decaprenyl diphosphate synthase [Silicibacter pomeroyi DSS-3] |
| ZP_010 . . . | 86139019 | decaprenyl diphosphate synthase [Roseobacter sp. MED193] |
| ZP_009 . . . | 83941379 | decaprenyl diphosphate synthase [Sulfitobacter sp. EE-36] |
| ZP_009 . . . | 83854856 | decaprenyl diphosphate synthase [Sulfitobacter sp. NAS-14. 1] |
| ZP_006 . . . | 69299873 | Farnesyltranstransferase [Silicibacter sp. TM1040] |
| ZP_010 . . . | 84683979 | Geranylgeranyl pyrophosphate synthase/Polyprenyl synthetase |
| | [Rhodobacterales bacterium HTCC2654] |
| ZP_009 . . . | 84500217 | decaprenyl diphosphate synthase [Oceanicola batsensis HTCC2597] |
| ZP_009 . . . | 83952381 | decaprenyl diphosphate synthase [Roseovarius nubinhibens ISM] |
| ZP_006 . . . | 69937106 | Trans-hexaprenyltranstransferase [Paracoccus denitrificans PD1222] |
| ZP_005 . . . | 68180845 | Trans-hexaprenyltranstransferase [Jannaschia sp. CCS1] |
| ZP_008 . . . | 78495595 | Polyprenyl synthetase [Rhodopseudomonas palustris BisB18] |
| AAY82368 | 67866738 | decaprenyl diphosphate synthase [Agrobacterium tumefaciens] |
| NP_353656 | 15887975 | hypothetical protein AGR_C_1125 [Agrobacterium tumefaciens str. |
| | C58] |
| ZP_008 . . . | 77688465 | Farnesyltranstransferase [Rhodopseudomonas palustris BisB5] |
| NP_531334 | 17934544 | octaprenyl-diphosphate synthase [Agrobacterium tumefaciens str. |
| | C58] |
| YP_484709 | 86748213 | Farnesyltranstransferase [Rhodopseudomonas palustris HaA2] |
| AAP56240 | 37903500 | decaprenyl diphosphate synthase [Agrobacterium tumefaciens] |
| YP_192388 | 58040424 | Decaprenyl diphosphate synthase [Gluconobacter oxydans 621H] |
| 29B: Subunit 1- Proteins that contain mitochondrial targeting sequence |
| T43193 | 11279237 | trans-pentaprenyltranstransferase homolog - fission yeast |
| | (Schizosaccharomyces pombe) |
| AAD28559 | 4732024 | trans-prenyltransferase [Homo sapiens] |
| AAI07275 | 78070698 | Trans-prenyltransferase [Mus musculus] |
| BAE48216 | 81157931 | subunit 1 of decaprenyl diphosphate synthase [Homo sapiens] |
| AAH49211 | 29165656 | PDSS1 protein [Homo sapiens] |
| Q33DR2 | 85700953 | Decaprenyl-diphosphate synthase subunit 1 (Solanesyl-diphosphate |
| | synthase subunit 1) (Trans-prenyltransferase) |
| XP_507706 | 55633583 | PREDICTED: similar to TPRT protein [Pan troglodytes] |
| XP_586717 | 76632198 | PREDICTED: similar to trans-prenyltransferase [Bos taurus] |
| XP_849908 | 73948851 | PREDICTED: similar to trans-prenyltransferase [Canis familiaris] |
| 29C: Subunit 2- Proteins that contain mitochondrial targeting sequence |
| O13851 | 60389474 | Decaprenyl-diphosphate synthase subunit 2 (Decaprenyl |
| | pyrophosphate synthetase subunit 2) |
| BAE48218 | 81157935 | subunit 2 of solanesyl diphosphate synthase [Mus musculus] |
| BAE48217 | 81157933 | subunit 2 of decaprenyl diphosphate synthase [Homo sapiens] |
|
[0214] |
| Examples of PHB-Polyprenyltransferase polypeptides |
| GI | PROTEIN DESCRIPTION |
|
| 51013645 | YNR041C [Saccharomyces cerevisiae] |
| 50285815 | unnamed protein product [Candida glabrata] |
| 50311051 | unnamed protein product [Kluyveromyces lactis] |
| 45200866 | AGL231Wp [Eremothecium gossypii] |
| 50555263 | hypothetical protein [Yarrowia lipolytica] |
| 68473193 | para-hydroxybenzoate: polyprenyl transferase [Candida albicans SC5314] |
| 50410039 | hypothetical protein DEHA0A14212g [Debaryomyces hansenii CBS767] |
| 83769349 | unnamed protein product [Aspergillus oryzae] |
| 70994900 | para-hydroxybenzoate-polyprenyltransferase precursor [Aspergillus fumigatus |
| Af293] |
| 19114131 | hypothetical protein SPAC56F8. 04c [Schizosaccharomyces pombe 972h-] |
| 39973573 | hypothetical protein MG01067. 4 [Magnaporthe grisea 70-15] |
| 85078920 | protein related to para-hydroxybenzoate polyprenyltransferase precursor |
| [Neurospora crassa N150] |
| 76660839 | PREDICTED: similar to para-hydroxybenzoate-polyprenyltransferase, |
| mitochondrial [Bos taurus] |
| 52138578 | para-hydroxybenzoate-polyprenyltransferase, mitochondrial [Homo sapiens] |
| 18088424 | COQ2 protein [Homo sapiens] |
| 47221448 | unnamed protein product [Tetraodon nigroviridis] |
| 58385249 | ENSANGP00000012220 [Anopheles gambiae str. PEST] |
| 50746583 | PREDICTED: similar to hypothetical protein CL640 [Gallus gallus] |
| 54638587 | GA21912-PA [Drosophila pseudoobscura] |
| 21355567 | CG9613-PA [Drosophila melanogaster] |
| 71005862 | hypothetical protein UM01450. 1 [Ustilago maydis 521] |
|
[0215]Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above Description, but rather is as set forth in the following claims:
